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Abstract 
Proteolytic enzymes play important roles in parasitic protozoa, including 
the organisms responsible for malaria, leishmaniasis and trypanosomiasis. 
Cysteine peptidases have attracted particular attention over recent years as 
some have been reported to play key roles in host-parasite interactions and 
virulence, and may constitute promising targets for new selective inhibitors and 
anti-parasite agents. 
The obligate intracellular protozoan parasite Eimeria (mainly E. tenella) 
belonging to the subclass of Coccidia (with other parasites such as Toxoplasma 
and Cryptosporidium), is responsible for coccidiosis, which inflicts a serious 
economical burden to the poultry industry. Invasion of host cells by Smelia 
involves the regulated release from specialised secretory organelles forming the 
apical complex, whose proteins' maturation, trafficking and secretion rely on 
proteolytic processing. A sequence encoding a cathepsin B-like cysteine 
peptidase of the clan CA, family C1 was identified in the genome database of E. 
tenella. The sequence corresponded to a single copy gene, and did not carry any 
introns. 
The E tenella enzyme, sharing 42% identity with the Toxoplasma gondfi 
toxopain-1, which is reportedly involved in the invasion of host cells, was 
expressed as a soluble inactive zymogen in E. coli. Recombinant cathepsin B of 
E. tenella was functionally expressed as a mature enzyme in the Pichia pastoris 
inducible system as a glycosylated protein, but the glycosylations did not 
apparently affect the enzyme's activity. The biochemical characteristics of the 
recombinant enzyme were consistent with what has been reported in the 
literature for cathepsin Bs. The cathepsin B of E. tenella was detected in oocyst 
and sporozoite extracts, and, more specifically, in microneme preparations. In 
the sexual stages, the enzyme localised to mature macrogametes in discrete 
granules, the size and location of which suggest that they are wall-forming 
bodies, organelles involved in the oocyst wall formation in Eimeria. These data 
suggest that the cathepsin B may play roles in both cell invasion by sporozoites 
and the formation of the protective wall of the oocyst. 
The genus Leishmania belongs to the family Trypanosomatidae, which 
includes the Trypanosoma species, and is the cause of leishmaniasis, which 
affects 2 million people and causes about 60000 deaths a year. Many peptidases 
encoded by the Leishmania genome are cysteine peptidases, some of which 
have been identified as important virulence factors, and therefore potential drug 
targets. Pyroglutamyl peptidases I (PPI) are cysteine peptidases of the clan CF, 
family C15, which hydrolyse N-terminal L-pyroglutamate (pGlu) residues. The 
pGlu modification is a post-transcriptional modification catalysed by the 
glutaminyl cyclase in human that confers relative aminopeptidase resistance and, 
in some cases, is essential to the modified peptides' activity. PPIs have been 
identified in a variety of organisms but no definitive biological function has been 
attributed to them. 
A single copy gene encoding a PPI was identified in the genome database 
of L. major. Active recombinant enzyme was successfully produced in E coli, 
and its biochemical properties coincided with those of mammalian PPls. The 
active site catalytic triad E101, C210, and H234 (L. major PPI numbering) was 
confirmed by mutagenesis. The PPI activity was detected in L. major 
promastigotes, and the enzyme localised to the parasite cytoplasm. PPi knock- 
out mutants were generated, and knock-out of the PPI activity did not seem to 
induce a phenotype in L. major. The parasites retained the properties in vivo and 
in vitro of L. majorwild type cells. The over-expression of the active PPI in L. 
major promastigotes seemed to impair metacyclogenesis and in vivo infectivity, 
while the over-expression of the C210A mutant did not have any detrimental 
effect. Susceptibility to a natural pGlu modified anti-microbial peptide, gomesin, 
was tested on the different cell lines, which were all equally susceptible. The data 
suggest that pGlu-modified peptides in L. major might be required for 
metacyclogenesis and modulation of the immune response in the host. 
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Chapter 1: General introduction 
Chapter I 
General introduction 
Proteolytic enzymes seem to play important roles in parasitic protozoa, 
including the organisms responsible for malaria, leishmaniasis and 
trypanosomiasis. Cysteine peptidases have attracted particular attention over 
recent years and have been the subject of extensive studies because of their 
importance in parasite survival, interaction with the host cells and pathogenicity 
(McKerrow, 1993; Rosenthal, 1999; Klemba and Goldberg, 2002). Despite the 
progress in combating infectious diseases and the constant search for new drugs 
or treatments, some parasites still inflict a dramatic social and economical burden 
to tropical or sub-tropical regions of the world (human and animal infections), as 
well as to developed societies (in particular with the development of intensive 
husbandry of domestic animals enhancing transmission of parasites). 
The protozoan parasite Eimeria (mainly E. tenella), belonging to the 
subclass of Coccidia (with other parasites such as Toxoplasma and 
Cryptosporidium), is responsible for coccidiosis, which is a serious problem in the 
poultry industry. Worldwide expenditures just for anti-coccidiodial drugs added to 
feed is estimated to be $250 to $300 millions annually and there is a rising 
problem of parasites becoming resistant to these coccidiostats 
(www. antecint. co. uk/main/oocide. htm). Also, the intensive use of drugs in farm 
animals raises public health concerns, as about 4% of eggs and 10% of chicken 
liver tested in the UK in 2003 contained residues of coccidiostats 
(hftp: //research. utu. fi/residues/). In December 1998, the European Union banned 
the use of four, widely used growth-promoting antibiotics used in aviary 
production, due to public concern that antibiotic residues in meat could lead to 
antibiotic resistance in humans. The ban may be broadened to more in-feed 
drugs within the next 5 years. Coccidiosis is not limited to the poultry industry and 
some Eimefia species can also affect cattle, sheeps and pigs, which constitutes a 
potential threat for other intensive livestock industries. There is, therefore, an 
increasing economic need to develop efficient new methods of prevention and 
treatment of coccidiosis. The interest in cysteine peptidases has been supported 
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by the fact that some of them seem to be promising targets for new selective 
inhibitors and anti-parasite agents (Selzer et aL, 1997; Rosenthal, 1999). 
The species of Leishmania parasites, belonging to the family for 
Trypanosomatidae (together with the species of Trypanosoma), are responsible 
for leishmaniasis diseases, varying in severity of symptoms depending on the 
species contracted. It affects a variety of mammalian hosts, and it is believed that 
12 million people are affected in the world, and potentially 350 million people are 
at risk of being infected. In developed countries, leishmaniasis has been on the 
increase as an opportunistic disease in immuno-deficient patients, infected with 
the human immunodeficiency virus (HIV). Treatment of the disease mainly relies 
upon the use of pentavalent antimonials, drugs that have been used since the 
1940's. Because of the length of time the drugs have been used and sometimes 
inappropriate dosage, parasites have been developing resistance to these drugs, 
making them less and less effective (Ouellette and Papadopoulou, 1993). In the 
state of Bihar in- northwestern India, unresponsiveness to pentavalent antimonials 
has increased from 34 to 64% between 1994 and 1997 (Thakur et al., 1998). 
Though other means of treatment exist, most of them are very expensive and 
have severe side effects. Despite constant efforts to develop new drugs, very few 
are getting to an advanced stage in chemotherapy trials, and complexity of the 
immune response generated by Leishmania infections has meant that no vaccine 
has been developed so far (Croft and Coombs, 2003). Available chemotherapy 
being inadequate and expensive, there is an urgent need to develop new and 
better drugs. Interest has been brought to cysteine peptidases of Leishmania as 
potential drug targets, as some of them have been shown to be important 
virulence factors (Mottram et al., 2004). 
1.1. Pepticlases: generalities 
Peptidases (also termed proteases or proteinases) catalyse the cleavage of 
peptide bonds in proteins or oligomeric peptides, either within the polypeptide 
chain (endopeptidase activity) or from amino or carboxyl ends (exopeptidase 
activity). Proteolytic enzymes are numerous and diverse; they represent about 
2% of all gene products (Rawlings and Barrett, 1999) and range from monomers 
of 10 kDa to multimeric complexes of several hundred kDa. The location of the 
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scissile bond in the peptidic chain and the preferred amino acid sequence around 
it differ between individual peptidases, but this could not be used to establish a 
comprehensive classification system (Rawlings and Barrett, 1999). In 1960, 
Hartley suggested dividing peptidases into groups depending on the catalytic 
mechanism used (McDonald, 1995). Five main catalytic types could be 
recognised based on the active site residue that provides the nucleophilic attack 
during the catalytic reaction. They are now known as serine, aspartic, metallo-, 
cysteine, and threonine peptidases. Serine, threonine and cysteine peptidases 
effect catalysis after formation of a tetrahedral transition intermediate, whereas 
aspartate peptidases and metallopeptidases require the intervention of a 
molecule of water for cleavage. In the early 1990s, with the increase of data on 
primary sequences of proteins and three-dimensional structures of peptidases, 
Rawlings and Barrett began to bring together sets of peptidases that were similar 
both in molecular structures and in evolutionary origin to create the MEROPS 
database (Rawlings et a/., 2002; www. merops. co. uk). This emphasises the 
growing interest in peptidases and the wealth of resources now available. 
Serine peptidases have a catalytic triad involving serine, aspartate and 
histidine (Rawlings and Barrett, 1994). They are divided into two groups in 
eukaryotes: regulatory peptidases with strict specificity and digestive enzymes 
with broader specificity, such as trypsin and chymotrypsin for example. in 
aspartic peptidases, 2 aspartates are involved in the catalytic process (Rawlings 
and Barrett, 1995b). Among eukaryotic aspartic peptidases, digestive enzymes 
and regulatory peptidases can be found as well as intracellular acid peptidases. 
Metallo-peptidases constitute a vast group of enzymes involving a metallic ion 
(zinc in most cases) in the catalytic process (Rawlings and Barrett, 1995a). 
Examples of metal lo-peptidases are matrix degradation enzymes such as 
elastases, and regulatory peptidases. Some enzymes utilize a catalytic threonine 
for cleavage (Seemueller et al., 1995) and other cryptic proteases may also exist 
(Sajid and McKerrow, 2002). Based on the fact that the majority of peptidases 
described so far in parasitic protozoa are of the cysteine class, the main focus of 
this review will be put on this type of proteolytic enzyme and they will be treated 
independently. 
Although a single peptide bond is cleaved during one catalytic reaction, 
the flanking amino acids in the substrate protein play a role in determining 
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peptidase specificity, as do the sequences flanking the catalytic amino acid 
residues on the peptidase. The convention used to identify substrate residues 
and binding pocket amino acids on the peptidases was elaborated by Schlechter 
and Berger in 1967. The substrate residues are designated as P, and the 
corresponding sites on the enzyme, as S. Prime residues are located on the C- 
terminal side of the cleavage site, whereas non-prime residues are on the N- 
terminal side. Thus, a five residue substrate site cleaved between the third and 
the fourth amino acid would be P3-P2-Pl-P'l-P'2. Sequences that directly flank 
the active site residues are often very conserved and play a role in the enzymatic 
specificity and substrate binding, along with helping to determine the chemical 
environment. Specificity strictness varies from one enzyme another; usually 
several peptide bonds are hydrolysed by the same peptidase, but sometimes 
only one specific bond is cleaved, provided they fulfil certain sequence or 
conformational requirements. The substrate specificity of an enzyme often gives 
good indication on the enzyme's biological role and importance, although it can 
vary between in vitro and in vivo conditions. 
1.1.1. Cystelne peptidases 
Classification 
The first cysteine peptidase was purified in 1879 from the papaya fruit 
Carica, papaya and named papain. The first crystallographic structure of a 
cysteine peptidase was also obtained using papain (Drenth et aL, 1968). Various 
cysteine peptidases have been identified since from a wide variety of eukaryotic 
organisms and the major mammalian peptidase have been designated 
cathepsins B, H, K, L, and S. All of the mammalian lysosomal cysteine 
peptidases are known as cathepsins, the major ones being cathepsins B and L, 
but not all cathepsins are cysteine peptidases. For instance, cathepsins D and E 
are aspartic peptidases, and cathepsins A and G are serine peptidases (Barrett 
and McDonald, 1985). Cysteine peptidases are grouped into clans (Barrett, 
1994), further divided into families depending on sequence similarities and 
substrate specificities (Fig. 1.1). The main focus of my studies will be on clan CA, 
family C1 cysteine peptidases. 
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Clan CD (H, Q 
Clan CE (H, E/D, C) Clan PC (C) 
Legumain-like Clan CF (E, C, H) 
Clan PB(C) (C) 
Clan CH (C, T, H) 
Clan PA(C) (H, D, C) Cysteine peptidase 
[EC. 3.4.22. XX] 
Clan CX (unassigned) 
Clan CL 
Clan CA (C, H, NAD) 
Papain-like 
Papain-family 
Cathepsin L-like 
(fam C 1) Cathepsin B-like 
subfamily subfamily 
Bleomycin-hydrolase 
subfamily 
FIG. 1.1. Cysteine peptidase superfamily. Classification in subfamilies was based on 
amino acid sequence around the active site (see Sajid and McKerrow, 2002). Clans are indicated 
in bold and the amino acids (in parentheses) show the order of the catalytic residues in the linear 
polypeptide sequence (Mottrarn et aL, 2003). 
Although cysteine peptidase's main role is in protein degradation, the 
multiplicity and apparent redundancy of the clan CA enzymes makes the 
discovery of their individual functions rather difficult. This is less the case for clan 
CD enzymes, whose specificity of functions seem much greater (Mottram et aL, 
2003). Nevertheless, the recent progresses in genetic knockouts have enabled a 
better insight into the function of cysteine peptidases and proved that they are 
less redundant than was thought. Cathepsin K in mammals, for example, has 
been demonstrated to be essential for bone remodeling (Chapman et aL, 1997) 
and linked to the genetic disorder pycnodysostosis (Gelb et aL, 1996). Some 
other cysteine peptidases are implicated in tumour invasion (Duffy, 1992) and 
arthritis (Trabandt et aL, 1990). Therefore, they have attracted increasing interest 
in the recent years as targets for human therapy, in particular in terms of 
research for new anti-cancer drugs. 
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1.1.1.2. Catalytic mechanism (Clan CA, family CI) 
Cysteine peptidases have also been referred as thiol or sulfhydryl 
peptidases. The catalytic mechanism of cysteine peptidases is close to those of 
serine peptidases with a nucleophile property conferred by the thiol group. This 
nucleophilic behaviour is further enhanced by the presence of an active site 
histidine, which acts as a proton acceptor. The '-SH' group of the cysteine side 
chain forms a thiolate-imidazoliurn -S"'HN= group with the imidazole group of 
the histidine (Polgar, 2004). The delocalised electron cloud over the thiolate- 
imidazolium group constitutes a charge relay diad, which allows an enzymatic 
activity within a pH range from around 4.0 (pK. of cysteine) to 8.5 (pKa of 
histidine), and is often stabilised by a highly conserved asparagine and the 
chemical environment of the catalytic reaction (pH, ionic force). After formation of 
the transient catalytic thiol-ester tetrahedral intermediate between the enzyme 
and the substrate, the peptidase returns to an active enzyme state. As many as 
one million peptide bonds per second can be degraded with such a mechanism. 
1.1.1.3. Structure and specificity 
The majority of family C1 cysteine peptidases are synthesised as 
immature precursors or zymogens, with a pro-domain and, sometimes, a 
carboxy-terminal extension. These are cleaved in an endogenous or exogenous 
manner to lead to the mature catalytic enzyme. The activation is a regulated 
process involving the proteolytic cleavage of the N-terminal pro-peptide in a pre- 
lysosomal compartment and release of this pro-region, which acts as self- 
inhibitor. The pro-regions are tightly bound to the catalytic cleft and block access 
to the active site (Cygler et aL, 1996) to maintain the peptidase in an inactive 
form during trafficking to the lysosome. The pro-region can also contain folding 
information for the enzyme (Pandey et aL, 2004). Final activation can by 
facilitated by decreasing the pH (Turk et aL, 2000) and this is favoured in the 
acidic pH environment of the lysosome. Most of the mature forms are monomeric 
(with the exception of the tetrameric cathepsin C) with a molecular mass ranging 
from 20 to 30 kDa (without the pro-region of approximately 60 to 100 amino 
acids). Most of the enzymes are endopeptidases, although cathepsins B and H 
also exhibit exopeptidase activity (Barrett and Rawlings, 2001). Although most 
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cysteine peptidases are located in lysosomes or lysosome-like organelles, some 
can also be located on the cell surface or secreted (Robertson et al., 1996). 
Trafficking of the mammalian peptidases requires glycosylation and mannose-6- 
phosphate residue recognition by the mannose-6-phosphate receptor (Kornfeld 
and Mellman, 1989). An alternative mechanism involves transmembrane 
receptors (McIntyre and Erickson, 1993). 
Some detailed analysis of the substrate binding sites have been 
performed, in particular on papain (Turk et aL, 1998), and shown that some 
residues have a role of specificity determinants. Preferences for certain residues 
at particular positions and recognition of specific motifs can vary from one 
peptidase to the other, although similarities are found among the same subfamily. 
Natural or synthesised low-molecular-weight inhibitors are often useful for 
determining binding pockets structures of cysteine peptidases and elucidating the 
relative importance of different binding determinants by co-crystallisation with the 
enzyme (Otto and Schirmeister, 1997). This avoids, in particular, the oxidation of 
the catalytic cysteine to sulfinic or sulfonic acid. Among the natural small 
inhibitors of papain-like cysteine peptidases, cystatins, stefins, kininogens and 
serpin can be cited. They have a low selectivity and are involved in humans in 
the control of cysteine peptidase activity and in the protection against self 
peptidases inappropriately escaping from lysosomes, as well as for exogenous 
organisms. A generic synthetic cysteine inhibitor widely used is E64 (L-trans- 
epoxysuccinyl-leucyl-amido (4-guanidino) butane) and inhibits, in particular, clan 
CA, family C1 peptidases. 
On this basis, specificity determinants for most clans of peptidases could 
be determined. The legumain-like family of cysteine peptidases (clan CD), for 
instance, possess a very strict specificity at the S1 site (Barrett and Rawlings, 
2001; Dickinson, 2002; Mottram et aL, 2003), are insensitive to E64 inhibition and 
present specificities at the P2 and P3 positions (Mathieu et aL, 2002). Papain-like 
peptidases are sensitive to E64 and possess specificity at the S2 position. 
Cathepsin B activity can be discriminated over cathepsin L activity using 
substrate peptides with, respectively, glutamate or alanine (Alves et al., 2001). 
The different amino acid composition of the active site, thus the different 
chemical environment, gives a different S2 specificity to cathepsins B and L. 
Structural differences could also be elucidated for these two subclasses of 
7 
Chapter 1: General introduction 
peptidases. For instance, cathepsin L possesses a conserved motif in the pro- 
region named ERFNIN (sequence Glu-X-Arg-X-(IleNal)-Phe-X-Asn-X-Ile-X-Asn, 
X being any amino acid), which cathepsin B does not have (Karrer et aL, 1993). 
Furthermore, cathepsin B is characterised by the presence of an insertion loop of 
20 amino acids, named the occluding loop because of its positioning in the active 
site, which seems to favour dipeptidyl carboxypeptidase activity (exopeptidase 
activity) (Naegler et aL, 1997). 
1.1.2. Cysteine peptidases in parasitic protozoa 
1.1.2.1. Generalities 
A large number of the peptidases described to date for parasitic protozoa 
are cysteine peptidases of clan CA, family C1. Frequently they are abundant and 
stage-regulated, and most are closely related to mammalian lysosomal cathepsin 
L. Many of the cathepsin L-like cysteine peptidases could be detected in 
lysosome-like organelles by immunoelectron microscopy. For example, 
Leishmania mexicana cathepsin L-like enzymes were localised in large 
organelles known as megasomes (large lysosomes) in the amastigote form of the 
parasite (Pupkis et aL, 1986). In some cases they occur on the surface or are 
secreted. Trafficking of cysteine peptidases in some parasitic protozoa differs 
from that of mammals and some parasites, including the trypanosomatids, lack 
the man nose-6-phos p hate pathway (Huete-Perez et aL, 1999) and may use a 
way involving a peptide loop in the pro-domain. Furthermore, to achieve proper 
targeting to an intracellular compartment or secretion, the N-terminal extremity of 
the enzyme is essential (Brooks et aL, 2000), and a hydrophobic signal peptide of 
about 15 to 22 amino acids upstream of the pro-region can be found. In some 
cases, a C-terminal extension may also be present, like for example for the CP13 
of L. mexicana (Mottram et al., 1997), but this sequence is not required for 
correct trafficking or activation of the enzyme (Mottram et al., 1997). 
The major cysteine peptidase of Trypanosoma cruzi, cruzipain, could be 
detected on the surface of epimastigotes in addition to its main lysosomal 
location (Parussini et al., 1998). Protozoan parasites such as Entamoeba 
histolytica are known to secrete cysteine peptidases. The parasites occur on 
mucosal surfaces in their hosts and this secretion of cysteine peptidase may 
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confer to them an advantage for tissue invasion (Que et aL, 2003; Pertuz Belloso 
et aL, 2004). Due to these extra-lysosomal locations, some parasite cysteine 
peptidases are adapted to a wide range of pH. 
Some structural differences can be found between mammalian and 
parasite peptidases. The ERFNIN amino acid motif in the pro-region of 
cathepsin-L is highly conserved in mammals, which is not the case in parasitic 
protozoa (Sajid and McKerrow, 2002). Furthermore, in some exceptional cases, 
cathepsin B-like enzymes lack the occluding loop or it is modified (Ward et al., 
1997). 
Phylogenetic analysis showed that cysteine pepticlases from diverse 
parasitic organisms are not closely related (Hughes, 1994), with the exception of 
the cysteine peptidases from Leishmania and Trypanosoma. Interestingly, the 
diversification of cysteine peptidases of Haemonchus contortus coincides with 
the emergence of mammals in evolution (Hughes, 1994). This might suggest that 
parasite cysteine peptidase diversification occurred as an adaptive response to 
mammalian hosts. Furthermore, isoenzymes encoded by multiple copies of a 
gene, for example the CPB genes coding for isoenzymes of cathepsin L-like 
enzymes in Leishmania mexicana, may have distinct roles in the interaction 
between the parasite and its host and reflect a highly adaptive process (Mottram 
et al., 1997). 
1.1.2.2. Identified protozoan cysteine pepticlases and their roles 
Members of all major peptidase classes (mainly cysteine peptidases but 
also several serine pepticlases and fewer meta I lo-pe ptid ases and aspartic 
pepticlases (McKerrow et aL, 1993)) have been reported and characterised in 
parasitic protozoa, and extensive studies have been performed on cysteine 
peptidases. Detailed biochemical data are still restricted to a few parasites and a 
few enzymes, and our understanding of the physiological roles of most of the 
enzymes studied is still limited. However, there has been in recent years an 
increasing amount of data suggesting that cysteine peptidases play various 
indispensable roles in the biology of parasites. Beside their catabolic and protein 
processing- functions, they have been reported to play key roles in host-parasite 
interactions and virulence in various parasitic organisms. Only a few examples 
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will be mentioned here, describing some of the cysteine peptidases best 
characterised so far. 
1.1.2.2.1. Cysteine peptidases of Apicomplexa 
1.1.2.2.1.1. Plasmodium 
Species of the genus Plasmodium can parasitise a wide range of hosts. P. 
falciparum is the agent responsible for the most virulent form of human malaria. 
Recent estimates suggest that the number of infected humans exceeds 
500,000,000, and that 1-2 million persons die each year. The life cycle is split 
between a vertebrate host and an insect vector, which is the Anopheline 
mosquito. In the human host the parasite is found primarily inside red blood cells. 
The parasite reproduces asexually until the red blood cells breaks open and a 
large number of merozoites is released, which will infect more red blood cells. 
The characteristic "chill and fever' (paroxysm) associated with malaria occurs 
periodically. The different malarias produce fevers of different frequency, 
depending on how long it takes to complete shizogony in erythrocytes (48 h for P. 
talciparum). Severe and complicated malaria is usually caused by delay in 
successfully treating an uncomplicated infection with P. falciparum. 
Three P. talciparum cathepsin-L like peptidases have been identified 
(falcipains-1, -2 and -3) and the main cysteine peptidase activity in the food 
vacuoles appears to be falcipain-2 (Singh and Rosenthal, 2001). The food 
vacuole also contains the aspartyl peptidases known as plasmepsins I and 11 
(Coombs et al., 2001), which have been more widely characterised than cysteine 
peptidases. Nevertheless, there is clear evidence that cysteine peptidases are 
involved in rupturing of red blood cells after schizogony and are therefore 
involved in parasite release (Sijwali and Rosenthal, 2004). Furthermore, all three 
peptidases are expressed by trophozoites and hydrolyse haemoglobin, 
suggesting roles in this process (Rosenthal et al., 2002; Sijwali and Rosenthal, 
2004). Falcipain-2 and falcipain-3 are food vacuole hemoglobinases, and 
falcipain-2, the principal hemoglobinase of P. talciparum, also hydrolyses ankyrin, 
suggesting additional activity against erythrocyte cytoskeletal targets (Hanspal et 
al., 2002). The definite function of falcipain-1 is still uncertain, as various roles 
have been attributed to the enzyme. Disruption of the gene encoding falcipain-1 
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showed the enzyme was not essential in the erythrocyte stage of the parasite or 
for erythrocyte invasion (Sijwali et aL, 2004), though apparently specific inhibition 
of falcipain-1 had previously been shown to inhibit erythrocytes invasion 
(Greenbaum et al., 2002). Another study suggested falcipain-1 may have an 
important role during parasite development in the insect vector (Eksi et aL, 2004). 
There is an apparent synergy between plasmepsin and falcipain in the 
degradation of haernoglobin (Gluzman et al., 1994; Sijwali and Rosenthal, 2004) 
and these enzymes may be considered as potential joint targets for anti-malarial 
drugs. Multiple orthologs of the falcipains exist and have been identified in other 
plasmodial species and the predicted mature forms of the peptidases of the 
different species are highly conserved (Rosenthal, 1996). For example, in P. 
vivax, vivapain-2 and -3 resemble falcipain-2 and -3 and are potentially 
appropriate therapeutic targets too (Na et aL, 2004). 
1.1.2.2.1.2. Toxoplasma 
Toxoplasma gondd is responsible for toxoplasmosis and belongs to the 
subclass Coccidia along with other parasites including Cry, 0 Ptosp fidium and 
Eimeria. Toxoplasma infection is common, virtually all warm-blooded animals, 
including humans can become infected and it is often transmitted to humans via 
domestic and feral cats. Infection is usually asymptomatic, but acute infection can 
cause lymphadenopathy and in case of immunodepression (for example, AIDS 
patients) leads to severe complications including encephalitis, pneumonitis and 
retinitis. Infection with T. gondii of pregnant women not-previously exposed to the 
parasite and therefore not immune to it may increase the probability of having a 
child born prematurely or even stillborn, especially if the infection occurs during 
the first three months of pregnancy. 
In T. gondfl, a cysteine peptidase gene has been identified and encodes 
an enzyme closely related to cathepsin B, named TOxopain-1 (Que et aL, 2002). 
Toxopain-1 is encoded by a single copy gene (TGCPI) and was reported to 
localise to rhoptries, secretory organelles required for apicomplexan parasite 
invasion. Evidence has been provided that it may be involved in cell invasion and 
rhoptry protein processing (Que et aL, 2002), as well as being critical for cell 
invasion in vivo (Que et aL, 2004). Upon release onto the host cell surface, a 
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number of microneme proteins have been shown to be cleaved, suggesting a 
role for peptidases at that point (Kim, 2004), though most of the process may 
involve subtilisin-like serine peptidases. 
1.1.2.2.1.3. Cryptosporldium 
Cryptosporldium is an intracellular parasite that infects the small intestine 
of an unusually wide range of mammals, including humans. The two species 
responsible for human cryptosporidiosis are C. parvum and C. hominis, the latter 
being restricted to human, and the former being able to infect various mammalian 
hosts (Xu et aL, 2004). Cryptosporidiosis is a self-limiting diarrhoea[ illness in 
immunocompetent humans, lasting 3 to 20 days. In immunodeficient patients (for 
example, infected with HIV) the symptoms can be a lot more severe, sometimes 
leading to death. Some species of Cryptosporidium have a major economic 
significance, as cattle can be infected. The parasites are transmitted mainly via 
contaminated water or food. Cryptosporidium infects the mucosal epithelium of 
the digestive and respiratory tracts. Infection is initiated when sporozoites excyst 
from an ingested sporulated oocyst in the small intestine of the host. Sporozoites 
invade host's intestinal cell lines, activate caspases and induce apoptosis (Ojcius 
et aL, 1999). 
Cysteine peptidase activity has been detected in partially excysted 
oocysts but its role still has to be evaluated (Forney et aL, 1996). Nevertheless, 
there is an indication that cysteine peptidase might be involved in mucus 
penetration by the parasites and in sporozoite and merozoite invasion of host 
cells (Brown S. M. A., PhD thesis). 
1.1.2.2.1.4. Eimeria 
The diseases caused, transmission, pathogenicity, as well as the 
characteristic biochemical and molecular features of the parasite, will be 
discussed in 1.2. 
Cysteine peptidase activity has been detected in Eimeria and using 
specific inhibitors it has been suggested that cysteine peptidases might be 
involved in invasion by sporozoites and merozoites of the host cells (Adams & 
Bushell, 1988; Coombs et aL, 1997), as well as in the penetration of mucus 
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layers (Brown S. M. A., unpublished data). However very little is known about 
cysteine peptidases of coccidian parasites and Toxopain-1 of Toxoplasma gondii 
is the only one characterised so far (Que et al., 2002). 
Little is known about other eimerian peptidases and few have been 
reported so far. Study of E. tenella oocysts revealed that proteins in crude oocyst 
homogenates were degraded in the absence of peptidase inhibitors, and that the 
degradation could be prevented fully by using both typical serine peptidase and 
cysteine peptidase inhibitors. This is strongly suggestive of the presence of these 
two types of peptidases (Michalski et al., 1994). Furthermore, in vitro incubation 
of sporozoites with serine peptidase and cysteine peptidase inhibitors 
significantly decreased host cell invasion, suggesting that these peptidases may 
be involved in invasion by Eimeria sporozoites (Adams & Bushell, 1988). 
Furthermore, a 46 kDa cysteine peptidase could be detected on the surface of 
the sporozoites of E. tenella (Brown S. M. A., unpublished data). Recent studies 
highlighted the expression of an aspartyl peptidase, named eimepsin, in the 
sporulated oocyst of E. tenella (Jean et al., 2001). Eimepsin has been found in 
the refractile body organelles (possibly a storage location) of resting sporozoites 
(Laurent et al., 1993) and within the apical tips of merozoites and invading 
sporozoites (Jean et al., 2000). This gives support to the possibility that eimepsin 
has a function in host cell invasion, as the apical tip of apicomplexan parasites is 
known to be involved in both attachment to and penetration of host cells. But the 
specific function of eimepsin in the parasite is still unknown. Metallo-peptidase 
activity could also be detected in sporulated oocysts using specific inhibitors 
(Kaga et al., 1998), but still very little is known about these enzymes. 
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1.1.2.2.2. Cysteine peptidases of trypanosomatids 
1.1.2.2.2.1. Leishmania 
Leishmania species are responsible for various diseases in humans. The 
diseases caused, transmission, pathogenicity, as well as the characteristic 
biochemical and molecular features of the parasite, will be discussed in 1.3. 
A total of 65 putative cysteine peptidases, grouped into clans and 13 
families, have been revealed in the L. major database (Mottram et al., 2004). 
Most of them belong to the same clan as papain (clan CA). A review of cysteine 
peptidases in Leishmania is presented in Table I. I. (from Mottram et al., 2004). 
Table 1.1. Cysteine pepticlases and cysteine peptidase Inhibitors of Leishmania 
major. Nomenclature for Clans and Families are described in the MEROPS database 
(hftp: //www. merops. sanger. ac. uk), (from Mottram et al., 2004). 
Clan Family Number Gene Peptidase/inhibitor Features Reference 
CA C1 1 CPA CPA Cathepsin L-like, lysosomal Mottram ef ah, 1998 
C1 8 CPB CPB Cathepsin L-like, lysosomal Mottram et aL, 1998 
C11 1 CPC CPC Cathepsin B-like, lysosomal Mottram et aL, 1998 
C2 27 - Contain calpain-like Some calcium-dependant 
domain 
C12 2- Ubiquitin C-terminal Ublquitin pathway 
hydrolase 
C19 15 - 
Ubiquitin hydrolase Ubiquitin pathway 
C48 I- SUMO-like Ubiquitin pathway 
C51 2- D-alanyl-glycyl CHAP domain. 
endopeptidase-like Function unknown 
C54 2 ATG4.1 ATG4 Autophagy Williams, Mottram and 
ATG4.2 Coombs, unpublished 
C65 1 Obutain Ubiquitin pathway 
CD C13 1 GP18 GPI: protein GPI protein anchor biosynthesis Hilley of aL, 2000; 
transmamidase Mottram of aL, 2003 
C14 1 MCA5 Metacaspase Caspase-like protein, Amoult et aL, 2002 
function unknown 
C50 I Separase Thought to control sister Amoult of aL, 2002 
chromatid separation during 
mitosis 
CF C15 1 PGP Pyroglutamyl- Hydrolyses N-terminal glutamyl Schaeffer, Mottram and 
peptidasel residues of proteins Coombs, unpublished 
PC(C) C56 1 PFP1 PfPI Similar to intracellular protease Eschenlauer, Coombs and 
of Pyrococcus, function unknown Mottram, unpublished 
1- 142 1 1CP Inhibitor of cysteine Inhibits Clan CA, family C1 Sanderson of aL, 2003 
peptidases; cysteine peptidases 
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Different peptidase activities have been detected in Leishmania and the 
proteins have mainly been located in the amastigote form of the parasites in the 
megasomes (Pupkis et al., 1986), which are large lysosomes. In the 
promastigote form of the parasite, major activities are thought to be located in the 
multi-vesicular tubule-lysosome (Mullin et al., 2001). 
The family C1 of clan CA comprises 3 identified and characterised 
enzymes. There are 2 cathepsin L-like enzymes; the peptidase CPA (single copy 
gene (Souza et al., 1992)), and the peptidase CPB (multiple copy gene located 
on a single tandem array of 19 non-identical copies in L. mexicana (Mottram et 
al., 1997), and 8 in L. major (Mottram et a/., 2004)). These enzymes possess an 
unusual carboxy-terminal extension of unknown function. The cathepsin B-like 
enzyme CPC is encoded by a single copy gene (Bart et al., 1997). Analysis of the 
peptidase activity showed a stage-specific expression of these different enzymes 
(Robertson and Coombs, 1994). Targeted gene disruption of all CPB genes 
resulted in a decrease in virulence compared to wild-type parasites, a reduction 
of infectivity to macrophages (Mottram et al., 1996) and a shift in the immune 
response to infection in mice from a predominantly Th-2 to a Th-1 response 
(Alexander et al., 1998; Buxbaum et al., 2003). Re-expression of multiple CPBs 
of the array in the null mutant restored most of the infectivity in mice, showing 
that the peptidase is a virulence factor (Mottram et al., 1996; Denise et aL, 2003). 
This suggests that these cysteine peptidases promote the parasite's resistance to 
macrophages' microbial activity and the host's immune response. 
Both L. major and L. pifanoi possess clan CA family C1 cathepsin L-like 
cysteine peptidase genes quite similar to the ones from L. mexicana (Sakanari et 
al., 1997; Rafati et aL, 2001), L. major possessing as well a cathepsin B-like gene 
(Sakanari et aL, 1997). Another example of immuno-evasion promoted by 
cysteine peptidase activity was described in Souza Leao et al., 1995. The 
degradation of host MHC class 11 molecules internalised by amastigotes forms of 
L. amazonensis was inhibited by cysteine peptidase inhibitors. 
There are other clan CA cysteine peptidases in Leishmania; notably 27 
family C2 peptidases with calpain-like domains have been identified in the L. 
major genome database. Calpains are involved in signal transduction pathways, 
and remodelling of cystoskeleton or membrane attachments. Other genes for 
clan CA peptidases have also been identified, and, among them, there are 19 
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genes for cysteine pepticlases of the families C1 2, C1 9, C48, and C65 involved in 
the ubiquitin pathway. 
Among the other clans of cysteine peptidases, clan CID peptidases, 
including glycosylphosphatidylinositol (GPI): protein transamidase (Hilley et aL, 
2000) and the family of caspase-like peptidases, the metacaspases (Amoult et 
aL, 2002), have attracted particular attention. The GPI: protein transamidase is 
involved in the biosynthesis of GPI-anchored proteins, and among the GPI- 
anchored proteins in Leishmania, the GP63 metal lo-peptid a se, thought to be 
involved in resistance to the host's immune response (Ellis et al., 2002; Yao et 
aL, 2003), can be found. Caspase-like peptidases are involved in apoptosis in 
many organisms. Programmed cell death in Leishmania is believed to be 
caspase-independent (Zangger et aL, 2002), and the reason for the presence of 
metacaspase remains unclear, and its function remains unknown. A gene 
encoding a pyroglutamyl peptidase I has also been identified (clan CF, family 
C15) and work on this enzyme will be presented in Chapters 4 and 5 of this 
thesis. 
1.1.2.2.2.2. Ttypanosoma 
Trypanosoma cruz! causes Chagas disease, also known as South 
American trypanosomiasis. The early stage of the disease is characterised by a 
mild febrile state, followed by severe heart and gastrointestinal problems some 
years later. The parasite invades muscle cells and as cardiac muscle is often 
infected, the illness may lead to death through heart failure. 
A major T. cruzi clan CA, family C1 cysteine peptidase is known as cruzain 
(or cruzipain, or gp57/51). It is encoded by multicopy genes present in tandem 
arrays on more than one chromosome (Eakin et aL, 1992), and is expressed in 
all life-cycle stages, though the highest expression rate is in the replicative insect 
epimastigote stage. Cruzain has a similar carboxy-terminal extension to that of L. 
mexicana CPB cysteine peptidase (Eakin et al., 1992) and its amino acid 
sequence shows high similarity with the cathepsin L-like enzymes of other 
Trypanosoma and relatively high similarity with Leishmania sequences (Sakanari 
et al., 1997). Cruzain, unlike most cathepsin L-like enzymes, also shows a 
carboxypeptidase activity, which is a characteristic of cathepsin B enzymes 
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(Judice et aL, 2004). The enzyme's specific function remains uncertain though it 
has been linked to differentiation from epimastigotes to the metacyclic stage 
(Harth et al., 1993; Tomas et al., 1997), and it has been described to have a 
kininogenase activity (Del Nery et al., 1997). Kininogens are multifunctional 
glycoproteins present in mammalian plasma and are potent inhibitors of papain- 
like cysteine peptidases. Cleavage of kininogens with cruzain leads to the 
production of a potent pro-inflammatory peptide and thus cruzain may be an 
important virulence factor (Del Nery et al., 1997). Furthermore, substrate 
cleavage analysis of the different isoenzymes of cruzain showed that they might 
have different substrate specificities (Del Nery et aL, 1997), as is the case for the 
cathepsin L-like isoenzymes of L. mexicana (Mottram et al., 1997). A more recent 
study also linked cruzain to host cell invasion through a kinin-independent 
pathway (Aparicio et al., 2004). There is some evidence as well that T. cruzi 
releases cysteine peptidase activity and this is implicated in the chronic heart 
disease (Morrot et al., 1997). 
African trypanosomes (including the human infective T. brucei 
rhodesiense and T. brucei gamblense, and the non-human infective T. brucei 
brucei causing Nagana in cattle) are responsible for the usually fatal African 
trypanosomiasis. The number of human cases occurring each year is estimated 
at more than 40 000 (hftp: //www. who. int/en/). Less is known about the 
peptidases of these African parasites compared to the American forms. The 
major cysteine peptidase of Trypanosoma bruce! is named trypanopain 
(Troeberg et al., 1996) (clan CA, family Cl). Its precise function is still unknown, 
though it may be involved in parasite differentiation during the life cycle (Pamer et 
aL, 1989). Cysteine peptidases also seem to be released into the bloodstream, 
which may cause platelet aggregation and complication of the infection (Troeberg 
et al., 1996), though these enzymes may only be active for a short period of time 
before they are inhibited by natural hosts peptidase inhibitors in the serum 
(Troeberg et aL, 1996). By using RNA interference to selectively knock down the 
cathepsin B activity of T. brucei, it was shown the cathepsin B activity, and not 
the trypanopain activity as previously thought, was essential to the parasite in 
culture and played a major role in host serum protein degradation by the 
bloodstream parasite (Mackey et aL, 2004). 
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There are at least two families of cysteine peptidases in T. congolese, the 
CP1 (Fish et a/., 1995) and CP2 families, which are 90% identical in their amino 
acid sequences and differ in their N-terminal sequences (Boulange et al., 2001). 
Congopain belongs to the C132-type of enzymes. Though the two types of 
enzymes are very similar in sequence, they differ in substrate specificity and pH 
optimum for activity (Boulange et al., 2001), suggesting distinct roles in vivo, as 
well as different effects on the tolerance they can elicit in cattle. The exact role for 
these enzymes in the parasite remains unknown, but it is thought they may have 
potential as anti-disease vaccines (Authie et al., 2001). 
During T. congolese infection, it was observed that a cysteine peptidase of 
the parasite (congopain) elicited an IgG1 antibody production in cattle which 
showed a degree of resistance to disease during experimental infections (Authie 
et al., 1993). Congopain is a 33-kDa lysosomal cysteine peptidase, inhibited by 
E64 (Authie et al., 1992), which shares similarities with the cruzain from T. cruzi 
and the mammalian cathepsin L and may be an attractive target for anti- 
trypanosome drugs (Lalmanach et a/., 2002). It is a major antigen in infected 
cattle and antibodies against this antigen inhibit the enzyme's activity (Authie et 
al., 2001). Unlike the related mammalian cathepsins B and L, congopain 
accommodates a prolyl residue at the P2' site (Chagas et al., 1997). 
1.1.3. Why are parasite cysteine peptidases good drug targets? 
Cysteine peptidase activity has been demonstrated in most parasitic 
protozoa and some of the cysteine peptidases well characterised show common 
features, for example the similar substrate specificity and similar genetic 
organisation of the cathepsin L-like cysteine peptidase of Leishmania and T 
cruzi. Therefore, there is good indication that in aiming to obtain novel anti- 
parasite drugs, it would be useful to target a series of cysteine peptidases of 
different organisms. Furthermore, some cysteine peptidases involved in human 
diseases are well characterised and already targeted by a library of compounds. 
Thirteen papain-like cysteine peptidases are encoded in the human genome and 
qualify as pharmaceutical targets for the treatment of osteoporosis, arthritis 
(Taubert et al., 2002), asthma, auto-immune diseases, and potentially for certain 
forms of cancer (Bromme and Kaleta, 2002). Recent advances in the design of 
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mammalian cysteine peptidase inhibitors were reviewed by Bromme and Kaleta, 
2002. To give an example, CLIK-148, a cathepsin-L specific inhibitor designed 
from analysis of the substrate-binding pocket, computer graphics and X-ray 
crystallographic data, has been demonstrated to be an effective protective drug 
in vivo against tumour-induced osteoporosis and bone metastasis of cancer cells 
due to bone collagen degradation and is without side effects (Katunuma et aL, 
2002). Therefore, a great methodological knowledge has already been developed 
to validate cysteine peptidases as drug targets, and a large number of inhibitors 
are already available to direct against often homologous parasite cysteine 
peptidases. 
Although a variety of homologous cysteine peptidases are present in the 
parasites' hosts, a number of structural and biochemical differences between the 
two counterparts have been elucidated. This constitutes a clear advantage in 
drug design, as anti-parasite compounds should not inadvertently target a host 
cysteine peptidase. Firstly, many parasitic cathepsin-B like peptidases cleave 
preferably substrates with arginine at the P2 position whereas cathepsin-L like 
peptidases cleave substrates with a hydrophobic amino acid at P2 (Rawlings & 
Barrett, 1994). It has been demonstrated that cathepsin L of Trypanosoma cruzi 
and Leishmania mexicana prefer hydrophobic residues at the P2 position of 
substrate, whereas cathepsin B of the same organisms can also accept basic 
residues (Del Nery et al., 1997; St Hilaire et al.,, 2000). For human cathepsin-B 
and cathepsin-L, the preferred residues are glutamate and alanine, respectively. 
Furthermore, some cysteine peptidases of parasites are difficult to classify, as 
some predicted cathepsin B-like enzymes based on sequence and structure 
homology show cathepsin L-like substrate specificity due to single amino-acid 
substitutions in the catalytic site (i. e. L. major cathespin B-like enzyme; Chan et 
al., 1999). Mammalian cathepsin-L have a highly conserved ERFNIN amino acid 
motif in the pro-region which is not in the parasite homologues and cathepsins B 
have an inserted "occluding" loop in the catalytic domain. All vertebrate 
cathepsins B have maintained the loop whereas some parasite enzymes have 
lost it in the evolution process, like Giardia, or modified the loop sequence or the 
glycosylation content of the loop (Sajid & McKerrow, 2002). Therefore, parasite 
cysteine peptidases do not conform to the general properties described for 
vertebrate cysteine peptidases. As parasites' cysteine peptidases have both 
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lysosomal and extra-lysosomal functions, they are adapted to more diverse 
chemical environments than their host homologues and are more stable over a 
wider pH-range than mammalian cysteine peptidases. The reduced stability of 
mammalian cysteine peptidases at pHs higher than 4.0 (lysosomal pH) may 
constitute a protection mechanism avoiding inappropriate proteolysis. Parasite 
cysteine peptidases are not so tightly restricted and different isoforms of the 
same enzyme can be located in different cell compartments (Parussini et al., 
1998). Furthermore, at least some parasite cysteine peptidases are trafficked in 
the cells through the primitive mannose-6-phosphate-independent pathway and 
N-glycosylation is not necessarily required. For example, the major route of 
trafficking of L. mexicana cysteine peptidases to lysosomes may occur via the 
flagellar pocket, as treatment with cysteine peptidase inhibitors leads to a build 
up of inactive cathepsin B-like cysteine peptidase in the flagellar pocket (Selzer 
et al., 1999) and experiments with mutated inactive cathepsin L-like cysteine 
peptidase led to build up of unprocessed precursor of the enzyme in the flagellar 
pocket as well (Brooks et al., 2000). The trafficking of cysteine peptidases in 
lower eukaryotic organisms may therefore differ significantly from that in 
mammals, which is mainly based on binding to specific receptors of mannose-6- 
phosphate residues on the surface of the enzyme (Kornfeld and Mellman, 1989). 
All of these features constitute potential advantages in targeting the 
cysteine peptidase family to develop new anti-parasite chemotherapy. 
1.1.4. Cysteine peptidase inhibitors as potential anti-protozoa drugs 
Over recent years, there has been a general increase of resistance of 
parasites against available drugs, and therefore there is an increasing need to 
develop new therapeutics and identify new drug targets. For example, 
Leishmania strains resistant to antimonials, currently the frontline drugs of 
chemotherapy against leishmaniasis, are becoming frequent (Werbovetz, 2002). 
Furthermore, antimonials show high toxicity. The same problem is encountered 
with anti-malarial agents (White, 1998) and anti-trypanosomiasis agents. The 
differences between parasite cysteine peptidases and their homologues in 
mammals have permitted the development of inhibitors and the use of parasite 
cysteine peptidases as chemotherapeutical targets. It has now been clearly 
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demonstrated that cysteine peptidase inhibitors can be used as anti-parasite 
agents (Robertson, 1999; Selzer et al., 1997 and 1999; Fujii et al., 2005) and as 
tools for the study of enzyme function (Greenbaum et al., 2004). As cysteine 
peptidases are often numerous in parasites, key issue that remain are 
identification of cysteine peptidases that are not redundant in function and play 
vital roles and to find good and specific inhibitors, often by chemical synthesis, 
screening of banks of molecules and rational drug design based on structural 
information. Through construction of homology-based enzyme models, structures 
of inhibitors can be predicted, then they can be synthesised and tested (Selzer et 
al., 1997; Scheidt et aL, 1998). Target validation can be achieved in different 
ways; firstly by demonstrating that the target is essential through genetic 
manipulation, secondly by showing that the parasite lines resistant to a specific 
inhibitor possess a mutated version of the target enzyme, and thirdly by proving 
there is a good correlation between inhibition of the target activity and the 
inhibition of the parasite's growth (Coombs and Mottram, 1997). 
Following this type of scheme, both reversible and irreversible inhibitors of 
cysteine peptidases have been identified for different parasites. In Lelshmania, 
cathepsin 13- and L-like enzymes are attractive new chemotherapy targets as 
they are required for parasite growth and are demonstrated virulence factors 
(Mottram et al., 1996; Mottram et al., 1998). Using models of both enzymes, 
inhibitors could be identified (Selzer et aL, 1997) and it is now clear that inhibition 
of both types of activities is required for parasite clearance (Mottram et al., 1997). 
Progression of L. major infection in vivo could be reduced using these inhibitors 
without toxicity (Selzer et aL, 1999). This brings good hope that new therapeutics 
against leishmaniasis will be commercially available in the future. Similar studies 
have been undertaken on Trypanosoma cruzi and Plasmodium falciparum. In T. 
cruzi, there are as many as 100 genes encoding cruzain. This may be a problem 
in the attempt of designing specific inhibitor. Nevertheless, an effective inhibitor 
has been identified and named KI 1777. It is a derivative of vinyl-sulfone 
compounds and may be used in human clinical trails for the treatment of Chagas 
disease in the near future (Jacobsen et aL, 2000). In P. falciparum strains, 
falcipain-2 is highly conserved (Singh and Rosenthal, 2001) and a series of 
peptidyl vinyl sulfones have been demonstrated to be good falcipain-2 and -3 
inhibitors of potential therapeutic use in the treatment of malaria (Shenai et al., 
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2003). Safety analysis for these different potent drugs suggest that the selectivity 
may be due to lack of redundancy of parasite peptidases, higher concentration of 
the host peptidases in intracellular compartments, and differential uptake of 
inhibitors by parasites (McKerrow et aL, 1999; Selzer et aL, 1999). So it seems 
that the development of ideal reversible, tight binding and very specific inhibitors 
(or less specific inhibitors that still work as cysteine peptidase' role in the parasite 
differs from those in the host) of cysteine peptidases for these parasites is on the 
way and there is hope that some will be commercially available in the future and 
provide new chemotherapies against major parasitic diseases. Exciting findings 
acquired in this area could also be applicable to other human diseases involving 
cysteine peptidase activities, such a cancer. 
1.2. Eimeria 
The genus Eimeria (Apicomplexa phylum, subclass Coccidia) includes 
more than 1700 species of obligate intracellular parasites that infect all classes of 
vertebrates and some invertebrates. An eimerian species was most probably the 
first protozoon ever visualised, by Antony van Leeuwenhoek in 1674 in the bile of 
a rabbit. As oocysts constitute the stage that leaves the host, usually in faeces, 
98% of all Eimeria species are known only from this life-cycle stage. The 
diseases caused by these parasites are referred to collectively as coccidiosis, 
and they vary tremendously in virulence. Some species cause diseases that 
result in mild symptoms that might go unnoticed and eventually disappear, while 
other species cause highly virulent infections that are rapidly fatal. 
Eimeria species are both site- and host-specific. Most species develop in 
the cells of the host's gastrointestinal tract, but some exceptions can be found. 
Eimeria species seem to be limited to specific locations in specific cells in a 
limited organ. Most species show high host specificity too (E. tenella only infects 
chickens), but some can cross genetic boundaries and infect several hosts. 
There has not been any evidence that Eimerla infects humans, though 
closely related genera, like Plasmodium, Cryptospotidium and Toxoplasma for 
example, can do so. Smetia infections in wild and domesticated animals are 
frequent and widespread, but harmless in most cases. It is only when many 
animals are confined together in a restricted area, as it is the case for chicken 
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flocks infected with the species E. tenella, that the parasite becomes a problem 
as animals are continually re-infected and eventually develop coccidiosis. It is 
particularly a problem for young birds, as adults may become immune. 
Coccidiosis is the most important death-causing agent in the poultry 
industry and is a major economical issue. At least 11 species of Eimeria can 
infect chickens, but the most pathogenic species is E. tenella. E. necatrix 
(responsible for intestinal coccidiosis), E. acervulina (responsible for upper 
digestive tract coccidiosis) and E. maxima (responsible for middle digestive tract 
coccidiosis). All cause chronic intestinal coccidiosis and are responsible for 
disease outbreaks, but are less significant than E. tenella. E. necatrix produces 
fewer oocysts, therefore the development of a sufficient level of environmental 
contamination requires more time, whereas E. acervulina and E. maxima are less 
pathogenic and mainly affect older birds. E. tenella develop in the cells of the 
caeca (two blind sacs near the end of the intestine). After three days of infection, 
the host chicken stops feeding, droops and by the fourth day, blood appears in 
the droppings. By the eight or ninth day, the bird is either dead due to excessive 
blood loss, or on its way to recovery. This type of coccidiosis is the most common 
in young chickens and is therefore a major problem. Furthermore, with the rising 
problem of resistance of eimerian strains to most chemicals used as anti- 
coccidial agents, there is a need to identify new drug targets and develop new 
drugs. 
1.2.1. Life cycle, transmission and pathogenicity 
Eimeria species are homoxenous; they have a direct life cycle that takes 
place within the same host. The infective stage is the sporulated oocyst, the 
environmentally-resistant form of the parasite which contains 4 sporocysts (Fig. 
1.2, b, d) containing 2 sporozoites each. Sporulated oocysts (Fig. 1.2, a, c) can 
survive in a litter for many months. 
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FIG. 1.2. Eimeria sporulated oocyst structure. Line drawings of the parts of 
hypothetical sporulated oocysts/sporocysts of Eimeria: a, completely sporulated oocyst showing 
major structural features with four sporocysts each with two sporozoites; b, sporulated sporocyst 
showing major features, including two sporozoites; c, end of an oocyst showing other possible 
structures, a micropyle and micropyle cap, present in some oocysts, especially those of 
ruminants; cl, another sporulated sporocyst showing a variety of structural features, some of 
which may be present on the sporocysts of different Eimeria species (a = anterior, p= posterior 
refractile bodies of sporozoite) (Duszynski, 2001). 
Unsporulated oocysts are released in the faeces of an infected host (Fig. 
1.3, u). Under the appropriate combination of environmental factors (conditions of 
moisture, temperature and direct exposure to sunlight) often optimal in a litter, the 
oocyst sporulates, which means that sporocysts and sporozoites develop. This is 
an aerobic process involving high oxygen consumption and an energy source 
from stored mannitol. Once sporulation is completed the metabolism is more lipid 
based. The diploid sporoplasm undergoes a meiosis (Fig. 1.3, v) followed by 
mitosis to form 4 sporoblasts (Fig. 1.3, w). Each sporoblast forms a sporocyst 
containing 2 sporozoites each (Fig. 1.3, x). This process takes about 2 days at 
room temperature. 
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x-w 
SPOROGONY 
FIG. 1.3. Complete life cycle of Eimeria. 
(http: //biology. unm. edu/biology/coccidia/eimeriabiol. html). 
A host is infected when it ingests sporulated oocysts from contaminated 
food or water (Fig. 1.3, a). The oocyst wall is mechanically (or/and enzymatically) 
broken in the stomach/gut of the host and the biochemical environment is 
favourable to the active process of excystation. Sporocysts are set free and 
exposed to enzymes of the bile, which leads to release of the sporozoites (Fig. 
1.3, b). The sporozoites move actively and enter epithelial cells for their further 
development (Fig. 1.3, c). In E. tenella, the sporozoites penetrate the villus 
epithelium of the caecum at the tip of the villi. In the cell, the parasite is engulfed 
in a parasitophorous vacuole where uninucleate sporozoites develop to 
multinucleate schizonts (Fig. 1.3, d) and schizonts undergo cytoplasm division to 
produce merozoites (around 900) (Fig. 1.3, e). The merozoites break out of the 
epithelium, disrupting the host cell and are released back into the intestinal lumen 
where they re-infect other epithelial cells (Fig. 1.3, f). Several cycles of asexual 
multiplication (schizogony or merogony) occur and lead to the formation of a 
large number of merozoites (Fig. 1.3, g-j). Merozoites of different generations 
differ in size and quantity. Eimeria infections are self-limiting as asexual 
generations are limited to 2 to 4 before sexual generation occurs. Then, instead 
of giving a further generation of schizonts, merozoites re-enter the epithelium and 
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begin the process of gametogony by which macrogametocytes (female gamete) 
(Fig. 1.3, k-o) or microgametocytes (male) (Fig. 1.3, o-r) are formed. The 
mechanism that triggers this developmental switch is still unknown. The 
microgametocyte buds off to produce many flagellated microgametes that leave 
the epithelial cells in which they were produced to enter cells containing 
macrogametocytes (Fig. 1.3, s). The process of fertilisation by which a 
microgamete actively enters a macrogamete, leads to the formation of an 
intracellular zygote and the granules present within the macrogamete coalesce to 
form the outer cyst wall. The oocyst disrupts the host's cell membrane, is 
released in the intestinal lumen and is discharged in the faeces (Fig. 1.3, t). The 
entire cycle from the infection to the production of oocyst lasts 6 days. 
A picture of a cell-invading merozoite is shown on Fig. 1.4. and a 
diagram of a sporozoite is provided in Fig. 1.5. A typical structural feature of 
apicomplexan parasites is the presence of a unique apical complex, composed of 
polar rings, rhoptries, micronemes, often a conoid, and other subcellular 
organelles that differ from species to species (Tomley, 1997). The apical complex 
is involved in cell invasion (Soldati et a/., 2001; Tomley and Soldati, 2001). The 
refractile bodies, typical of the sporozoite stage, are composed of lipid 
components that might be incorporated into the parasitophorous vacuole 
(Entzeroth et al., 1998). 
FIG. 1.4. Electron-micrograph of second generation merozoites of E. tenelia. 
(Courtesy of Prof D. Ferguson, Oxford). C: conoid, D: dense granules, M: micronernes, R: 
rhoptry. 
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FIG. 1.5. Structure of a sporozoite of Eimeria species (www. saxonet. de). 
The release of the merozoites induces rupture of host's epithelial cells, 
destroying tissue and causing haernorrhages in epithelial capillaries. This will 
lead to villous atrophy in the intestine resulting in malabsorption and 
accumulation of cell debris, blood clots, and necrotic materials in the caecum of 
infected birds with E. tenella causes necrosis of the organ, sometimes leading to 
death. Not all species of Eimeria cause such dramatic symptoms. The 
pathogenicity will very much depend on the type of species ingested, the number 
of sporulated oocysts ingested, the age of the host (old chicken for example may 
be immune against E. tenella), and the environmental conditions (such as 
crowding effect; Williams, 2001). 
1.2.2. Biochemical and molecular biology features 
Studies of the biochemistry of Eimeria have been made difficult by its 
intracellular location. It is therefore difficult to obtain enough material for analysis 
and parasites cannot be grown outside of the host cells. It is mainly oocysts and 
sporozoites, the extracellular stages of the life cycle of the parasite, that have 
been biochemically characterised. 
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Among the most peculiar features encountered in Eimeria, there are 
plastid-like organelles, the presence of a mannitol-cycle, and pyrophosphate- 
linked glycolytic enzymes involved in carbohydrate metabolism. This makes 
Eimeria an interesting organism, with some biochemical characteristics of 
mammals, anaerobic organisms, plants and fungi. 
1.2.2.1. Genomic organisation 
The genome organisation of Eimeria has been reviewed by Shirley (2000) 
and Shirley and Harvey (2000). Omeria species have a nuclear genome of about 
60 Mbp contained on about 14 chromosomes of 1 to above 7 Mbp. The genome 
is currently being sequenced, and a 5-time coverage of the Houghton strain 
genome has been obtained by shotgun reads 
(www. sanger. ac. uk/Projects/E_tenella/). Annotation is underway and will be 
available on the GeneDB database. The GC content of the genome has been 
determined for a few species and is around 50% (53% for E. tenella), there is an 
abundance of the tri-nucleotide repeat GCA (Shirley, 2000), the codon usage has 
been determined for nine genes of E. tenella (Ellis et aL, 1994) and bias was 
associated with the over-representation of G- or C-rich codons. Additional to the 
nuclear genome, a6 kb mitochondrial DNA molecule and a circular plastid DNA 
molecule of about 35 kb could be detected (Williamson et a/., 1994). The plastid 
DNA molecule is contained in a plastid-like organelle, and it has been suggested 
that it could have a green algae origin (Kohler et aL, 1997). The position of the 
plastid-like organelle in the cells and its full biological function are unknown, 
though it has been suggested for other apicomplexan parasites (T. gondfl, P. 
falciparum, Sarcosystis muris, and Babesia ovis) that it contains some 
components of the respiratory chain (Hackstein et aL, 1995), proteins involved in 
haem synthesis, in Type 11 fatty acid biosynthesis (Vollmer et aL, 2001), tRNAs 
and transcription factors (Wilson and Williamson, 1997), and proteins for 
isoprenoid biosynthesis (important for protein prenylation and signal transduction 
regulation) (Vial, 2000). Furthermore, spherical virus-like particles could be 
revealed on electron microscopy and viral-like double-stranded RNA molecules 
could be detected (Ellis and Revets, 1990), but the role of these RNA viruses in 
the biochemistry of Eimeria is unknown so far. 
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Further analysis of the function of the genes requires good molecular 
biology tools. There is hope that transfection technologies will provide a good 
method of study, as transient transfection in sporozoites of E. tenella could be 
performed (Kelleher and Tomley, 1998). But no gene knock-out or RNA 
interference experiments have been successful so far, as studies are mainly 
limited to the extracellular non-replicative forms of the parasite and in-vitro 
propagation of the life-cycle is very inefficient (Tierney and Mulcahy, 2003). 
1.2.2.2. Energy metabolism 
The major energy sources for Smeria through its life cycle are 
carbohydrate compounds (routinely mannitol, and glycogen and amylopectin as 
storage forms), though lipids might be metabolised too (Coombs et al., 1997). 
The presence of anaerobic-specific enzymes (like PPi-PFK, 
phosphofructokinase, Muller et al., 2001) in Eimeria suggests that the parasite 
may be adapted to this metabolic mode (Denton et aL, 1994). Sporozoites for 
example may be facultative anaerobes. A surprising feature is the presence of 
mannitol at high level in unsporulated oocysts (Schmatz et aL, 1989). This is a 
carbohydrate previously detected only in fungi, with mannitol-cycle associated 
enzymes. The mannitol cycle occurs in stages other than the oocyst, such as 
sporozoites (Michalski et al., 1992). The function though is still uncertain, though 
there is good evidence that it may be required during sporulation (Allocco et al., 
1999). Respiratory chain and other catabolic pathways are similar to the typical 
eukaroytic pathways and were reviewed in detail by Coombs eta/. (1997). 
Interestingly, the shikimate pathway, necessary for synthesis of aromatic 
amino acids and absent from mammals, is present in coccidia (Roberts et aL, 
1998). This provides an additional potential target for chemotherapy and some 
herbicide-like compounds have been found to have some efficacy against 
enzymes of the shikimate pathway in apicomplexan parasites, like in Plasmodium 
falciparum (McConkey, 1999). 
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1.2.3. Treatment and control 
Avian coccidiosis is considered to be one of the most important 
veterinary diseases of domestic animals. Over the years, many anti-coccidial 
compounds have been shown to have efficacy and have been used as feed 
additives to control the disease. The major drugs currently used against E. 
tenella are polyether ionophores (Dutton et aL, 1995). A list of commercially 
available anti-coccidial drugs and their mechanism of action is given in Table 1.2. 
Table 1.2. Mechanism of action of commercially available avian anticoccidial drugs. 
(From Coombs et aL, 1997). 
Compound class Examples Mechanism of action 
Polyether ionophore Salinomycin Perturb ion gradients 
Lasalocid 
Maduramicin 
Semduramicin 
Carban il ide/pyrim Wine Nicarbazin Oxidative phosphorylation uncoupler? 
Febrifugine Halofuginone Not known 
Triazine Diclazuril Pyrimidine metabolism? 
Toltrazuril Mitochondrial respiration? 
Chlorophyll a-D1 complex? 
Quinolone Decoquinate Mitochondrial respirationlelectron transport 
Buquinolate Topoisomerase? 
Pyridinol Clopidol Mitochondrial respiration/electron transport 
Thiamine analogue Amprolium Thiamine uptake and utilisation 
Nitrobenzamide Zoalene Nicotinamide antagonist? 
Nitromide 
Guanidine Robenidine Oxidative phosphorylation uncoupler? 
BenzyIpurine Arprinocid Purine salvage? 
Ion chelation (N-oxide active metabolite? ) 
Organic arsenical 
Polyketide 
Sulphonamide 
Aminopyrimidine and 
sulphonamide 
Roxarsone 
Oxytetracycline 
Chlortetracycline 
Sulphadimethoxine 
Sulfaquinoxiline 
Ormethoprim and 
sulphadimethoxine 
Binds protein sulphydryl groups? 
Protein synthesis? 
Dihydropteroate synthetase 
Dihydrofolate reductase and 
Dihydropteroate synthetase 
However, resistance to these drugs has occurred (Augustine et al., 1996) 
and effort has been put in attempts to understand better the parasite's biology 
and the host immune response to the parasite to find alternative ways of control, 
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like the development of vaccines. The basis of this approach is the observation 
that it is possible to acquire protective immunity to Eimeria species, which can be 
boosted by increasing the exposure to the parasite's antigens. Current vaccines 
are composed of oocysts (usually attenuated to avoid averse effect) of various 
species of Eimeria. Commercial live vaccines are already available, like 
Coccivac@ (1952), lmmunocox@) (1987), Paracox@ (Shirley, 1989), Livacoxe 
(1993). Vaccine efficacy has been reviewed by Chapman et a/. (2002). 
Vaccination is the only alternative to chemotherapy at the moment, and in 
practice the administration of drugs remains the easiest, most cost effective way 
and probably the most effective way of controlling the disease (WaIdenstedt et 
al., 1999). But the intensive use of drugs in farm animals raises public health 
concerns as residues of coccidiostats can be found in the meat and this might 
lead to antibiotic resistance in humans. Rotating treatments involving an 
alternation of the administration of drugs and vaccines, or of different vaccines, or 
of different drugs can be used. Therefore, there are already methods of control 
available but none seems ideal and absolutely efficient; therefore there is a 
constant need for identifying new potential drug targets, developing new drugs or 
new control strategies. Increasing knowledge of the parasite's biology in 
concordance with genome sequencing projects should bring useful information 
for the identification and validation of better anti-coccidial agents. 
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1.3. Leishmania 
The genus Leishmania belongs to the family of Trypanosomatidae, of the 
order Kinetoplastida. They are flagellated parasites that occur as intracellular 
amastigotes in vertebrate hosts and promastigotes in invertebrate vectors. About 
21 species have been identified to date, most of them having a specific 
mammalian reservoir (mainly rodents), and some of them being human 
pathogens. The parasite is endemic in areas of the tropics and subtropics, in a 
total of 80 countries in South and Central America, Southern Europe, Asia, the 
Middle East, and Africa, with sporadic cases elsewhere (Fig. 1.6). 
FIG. 1.6. Leishmaniasis distribution in the world. 
(srs. wehi. edu. au/media/images/handmantworld_map. jpg) 
Leishmania affects 2 million people and causes about 60000 deaths a year 
(Croft et al., 2002; Reithinger et al., 2002), and there has been an ever increasing 
number of cases reported every year over the last 20 years. The last 10 years 
have also seen an emergence of leishmaniasis as an important opportunistic 
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infection in immuno-depressed patients; in particular those infected with the 
human immunodeficiency virus (HIV) (Ambroise-Thomas, 2001). Infection with 
Leishmania is also a frequent cause of clinical disease in the dog, especially in 
tropical, sub-tropical and temperate areas. 
Different Leishmania strains are responsible for different forms of the 
disease in humans, with different severity of symptoms. The four types of 
diseases are: visceral, cutaneous, diffuse cutaneous and mucocutaneous 
leishmaniasis. According to the human clinical criteria, canine leishmaniasis is 
classified as visceral, although the term "generalized canine leishmaniasis" might 
be more appropriate because it involves visceral and cutaneous tissues (Alvar et 
aL, 2004). 
Visceral leishmaniasis is caused mainly by the Leishmania species of the 
complex donovant, L. donovan! chagasi (in the Middle East and Asia mainly), and 
L. donovani donovani, L. donovan! infantum and L. donovani archibaldi (in South 
America, mainly eastern Brazil) (Desjeux, 2004). The parasite infects 
macrophages throughout the reticuloenend9thelial system, and eventually 
reaches spleen, liver and bone-marrow cells, resulting in death of the patient if 
not treated. 
Cutaneous leishmaniasis is caused mainly by L. major, L. tropica, and L. 
aethippica (in Africa and Asia); and L. guyanensis, L. panamensis, and L. 
mexicana (in South and Central America). In this case, parasites only multiply in 
the macrophages at the site of inoculation, which results in a single lesion. 
Healing can be spontaneous, resulting in immunity, in untreated patients. 
Diffuse cutaneous leishmaniasis in caused by L. aethlopica in Africa, and 
by L. amazonensis in Central and South America. Symptoms are the appearance 
of widespread nodules in the skin, which are difficult to treat and do not heal 
spontaneously. 
Mucocutaneous leishmaniasis is caused by L. brazifiensis and L. 
panamensis in South America only. Parasites are inoculated by a sand fly bite at 
any location on the body, which forms a small lesion that heals spontaneously. 
But the parasites invade and erode cartilaginous tissues (nose and palate) 
causing disfigurement and eventually death from secondary infections if 
untreated. 
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Leishmaniasis is therefore an important human disease, in constant 
progression and emergence of resistance to available drugs is an increasing 
problem. It is essential new drugs are identified in order to increase chances of 
controlling the disease. 
1.3.1. Life cycle and transmission 
The life cycle of Leishmania alternates between a vertebrate and an 
insect host (Fig. 1.7). The natural reservoir hosts, besides humans, include dogs 
and various wild animals. The vectors are small Dipteran insects (sandflies) of 
the genus Phlebotomus and Lutzomyia. 
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FIG. 1.7. Life cycle of Leishmania species. (www. wehi. edu. au/media/images/ 
leishmania_cycle. gifl. 
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Amastigotes (in the vertebrate host) have virtually no flagellum (Fig. 1 8). 
They are ingested by macrophages by phagocytosis. The parasites, resistant to 
lysosomal enzymes released into the phagolysosome, multiply by binary fission 
within the macrophages (Pearson et al., 1981). This makes the macrophage die 
eventually and release the parasites that can infect new macrophages. The 
sandfly vector (female only) ingests the infected macrophages from the blood or 
skin, while having a blood meal. The parasites then transform into procyclic 
promastigotes in the midgut of the insect (Walters, 1993). Promastigotes are 
more elongated, flagellated forms (15-20 ltm in size), with the kinetoplast near 
the anterior end, which multiply by binary fission too (Fig. 1.9). About 10 days 
after ingestion of the parasites, the insect vector feeds again, and metacyclic 
promastigotes parasites, which have migrated from the midgut to the proboscis, 
are injected into the vertebrate host's skin. The parasites are then phagocytosed 
by macrophages, and they revert to the amastigote form before dividing again 
(Sacks, 1989). 
B 
FIG. 1.8. Ultrastructure of Leishmania mexicana amastigotes (from Coombs et al, 
1986). The two electron microscopy images show that the lysosomes (Lys) occupy a significant 
proportion of the cytoplasm, while organelles of the secretory pathway are less conspicuous. The 
flagellum of the amastigote stage only just emerges from a flagellar pocket (fp). The posterior end 
of the amastigotes is often intimately connected to the membrane of the macrophage 
phagolysosome compartment (arrowheads). N, nucleus; M, mitochondrion; k, kinetoplast. Scale 
bars: 500 nm. 
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FIG. 1.9. Ultrastructure of Leishmania mexicana promastigotes (from Waller and 
McConville, 2002). Tubular 'early' endosomes (endo) are closely associated with the flagellar 
pocket (fp). A single Golgi apparatus is also proximal to the flagellar pocket and is flanked by a 
transitional endoplasmic reticulum (tER). Multivesicular bodies (MVBs) can be seen arising. The 
lysosome compartment, termed the multivesicular tubule (MVT) extends from near the flagellar 
pocket, in close proximity to IVIVBs, to the posterior end of the cell. One or two microtubules (mt) 
run along the length of the MVT-lysosome. Acidocalcisomes (ac) cluster principally in the 
posterior of the cell (note that glutaraldehyde and osmiurn fixation extracts the contents of some 
of the acidocalcisomes). N, nucleus. Scale bars: 500 nm. 
1.3.2. Biochemical and molecular biology features 
Studies of the biochemistry of Leishmania have been possible due to the 
relatively easy maintenance of the promastigote form of the parasite in culture. 
The promastigotes multiply by binary fission and differentiate into metacyclic 
promastigotes when reaching the stationary phase of growth. This has made 
genetic manipulations, and studies of particular gene's functions possible. 
Among the most peculiar features present in Leishmania, is the 
kinetoplast, a unique cellular structure located within the single mitochondrion 
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and possessing its genetic information. The kinetoplast is located at the base of 
the flagellum near the anterior end (Fig. 1.8). At the metabolic level, glycolysis is 
a regulated event that takes place in the glycosomes, which are specific 
organelles related to peroxisomes (Parsons, 2004), and oxidative stress is 
regulated using trypanothione, an antioxidant absent from the mammalian host, 
which utilises glutathione instead. 
1.3.2.1. Genomic organisation 
Leishmania is a diploid organism. The haploid genome of Leishmania 
major Friedlin (the subject of this study) is composed of 36 chromosomes, that 
vary in size from 326.9 to 2821.3 kb, with a total genome size of 34.7 Mb (Zhou 
et aL, 2004). In terms of codon usage, the G+C content at the third codon 
position represents the main source of codon usage variation (Alvarez et aL, 
1994). The genome is divided into transcription units (Myler et aL, 2000), which 
are transcribed into polycistronic mRNAs. The control of gene expression is 
mainly post-transcriptional, using trans-splicing and polyadenylation, which 
require the addition of a 5' cap and a 3' poly A tail. At the 5' end of all mRNAs, a 
splice leader sequence (SQ is added by trans-splicing (Graham, 1995). The SL 
sequence is composed of a non-translated 39-41 nucleotide sequence, which is 
well conserved between trypanosomatid species (Gibson et al, 2000). At the 3' 
end no specific signal for the addition of the poly A tail has yet been described, 
although polypyrimidine tracts have been identified. 
Additional to the nuclear genome, the kinetoplast contains a catenated 
network of DNA (kDNA), which can be divided into 2 groups: maxicircles and 
minicircles, where maxicircles are found at a copy number of 20-50 per 
kinetoplast, and minicircles are present at about 10000 per kinetoplast. 
Maxicircles are homogeneous circular DNA molecules, 20-35 kb in size, which 
have many of the characteristics of conventional mitochondrial DNA, encoding 
proteins involved in energy production. Minicircles are a heterogeneous group 
and 0.5-1.5 kb in size, which differ in sequence number and types from species 
to species. They do not encode proteins, but encode for guide RNAs (gRNAs), 
which have a role in the maturation of the mitochondrial mRNAs, a process 
known as RNA editing, a process typical of trypanosomatids (Schneider, 2001). 
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After transcription, U nucleotides are inserted, and create open reading frames 
from non-sense sequences at the RNA level (Benne et al., 1986). U deletions 
can also occur, but at lower frequencies. The small RNA molecules transcribed 
from the minicircles and maxicircles contain the editing information (Simpson et 
al., 2004). RNA editing is used as a mechanism of regulation of mitochondrial 
gene expression (Worthey et al., 2003). 
1.3.2.2. Energy metabolism and trypanothione 
Leishmania species present a number of particular biochemical features. 
First, they present a unique compartmentation of glycolysis within unusual 
peroxisomes called glycosomes. Like peroxisomes, glycosomes are bounded by 
a single-membrane. In Leishmania amastigotes, glycosomes comprise 1% of the 
total cell volume (Coombs et al., 1986). Some enzymes commonly found in 
peroxisomes are also found in the glycosomes (Wiemer et al., 1996). So the 
glycosomes might have evolved from peroxisomes, but might also reflect 
recruitment of proteins from a photosynthetic organism through lateral gene 
transfer by endosymbiosis (Hannaert et a/., 2003) or phagocytosis (Waller et a/., 
2004). This photosynthetic organism is thought to have been an alga, as some 
pathways are related to those of algae, plants and chloroplasts (Hannaert et al., 
2003), and some plastid-like proteins are found in the glycosome. Glycolysis 
occurs as a result of a cooperation between the cytoplasm, the mitochondrion 
and the glycosome, and purines, which the parasite cannot synthesise de novo, 
are also salvaged using enzymes associated with glycosomes. Although some 
enzymes of glycolysis are similar to those of the mammalian host, the glycosome 
possesses unique enzymes of algal origin, which may be interesting for drug 
design (Parsons, 2004). 
Another interesting characteristic is that Leishmanla parasites regenerate 
thiols using trypanothione (a glutathione-spermidine conjugate), rather than 
glutathione (Henderson and Fairlamb, 1987). This is the anti-oxidant used to 
reduce hydrogen peroxide and other oxidants. Trypanothione and the enzymes 
involved in its synthesis and recycling are absent from the mammalian host and 
so have been proposed as suitable targets against which to develop drugs 
(Faidamb and Cerami, 1992; Chibale and Musonda, 2003). 
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1.3.3. Treatment and control 
As a first strategy of control of the disease, the elimination of natural 
reservoirs such as dogs, rodents and insect vectors has been used. Sandfly 
population control is an ongoing process and continued surveillance is required 
to keep the population low. However, this is possible only under certain 
environmental conditions. Therapy against leishmaniasis mainly relies upon 
pentavalent antimonials, which have been used since the 1940's, and include 
sodium stibogluconate or meglumine antimonite; a prolonged course being 
necessary for treatment. The mode of action is unclear, but the retention in 
macrophages and conversion to more toxic trivalent derivative are important 
factors (Shaked-Mishan et al., 2001). Pentamidine is used as an alternative to 
antimonials, in case the latter are not effective (Amato et al., 1998). But 
pentamidine resistance has been described, relying on the decrease in 
mitochondrial membrane potential, which prevents the accumulation of the drug 
in the mitochondrion and thus reduces its toxicity (Basselin et aL, 2002). 
Amphotericin B, an antibiotic, is also used, where resistance to other drugs 
occurs (Olliaro and Bryceson, 1993). Many of these treatments present severe 
side effects, or are too expensive for extensive use in developing countries. 
Antimonials have a cumulative toxicity and parasites are increasingly becoming 
resistant to these drugs (Croft et a/., 2002). Pentamidine is expensive and more 
toxic; amphotericin B has lower toxicity but is even more expensive. Vaccines 
have not been successful so far due to the complexity of the immune response 
caused by the parasite (Croft and Coombs, 2004). Recently a new compound 
inhibiting various enzymes of cell signalling pathways, miltefosine, has been 
registered for use against leishmaniasis (Seifert et al., 2003), but there is a need 
for new drug discovery and validation of new treatments. 
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1.4. Aims of this study 
The overall aim of this project was to identify and characterise cysteine 
peptidases as possible drug targets in the parasitic protozoa Eimeria and 
Leishmania. 
This project was divided into 2 parts: 
- Identification of cathepsin B-like peptidases (clan CA, family Cl) in Omeria 
tenella, production of active recombinant enzyme for biochemical 
characterisation and drug screening, and production of specific antibodies to 
study the localisation of the enzyme in the parasite. 
- Identification and characterisation of genes encoding a pyroglutamyl 
peptidase I (cysteine peptidase of the clan CF, never described before in 
parasites) in Leishmania major, production of active recombinant enzyme for 
biochemical characterisation, and study of its role by gene replacement and over- 
expression in the parasite. 
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Chapter 2 
Material and Methods 
2.1. Parasites 
2.1.1. Eimeria tenella sporozoite preparation 
A suspension of sporulated oocysts of E. tenella (H strain) at a 
concentration of 107 cells/ml in 5% (w/v) sodium hypochlorite, 1% (w/v) 
amphotericin B was kindly provided by Intervet, Schwabenheim, Germany. About 
108 sporulated oocysts were washed in phosphate-buffered saline (PBS) (20 mM 
sodium phosphate buffer, 150 mM sodium chloride, pH 7.4), with 3 min 
centrifugation at 13000 g at room temperature to sediment them between each 
wash. The oocysts were resuspended in 5 ml PBS and 5 ml 3 mm sterile glass 
beads (Sigma, Poole) were added. The sample was vortexed for a few minutes, 
checking regularly by phase contrast microscopy for release of sporocysts. The 
sporocysts suspended in the liquid phase were transferred into a fresh tube, the 
beads were washed with PBS and the liquid phase containing sporocysts was 
added to the first batch of sporocysts. The combined sporocyst sample was 
centrifuged at 800 g for 5 min at room temperature. The cloudy supernatant was 
removed and pelleted sporocysts were resuspended in 1% (w/v) 
taurodeoxycholic acid containing 0.25% (v/v) trypsin (Sigma, Poole, ref. T4549) 
and placed in a shaking water bath at 440C for 1 h. Subsequently, the excystation 
mixture was filtered through a non-absorbent cotton wool column and the -95% 
pure sporozoites were collected in the flow through (contaminated by some cell 
debris). The sporozoites were sedimented at 3000 g for 5 min at room 
temperature and used immediately or stored at -200C. The efficiency of 
excystation of 6 to 12 months old sporulated oocysts was about 50%. The 
sporulated oocysts used were not older than 12 months. The overall efficiency of 
sporozoite purification was 30 to 35%. 
2.1.2. Leishmania major culture 
Leishmania major (MHOM/IU80/Friedlin) promastigotes were cultured in 
HOMEM medium (Berens et al., 1976) (GibcoBRL, Paisley) with 10% (v/v) heat 
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inactivated foetal calf serum (HIFCS) at 2511C with air as the gas phase. Cultures 
were inoculated at _105 cells/ mi and cells were sub-passaged when stationary 
phase was reached (1-2 x 107 cells/ml) (after about one week). 
L. major metacyclic promastigotes were purified from stationary phase 
cultures as described by Da Silva and Sacks, 1987. Briefly, promastigotes were 
pelleted at 1300 g for 10 min at 40C, washed in PBS and resuspended in PBS at 
108 cells/mi. Peanut agglutinin (Vector Laboratories, Burlingame, CA, US) was 
added at 50 [tg/ml (w/v) and the sample was incubated 25 min at room 
temperature. The supernatant contained the non-agglutinated metacyclic 
promastigotes. 
L. ma r amastigotes were purified from infected BALB/c mice by Susan VO 
Baillie (University of Glasgow) as described (Hart et al., 1981) and incubated at 
250C in presence of 30 ILLg/ml gentamicin (Sigma, Poole). 
The densities of all cultures were determined using an improved Neubauer 
haernacytometer (Weber Scientific, Hamilton, NJ, US). 
2.1.3. L. major harvest and lysis 
Parasites were harvested by centrifugation at 1300 g for 10 min at 40C, 
washed twice in PBS, and stored at -800C until use. Parasites were lysed by 
resuspension to a concentration in parasite equivalents of 2x 109 cells/ml in lysis 
buffer, composed of 50 mM Tris/HCl pH 8.0,0.25% (v/v) Triton X-100,20% (v/v) 
glycerol, and, unless stated otherwise, a cocktail of peptidase inhibitors (10 [IM 
(2S, 3S)-3-(N-{(S)-I -[N-(4-guanidinobutyl) carbamoyl]3-methylbutyl}carbamoyl) 
oxirane-2-carboxylic acid [E-64], 2 mM 1,10-phenanthroline, 4 l. LM pepstatin A, I 
mM phenylmethylsulfonyl fluoride [PMSF]). The mixture was incubated for 10 min 
on ice and centrifuged at 13000 g for 15 min at 411C. The supernatant (designated 
as the soluble fraction) was separated from the pellet, and the pellet (designated 
as the membrane-bound fraction) was resuspended in the same volume as 
before in lysis buffer. Both samples were either used immediately or stored at - 
200C until use. 
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2.1.4. L. major cryo-preservation 
Stationary phase L. major promastigotes were pelleted at 1300 g for 10 
min and resuspended at 108 cells/ml in HOMEM medium with 10% (v/v) HIFCS. 
One ml of cell suspension was mixed with 1 ml of HIFCS containing 30% (v/v) 
glycerol in a cryotube vial (Nunc, Roskilde, Denmark), and placed overnight at - 
700C in an isopropyl alcohol bath (for slow decrease of temperature), before 
transfer to liquid nitrogen (-196"C) for long-term preservation up to several years. 
2.1.5. Bloassay for leishmanicidal activity 
Promastigote viability was measured using the 3-(4,5-dimethylthiazol-2-yi)- 
2,5-diphenyl tetrazoliurn bromide (MTT) assay as described in Silva et aL, 2000. 
The assay is based on the loss of mitochondrial activity associated with cell 
death, and therefore loss of the capacity of reduction of MTT (yellow) into 
formazan (blue). L. major promastigotes were pelleted at 1300 g for 10 min and 
resuspended at 5.5 x 107 cells/ml in PBS. 5x 106 L. major cells were incubated in 
a microtiter plate with gomesin and gomesin analogues at various concentrations 
in a total volume of 100 gl. Gomesin and gomesin analogues were kindly 
provided by Dr Antonio de Miranda (Sao Paolo, Brazil). The primary amino acid 
structure of gomesin is ZCRRLCYKQRCVTYCRGR* (using the single letter 
amino acid code, were Z stands for pyroglutarnate and the asterisk indicates an 
a-amide) (Silva et al., 2000). The gomesin analogues were [Ala']-gomesin, 
where the N-terminal pyroglutarnate was replaced by an alanine, and Ac-[Alal]- 
gomesin, where the N-terminal pyroglutarnate was replaced by an acetylated 
alanine. After an incubation of 1h at 250C, 100 gl of 2 mg/ml MTT dissolved in 
PBS was added (final concentration of 1 mg/ml), the mixture was incubated for 1 
h at 2511C, and then the absorbance at 620 nm was read using a microtiter plate 
reader. 
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2.2. Molecular biology techniques 
2.2.1. Isolation of genomic DNA from E. tenella and L. major 
1x 108 E. tenella sporozoites or L. major promastigotes were pelleted by 
centrifugation at 1300 g for 10 min at 4*C and the cells were resuspended in 150 
l. d of TELT buffer (50 mM Tris-HCI pH 8.0,62.5 mM ethylenediamine tetraacetic 
acid [EDTA], 2.5 M LiCl, 4% (v/v) Triton X-100) (Medina-Acosta and Cross, 
1993). The suspension was incubated for 5 min at room temperature, before 
addition of 150 ýd of phenol-chloroform (1: 1, v/v). The sample was gently mixed 
by inversion and centrifuged at 13000 g for 5 min at 411C. The aqueous phase 
was transferred to a new microfuge tube and 0.1 volume of 3M sodium acetate 
and 2 volumes of 100% ethanol were added to precipitate the DNA. The mixture 
was incubated 5 min on ice before centrifugation at 13000 g for 5 min at room 
temperature. The DNA pellet was washed with 70% (v/v) ethanol, air dried briefly 
and resuspended in 50 pl of TE buffer (10 mM Tris/HCl pH 8.0,1 mM EDTA). 
After RNAse H (Sigma, Poole) treatment (1 mg/ml) for 1h at 370C, the sample 
was stored at 40C. 
2.2.2. Isolation of genomic DNA from Pichia pastoris 
A single colony was used to inoculated 10 ml of YPD medium (1 % (w/v) 
yeast extract, 2% (w/v) peptone, 2% (w/v) glucose) and grown overnight at 30*C, 
300 rpm shaking. Cells were pelleted at 1500 g for 10 min, washed with 10 ml of 
sterile water and resuspended in 2 ml of SCED solution (1 M sorbitol, 10 mM 
sodium citrate, pH 7.5,10 mM EDTA, 10 mM dithiothreitol [DTT]). To disrupt the 
yeast cell wall, 0.3 mg of lyticase (227 U/mg, Sigma, Poole) was added and 
incubated without shaking at 370C for 30 min. Then 2 ml of 1% (w/v) sodium 
dodecylsulfate (SIDS) were added, and the mixture was incubated for 5 min on 
ice, before addition of 1.5 ml of 5M potassium acetate, pH 8.9, and centrifugation 
at 10000 g for 10 min at 40C. Two volumes of ethanol were added to the 
supernatant and the mixture was incubated for 15 min at room temperature, 
before centrifugation at 10000 g for 20 min at 4*C. The pellet was resuspended in 
0.7 ml of TE buffer and 1 volume of phenol/chloroform (1: 1) was added, before 
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centrifugation at 10000 g for 10 min at 40C. One volume of chloroform was added 
to the aqueous phase, and centrifuged as before. Then 0.5 volume of 7.5 M 
ammonium acetate, pH 7.5, and 2 volumes of ethanol were added to the 
aqueous phase, and the mixture was incubated for 10 min on dry ice. The 
sample was centrifuged at 13000 g for 20 min at 40C, the pellet was washed with 
1 ml of 70% (vIv) ethanol, air dried and resuspended in 100 ltl of TE buffer. The 
DNA was stored at 411C. 
2.2.3. Isolation of total RNA 
2.2.3.1. E. tenella 
Total RNA from E. tenella sporulated oocysts; (H strain) was isolated using 
the method described in Johnston et al., 1998. The RNA obtained was further 
DNase treated for 30 min at 370C using 1 U/ýtg of RNA isolated (DNase 1, 
RNase-free, Sigma, Poole) before storage at -70"C. 
2.2.3.2. L. major 
1x 108 L. major promastigotes were pelleted at 1500 g for 10 min at 40C 
and resuspended in 1 ml of TRIzol@ reagent (GibcoBRL, Paisley). The 
suspension was incubated at room temperature for 5 min, 0.2 ml of chloroform 
was added and the suspension was incubated at room temperature for 2 min, 
before being centrifuged at 13000 g for 15 min at 40C. The upper aqueous phase 
was transferred to a fresh tube and 0.5 ml of isopropyl alcohol was added. The 
suspension was mixed vigorously and incubated at room temperature for 10 min, 
before being centrifuged at 12000 g for 10 min at 411C. The supernatant was 
discarded and 1 ml of 70% (v/v) ethanol was added to the RNA pellet, mixed and 
centrifuged at 7500 g for 5 min at 40C. This step was repeated, before air-drying 
of the pellet, and resuspension in 100 pl of double distilled water (ddH20). The 
RNA obtained was further Dnase-treated for 30 min at 370C using 1 U/Pg of RNA 
isolated (DNase 1, RNase-free, Sigma, Poole) before storage at -700C. All 
equipment and reagents were made RNAse-free by treatment with 
diethylpyrocarbonate (DEPC) at 0.01 % (v/v). 
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2.2.4. Polymerase chain reaction (PCR) 
PCR was used to amplify fragments of DNA situated between two known 
regions. All oligonucleotides (or primers) were synthesised by MWG-Biotech, 
Ebersberg, Germany. The two primers used in each amplification had sequences 
complementary to those flanking the region to amplify. The annealing 
temperature and elongation time for the PCR cycles where optimised for each 
reaction. A summary of all the primers used, their sequences and melting 
temperatures (Tm) is presented in Table 2.1. The machine used was the 
GeneAmp PCR system 2400 (Perkin Elmer, Beaconsfield). If Trn was high, the 
maximum temperature used for annealing was 650C. 
For reactions using the Taq polymerase system (Promega, Southampton), 
the final concentrations of the PCR reagents were IX Thermophilic DNA buffer 
(provided with the enzyme), 1.5 mM MgC12,0.5 mM dNTPs mix, 100 pmol of 
each primer, 50-100 ng of cDNA or gDNA, 1 unit of Taq, in a total volume of 50 
pl. PCR cycles were: 940C for 2 min, 1 cycle; 940C for 1 min, Trn-511C for 1 min, 
720C for 1x (number of kb of fragment to amplify) min, 30 cycles; 7211C for 7 min. 
For reactions using the High Fidelity PCR system (Roche, Lewes), the 
final concentrations of the PCR reagents were 1X PCR buffer 2 (with 1.5 mM 
MgCl2 final concentration, provided by the manufacturer), 0.5 mM dNTPs mix, 
100 pmol of each primer, 50-100 ng of cDNA or gDNA, 2.5 units of High Fidelity 
enzyme, in a total volume of 100 til. PCR cycles were: 800C for 5 min, 1 cycle; 
940C for 2 min, 1 cycle; 940C for 15 s, Trn-511C for 30 s, 720C for 1.5 x (number of 
kb of fragment to amplify) min, 30 cycles; 720C for 7 min. 
For reactions using the Long Template PCR system (Roche, Lewes), the 
final concentrations of the PCR reagents were 1X PCR buffer 2 (with 2.75 mM 
MgCl2 final concentration), 0.5 mM dNTPs mix, 100 pmol of each primer, 50-100 
ng of gDNA, 3.75 units of polymerase enzyme mix, in a total volume of 50 ýd. 
PCR cycles were: 9411C for 2 min, 1 cycle; 940C for 10 s, Tm-50C for 30 s, 6811C 
for Ix (number of kb of fragment to amplify) min, 25 cycles; 6811C for 7 min. 
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Table 2.1. Summary of the primers used, their sequences and Tm (melting 
temperature In OC). A, adenine; T, thymine; C, cytosine; G, guanine; 1, inosine. 
RACE Primers Sequence (5'-3') Tm 
CatBGSP AGCAGGTACGGCAGCAACTC 61.4 
CatBGSP1 TGCCGACGGAAGTGATCCCGC 65.7 
CatBGSP2 ACAACCTCATGGCCTCCTGG 61.4 
AAP GGCCACGCGTCGACTAGTACGGG[IGGGIIGGGIIG >75 
AUAP GGCCACGCGTCGACTAGTAC 54.7 
sl TAACGCTATATAAGTATCAGTTTC 65 
PPracel GGGTGGCGCTTCAGGCCCTCCG 71T 
PPrace2 GTGATGAACACGACGATGCCCG 64 
QCracel GCAGGCTCGAGTGGGGTGTTG 65.7 
QCrace2 GATGAGACAGAGCAGGATGCCCATG 66.3 
PCR Primers Sequence (5'-3') Tm 
pETNdeCatBfor GTTGTCATATGCCCTCCGATGAMGGG 66.6 
PETXhoCatBrev GCCTCTCGAG17ATAGGTCCTGCGCTGACGGCAG >75 
pETCatB31 or AAGGCATATGGGTACTTACCMCTTTCTATTCAG 66 
pETCatB31rev GCCTCTCGAGTCATAGGTCCTGCGCTGACG 73.6 
pGAPCatBfor ATCACAGCAGCCTCGAGAAGCGGGAGGCCGAAGCTATGCCCTCCGATG >75 
pGAPCatBrev GGTGCCGCGGTAGGTCCTGCGCTGACGG >75 
pGAPCatBre%19 .2 GGTGCCGCGGTTATAGGTCCTGCGCTGACGG >75 
pPIC9CatBfor GCGGCTACGTAATGCCCTCCGATGATTTGGG 72.1 
pPIC9CatBrev GGTGCCTAGGTTATAGGTCCTGCGCTGACGG 73.5 
TAOM GCAAATGGCATTCTGACATCC 57.9 
5'AOX1 GACTGGTTCCAATTGACAAGC 57.9 
a-factor TACTATTGCCAGCATTGCTGC 57.9 
LmPPfor CGCTTCATATGCTGCACTCCAAGGCG 68 
LmPPrev CGATGGTCGACTCACATGGTCATCAAAG 66.6 
OEforLmPP GGAGAGATATCATGGGCAGCCATCATCATCATC 71.9 
OErevLmPP GCTTGGATCCTCACATGGTCATCAAAGACAGCAGG 71.7 
Hind5lor CTGCTAAGCTTGCTGCTACTCGCCTACTTGCCTCG 74.2 
Sal5'rev AGTGGTCGACTTrAAGCGGTGCGGAACTGCGAGG 74.3 
SmaTfor GACCCCCGGGCGAAGACATCGTTCGCAGCGAAGG >75 
Bgl3'rev CTCCAGATCTTACCCGTTTCACGTTACACGGCTG 71.9 
CheckKOPPFor CTGCGGCAGCTTGTCCTGCTACTAGTG 69.5 
CheckKOPPRev GCACCGCTCCTTCGCTGCGAACG 69.6 
QCfor TCTGCATATGCTCACCTGGAAGAGCAACC 68.1 
QCrev TTGTAAAGCTTTCATTCMACGCGTCCAG 64 
QCshortfor GCGGCATATGCTGAAGCCGAGTCTGTCCGCG 74.8 
Mutagenesis Primers Sequence (51-31) Tm 
mutCatBXa or GGTGMGCGGAGATCGAGGGGCGTCTGGAAACTGACAAG >75 
mutCatBXarev CTTGTCAGMCCAGACGCCCCTCGATCTCCGCAAACACC >75 
mutCatBTEVfor CTGCCTGTGAAGGAGATTGTGGACTCGCAGCGGGTTCTGGAAACTG >75 
mutCatBTEVrev CAGTTTCCAGAACCCGCTGCGAGTCCACAATCTCCTTCACAGGCAG >75 
mutCPPfor CAGGGCGCTACCTGGCCAACTGCGCCCTC >75 
mutCPPrev GAGGGCGCAGTTGGCCAGGTAGCGCCCTG >75 
mutHPPfor GGCATCTTCGTTAGCGTTGTCGATCCG 68 
mutHPPrev CGGATCGACAACGCTAACGAAGATGCC 68 
mutEl PPfor GGCTCATCTGCGTTCAGGTGCAGGGCTGC 73.7 
mutEl PPrev GCAGCCCTGCACCTGAACGCAGATGAGCC 73.7 
mutE2PPfor CAGGGCTGCAACCAGCTCTTTTCTAGCG 695 
mutE2PPrev CGCTAGAAAAGAGCTGGTTGCAGCCCTG 69.5 
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2.2.5. Reverse transcription (RT)-PCR 
2.2.5.1. cDNA synthesis 
Five gg of total RNA from E. tenella sporozoites or L. major promastigotes 
were added to 10 pmol of oligo-dT primer in a total volume of 11 ýd. The mix was 
incubated for 10 min at 700C and placed on ice for 1 min. Four ýd of 5X First 
Strand buffer (provided with the enzyme), 2 [ti of 0.1 M DTT, 1 ýd of 10 mM dNTP 
mix and 40 units RNase OUT (GibcoBRL, Paisley) were added and the mix was 
equilibrated at 420C for 5 min before addition of 200 units of SUPERScript 11 
(GibcoBRL, Paisley). The sample was incubated for 50 min at 420C, then 15 min 
at 7011C to terminate the reaction. After incubation on ice for a few minutes, 2 
units of RNase H (Sigma, Poole) were added and the mix was incubated for 20 
min at 370C to eliminate the template RNA, before storage at -200C. As a 
negative control and to rule out that any subsequent PCR may produce 
fragments from amplification on remaining gDNA, a sample of RNA was treated 
as described above, except that the addition of SUPERScript 11 enzyme was 
omitted. This sample was used as template for negative control PCRs on cDNA. 
2.2.5.2. Rapid amplification of cDNA ends (RACE) 
2.2.5.2.1. Gene encoding a cathepsin B-like enzyme In E. tenelia 
To confirm the chosen start methionine, an experiment of rapid 
amplification of cDNA ends was performed at the 5' end (5' RACE system kit, 
GibcoBRL, Paisley). Total mRNA from sporozoites was transcribed into single- 
stranded cDNA using SUPERScript 11 reverse transcriptase and the specific 
primer CatBGSP. Excess dNTPs and primer were removed from cDNA and a 
homopolymeric tail of dCs was added to the end of the single-stranded cDNA 
using terminal deoxynucleotidyl transferase, following the manufacturer's 
instructions. The 5' end was then amplified from dC-tailed cDNA using the 
abridged anchor primer (AAP) and the specific nested primer CatBGSP1 with the 
Taq polymerase, followed by a secondary amplification using the abridged 
universal anchor primer (AUAP) and the catBGSP2 primer with the Taq 
polymerase. 
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2.2.5.2.2. Gene encoding a pyroglutamyl peptidase I-like enzyme in L. major 
PCR on total clDNA was performed using a primer with a sequence 
complementary to the splice leader (SL primer) and the PPracel primer, with the 
Taq polymerase. PCR product was diluted 1: 50 (v/v) in ddH20 and 2 PI were 
used as a template for a semi-nested PCR using the SL and the PPrace2 
primers, with the Taq polymerase. 
2.2.5.2.3. Gene encoding a glutaminyl cyclase-like enzyme in L. major 
The same method as in 2.2.5.2.2. was used, with the SL and QCracel 
primers for the first PCR, and the SL and QCrace2 primers for the second PCR. 
2.2.6. Site-directed mutagenesis 
Site-directed mutagenesis was used to introduce site-specific mutation in 
the gene encoding the cathepsin B-like enzyme of E. tenella in order to introduce 
Factor Xa (with the primers mutCatBXafor and mutCatBXarev, 7 point-mutations 
required) or Tabacco etch virus (TEV) protease Nla (with the primers 
mutCatBTEVfor and mutCatBTEVrev, 12 point-mutations required) cutting sites 
into the translated protein. The pET28a(+) construct with the sequence for the N- 
terminal His-tagged E. tenella cathepsin B was used as a template. 
The method was also used for generating active site mutants of the 
pyroglutamyl peptidase I (PPI) of L. major. Based on the work of Le Saux and co- 
workers (Le Saux et aL, 1996), the choice was made to mutate cysteine-210 to 
alanine (using the primers mutCPPfor and mutCPPrev), histidine-234 to serine 
(using the primers mutHPPfor and mutHPPrev), glutamic acid-101 to glutamine 
(using the primers mutElPPfor and mutEIPPrev) and glutamic acid-107 to 
glutamine (using the primers mutE2PPfor and mutE2PPrev) (L. major PPI 
numbering). The most likely glutamic acid residue to be part of the catalytic triad 
was Glu-101, but the very close Glu-107 was mutated too. One or 2 point- 
mutations were required, and the pET28a(+) construct with the sequence for the 
N-terminal His-tagged L. major PPI was used as a template. 
The QuickChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, 
CA, US) was used. The reactions contained 1X reaction buffer (provided with the 
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kit), 100 ng of plasmid DNA (expression vector carrying the gene to mutate), 2 
liM of each forward and reverse primer, I ýtl of dNTP mix, 2.5 units of Pfu Turbo 
DNA polymerase. Cycles were: 951C for 30 s, I cycle; 9511C for 30 s, 5511C for 1 
min, 680C for 7 min, 18 cycles. Then 10 units of Dpnl enzyme (provided with the 
kit) were added and incubated at 37*C for 2 h, to remove any residual methylated 
template. Fifty ýtl of E. coli XL-1 Blue Supercompetent cells (provided with the kit) 
were transformed with 1 ltl of PCR using the heat shock method (see 2.2.7.5.1. ) 
and 250 ltl were plated on Luria-Bertani (LB) agar (1 % tryptone (w/v), 0.5% yeast 
extract (w/v), 1% NaCl (w/v), 20% (w/v) agar) plates. The plates were incubated 
overnight at 370C. Plasmid was extracted from colonies, sequenced and re- 
transformed in E. coli BL21 (DE3) for expression. 
2.2.7. DNA fragment cloning 
Cloning of DNA fragments was done using 2 different strategies. The first 
one involved digestion by restriction enzymes of both DNA insert and vector 
recipient prior to ligation of the 2 fragments together. The second involved 
cloning of PCR products by amplification with the Taq polymerase. Taq 
polymerase adds a single A-nucleotide to the 3' ends of the PCR product, which 
can then be inserted in the pGEM-T Easy vector (Promega, Southampton), 
containing a 3' single T-nucleotide overhang. 
2.2.7.1. Digestion of DNA with restriction enzymes 
Typically, restriction digests used 3 units of restriction enzyme in a total 
volume of 20 pl per 500 ng of DNA to digest, and reactions contained 1X buffer 
(final concentration). The buffer used in each case was provided with the enzyme 
by the manufacturer (Promega, Southampton). For multiple digests, compatible 
buffer systems were chosen. The reactions were incubated 1-4 h at 370C or 2511C 
(depending on the enzyme). 
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2.2.7.2. Isolation of DNA fragments 
PCR products or DNA fragments obtained by restriction digests were 
separated on 1% (w/v) agarose gels containing 0.5 ýtg/ml of ethidiurn bromide, in 
0.5X TBE (45 mM Tris-borate, I mM EDTA). The DNA ladder 1 kb Plus 
(Promega, Southampton) was used. DNA was visualized using a transilluminator 
(UVP Laboratory Products, Cambridge) at 312 nm. Fragments of DNA were 
purified from the gel using the QlAquick gel extraction kit (Qiagen, Crawley). 
2.2.7.3. Ligations, 
Ligations of fragments into the pGEM-T Easy vector (Promega, 
Southampton) used 50 ng of vector, 150 ng of insert, 1X buffer and 3 units of T4 
DNA ligase. The reactions were incubated 16 h at 41C. A positive control (using 
the control insert DNA) and a background control (vector without insert DNA) 
were used. 
Ligations of gel-purified digested DNA fragments and expression vector, 
or L. major transfection vectors, used 500 ng of insert, 250 ng of vector, 1X buffer 
and 3U of T4 DNA ligase (Promega, Southampton). Reactions were incubated 
for 16 h at 160C. The only E. coli expression vector used was the pET28a(+) 
vector (Novagen, Nottingham) and L. major transfection vectors were derivatives 
of the pXG vector, developed by Beverley and co-workers (Ha et al., 1996). 
2.2.7.4. Competent cells 
2.2.7.4.1. E. coli 
E. coli DH5cc competent cells were from Promega, Southampton. 
BL21(DE3), JM109(DE3) and HMS174(DE3) cells were made competent the day 
of use using the calcium chloride method described in Sambrook et al., 1989. A 
single colony was picked from LB agar plate and grown overnight at 370C in 5 ml 
of LB broth. This culture was used to inoculate 100 ml of LB, and the cells were 
grown at 370C until the cell density reached an optical density (OD) at 600 nm of 
0.4-0.6. Cells were then pelleted at 2500 g for 10 min at 411C, resuspended in 10 
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ml of ice-cold sterile 0.1 M CaC12, pelleted again as before and resuspended in 2 
ml ice-cold 0.1 M CaC12. Cells were stored on ice until use. 
2.2.7.4.2. Pichia pastoris 
P. pastoris X-33 and KM71 cells were made electro-competent the day of 
use using the sorbitol method described in the Invitrogen (Paisley) "Pichia 
Expression Kit" manual (Version F, catalog no. K1710-01), with some 
modifications. A single colony was used to inoculate 5 ml of YPD medium and 
grown overnight at 3011C. One ml of this culture was used to inoculate 500 ml of 
YPD and grown to OD600 Of 1.3-1.5. Cells were centrifuged at 1500 g for 5 min at 
40C, resuspended in 100 ml YPD medium, 20 mM N-2-hydroxyethylpiperazine- 
N'-2-ethanesulphonic acid (HEPES) pH 8, and 2.5 ml of 1M DTT was added. 
The mixture was incubated at 300C for 15 min without shaking. The suspension 
was brought to 500 ml with ice-cold sterile water. The cells were sedimented as 
before, resuspended in 250 ml ice-cold sterile water, sedimented again as 
before, resuspended in 20 ml ice-cold 1M sorbitol, sedimented as before and 
resuspended in 1 ml of ice-cold IM sorbitol. The cells were stored at 4"C until 
use. 
2.2.7.5. Transformation of competent cells 
2.2.7.5.1. E. coff 
E coli cells were transformed with the ligation products using a heat 
shock method (Sambrook et aL, 1989). Ten ng of DNA was incubated with 200 gl 
of competent cell suspension on ice for 20 min, heat shocked for 50 s at 4211C, 
and incubated on ice again for 2 min. One ml of LB was added and the mixture 
was incubated at 370C for 1h before plating of 100 gl on a. LB agar plate 
containing the appropriate antibiotic for selection. In the case of pGEM-T Easy 
ligation product transformation in DH5a, a white/blue selection was used, by 
adding isopropylthio-P-D-galactoside (IPTG) (40 gg/ml) and 5-bromo-4-chloro-3- 
indolyl-P-D-galactoside (X-gal) (40 ;. tg/ml). White colonies correspond to positive 
clones containing a DNA insert in the P-galactosidase gene, which leads to the 
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expression of an inactive P-galactosidase not able to act on the chromogenic 
substrate X-gal. 
2.2.7.5.2. Pichia pastoris 
pPIC9 and plasmid derivatives were linearized with Sacl, and pGAPZaA 
and plasmid derivatives were linearized with Awil. Linearized DNA was 
transformed by electroporation as described in the Invitrogen (Paisley) "Pichia 
Expression Kit" manual (Version F, catalog no. K1710-01) using the Bio-Rad 
(Hemel Hempstead) GenePulser at a charging voltage of 1500 V, capacitance of 
25 ýF and resistance of 200 Q. Eighty gl of competent cell suspension were 
incubated with 10 jig of linearized DNA in an ice-cold 0.2 cm electroporation 
cuvette (BioRad, Hemel Hempstead) for 5 min on ice. Reactions were pulsed 
once and 1 ml of ice-cold 1M sorbitol was immediately added to the reaction. 
The reaction was transferred to a new tube and either 300 gi were directly plated 
on RBD plates (1 M sorbitol, 2% (w/v) glucose, 1.34% (w/v) Yeast Nitrogen Base 
with Ammonium Sulfate without amino acids [GibcoBRL, Paisley], 4x 10-5% (W/V) 
biotin, 0.005% (w/v) amino acids (L-glutamic acid, L-methionine, L-lysine, L- 
leucine, L-isoleucine [Sigma, Poole]), 20% (w/v) agar), in the case of 
transformation of the KM71 cells with the pPIC9 and plasmid derivatives, or the 
reaction was incubated for 2h at 3011C before plating of 300 ýtl on YPB plates 
containing 100 [ig/ml of Zeocin, in case of transformation of the X-33 cells with 
the pGAPZaA and plasmid derivatives. Plates were incubated at 30*C for 3-4 
days. 
2.2.7.6. Plasmid DNA purification 
The isolation of plasmid DNA from E. coli was performed using the 
QlAprep Miniprep kit (Qiagen, Crawley). The presence of the correct insert was 
checked by restriction digests, which were separated by agarose gel 
electrophoresis. 
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2.2.7.7. DNA sequencing 
Plasmid DNA was sent to GRI Genomics (Braintree, UK) for sequencing. 
Sequences were analysed using the Vector NTI program (Informax, Bethesda, 
MA, US). 
2.2.8. L. major prornastigotes transfection 
2.2.8.1. Strategy for L. major pyroglutarnyl peptidase I (PPI) gene cloning 
for over-expression and knockout 
For over-expression of the native and cysteine-210-mutated PPIs in L. 
major, the vector pGL102 was chosen (derivative of pXG vector [Cruz et al., 
1991a]). The restriction sites Smal (5' end) and BamHI (3' end) were chosen on 
the vector. As another Smal site exists in the gene, the engineered site was the 
one for EcoRV, cohesive end, which will religate into the Smal site on the vector 
after digestion. The restriction sites were added to the ends of the fragment by 
PCR on -100 ng of either the pETLmPP plasmid, or the pET28a(+) construct 
with the sequence for the cysteine-210-mutated N-terminal His-tagged L. major 
PPI, using the primers OEforLmPP and OErevLmPP. 
The 834 bp excised bands were gel-purified, digested with EcoRV and 
BamHl, re-gel purified and cloned into pGL102 previously digested with Smal 
and BamHl to give the final plasmids pGL102LmPPI and pGL102LmPPI*. The 
sequence was confirmed using the PCR primers for sequencing. 
For gene knockout, the vector pGL345 was chosen (derivative of pXG 
vector, hygromycin selection). Flanks at the 5' (- 500 bp) and 3' (- 1 kb) ends of 
the PPI gene were selected in the L. major database. Restriction sites for Hind I 11 
(5' end) and San (3' end), or Smal (5' end) and Bg1l 1 (3' end) were, respectively, 
introduced by PCR at the ends of the 5' flank and the 3' flank. PCR used the 
primers Hind6for and Sal5'rev for the 5' flank, and the primers SmaVor and 
Bgl3'rev for the 3' flank. 
The excised 5' flank band was gel-purified, digested with HindIll and San, 
re-purified and cloned into pGL345 previously digested with the same enzymes. 
The excised 3'flank band was gel-purified, digested with Smal and Bglll, re-gel 
purified and sub-cloned in the pGL345 plasmid containing the 5'flank previously 
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digested with the same enzymes to give the pGLLmPPKO. The hygromycin 
selection marker was replaced by the blasticidin resistance marker (cut from the 
pGL842 vector) on the plasmid by digestion with Spel and BamHl. 
2.2.8.2. DNA preparation 
In the case of episomal constructs for over-expression, 20 gg of circular 
plasmid was ethanol-precipitated (Sambrook et al., 1989), resuspended in 20 pl 
of sterile water, and stored at -200C. 
In the case of integrative constructs for gene replacement, 40 pg of 
plasmid was linearised by digestion with Hindill and BgIll. The digested DNA 
fragments were separated on ethidiurn bromide-free agarose gel, fragments were 
revealed by gel immersion in a 6.5 x 10-4% (w/v) methylene blue solution, gel 
extracted with the QlAquick gel extraction kit (Qiagen, Crawley), ethanol 
precipitated (Sambrook et aL, 1989), resuspended in 20 [d of sterile water, and 
stored at -2011C. 
2.2.8.3. Transfection 
L. major promastigotes from log-phase cultures at a density of about 0.5- 
1X 107 cells/ml were preferentially used. About 108 cells were used per 
transfection. The cells were pelleted at 1300 g for 10 min at 40C, washed twice in 
sterile ice-cold electroporation buffer (120 mM KCI, 0.15 mM CaC12,10 MM 
K2HP04,25 MM HEPES, 2 mM EDTA, and 5 mM MgC12, pH 7.6), and 
resuspended in electroporation buffer to a concentration of about 2x 108 cells/mi. 
Cells (0.5 ml per transfection) were put in contact with the DNA to transfect (20 
lag) and incubated on ice for 15 min. A no DNA control, to check efficiency of 
drug selection, and empty vector control to compare phenotypes (for episomal 
expression only), were always included. The mixture was placed into an ice-cold 
4 mm Gene Pulse cuvette (BioRad, Hemel Hempstead) and pulsed twice at 25 
gF, 1500 V, (3.75 kV/cm) on the BioRad Gene Pulser II apparatus. At least 10 s 
separated the 2 pulses. The cells were then incubated on ice for 20 min before 
being transferred to 5 ml HOMEM medium with 10% HIFCS and incubated at 
250C overnight. The next day, the cells were placed in medium containing the 
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appropriate selection drug (depending on the construct transfected). All selection 
drugs were from Calbiochem, Nottingham. Hygromycin B was used at a final 
concentration of 50 gg/ml; blasticidin S hydrochloride at 15 gg/ml; neomycin 
(G418) at 50 gg/ml; and puromycin at 40 gg/ml. Clonal dilution (from 1: 2 (vIv) to 
1: 64 (v/v), serial dilution) was performed on transfected cells in 96-well plates, in 
order to isolate clonal populations. Genomic DNA was extracted from drug- 
resistant clones and correct integration was confirmed using the CheckKOPPFor 
and CheckKOPPRev primers. 
2.2.9. Southern-blot analysis 
2.2.9.1. Southern blotting of DNA fragments 
Southern blotting allows detection of specific sequences within the 
genomic DNA. Between 2 and 10 ýtg of gDNA were digested to completion using 
specific restriction enzymes, and the DNA fragments were separated on a 1% 
(w/v) agarose gel in 1x TBE buffer. The DNA was blotted according to the 
Southern method (Sambrook et aL, 1989). After electrophoresis for 8h at 50 V, 
the gel was incubated in 125 mM HCI for 30 min under gentle agitation to allow 
the depurination of the DNA. The gel was then incubated for 30 min in 1.5 M 
NaCl, 0.5 M NaOH (for DNA denaturation), and 30 min in 1M Tris pH 7.5,1.5 M 
NaCl (for neutralisation). Each wash was interspersed by a 10 min wash in 
ddH20. The DNA was transferred by capillarity onto a Hybond-N+ nylon 
membrane (Amersham) in 20X SSC (300 mM tri-sodium citrate, 3M NaCl, pH 7) 
using standard methods (Sambrook et aL, 1989). The DNA was then fixed onto 
the membrane by ultraviolet (UV) cross-linking (Spectrolinker XL-1000 UV linker, 
Spectronics Corporation, Westbury, NY, US). 
2.2.9.2. Southern hybridisation with nucleic acid probes 
Nylon membrane was pre-incubated at 6511C for 4h in 20 ml of Church- 
Gilbert hybridisation solution (340 mM Na2HP04,158 mM NaH2PO4,240 mM 
SDS, 1 mM EDTA), supplemented with 0.2 mg/ml of denatured salmon sperm 
DNA (GibcoBRL, Paisley). Thirty ng of nucleic acid probe was prepared from 
agarose gel-purified restriction endonuclease fragments using the Prime-It 11 
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Random Primer kit (Stratagene, La Jolla, CA, US) according to the 
manufacturer's instruction. Labeled A nucleotides were introduced using 50 ýLCi 
of a 32 dATP (Perkin Elmer, Beaconsfield) per probe, and the dATP buffer from the 
kit. Probe was purified on a Microspin S-200 HR column (Amersham, Chalfont 
St. Giles) and boiled for 5 min before incubation on ice for 2 min. The membrane 
was hybridised by incubation with the labeled probe in 20 ml of Church-Gilbert 
solution at 650C overnight. Membranes were then washed under high stringency 
2 times for 5 min in 2X SSC, 0.1% (w/v) SDS, followed by 15 min in 1X SSC, 
0.1% SIDS, and 2 times for 10 min in O. 1X SSC, 0.1% SIDS. All wash solutions 
were pre-warmed at 6511C. Membranes were sealed in polythene and exposed to 
X-ray film (Konica Medical Film) for I to 10 days. Hybridisation signals were 
detected with a film processor (X-Ograph imaging system Compact X4). 
2.3. Biochemical methods 
2.3.1. Recombinant protein expression 
2.3.1.1. In E. coli 
For all expression experiments in E. coli the pET28a(+) vector (Invitrogen, 
Pailsey) was used. 
For expression in Ecoli of the pro-mature cathepsin B of E tenella with a 
N-terminal His-tag, the cloning was performed between the Ndel site and the 
Xhol site. The recognition sequences for these restriction enzymes were firstly 
added to the sequence by PCR, with the primers pETNdeCatBfor and 
pETXhoCatBrev. The full-length product was cloned into pGEMT-easy and the 
resulting plasmid was cut with Ndel and EcoRl, and HindIll and Xhol. The 
NdellEcoRl band was gel purified and subcloned into pET28a(+). The resulting 
plasmid was cut with HindIll and Xhol and the HindlillXhol band was inserted. 
This construct was transformed in E. coli strains BL21(DE3), JM109(DE3), or 
HMS174(DE3) competent cells for expression. Cells were grown to an OD60onm Of 
0.4 to 0.6 in LB containing 50 pg/ml kanamycin (Sigma, Poole) before being 
induced for 4h with 0.5-1.5 mM I PTG at 25 or 37*C. 
For expression in E. coli of the truncated pro-mature cathepsin B of E. 
tenella with a N-terminal His-tag, the cloning was performed between the Ndel 
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and the Xhol sites. The procedure was the same as above. The primers used 
were pETCatB31for and pETCatB31rev. The protein was expressed in the 
BL21 (DE3) cells, by induction 4h with 1 mM IPTG at 37"C. 
For expression in Ecoli of the pro-mature cathepsin B of E tenella with a 
N-terminal His-tag and carrying the mutation for the Factor Xa and the TEV 
protease cleavage sites in the protein, proteins were expressed in the BL21 (DE3) 
cells, by induction 4h with 1 mM IPTG at 370C. 
For expression in E. coli of the native pyroglutamyl peptidase I of L. major 
with a N-terminal His-tag, the cloning was performed between the Ndel and the 
SO sites. The procedure was the same as before. The primers used were 
LmPPfor and LmPPrev. The protein was expressed in the BL21(DE3) cells, by 
induction 5h with 1 mM IPTG at 20*C. 
For expression in E. coli of the active site mutated pyroglutamyl peptidase 
I of L. major with a N-terminal His-tag, proteins were expressed in the BL21 (DE3) 
cells, by induction 5h with 1 mM IPTG at 20"C. 
For expression in E. coli of the native and truncated glutarninyl cyclase 
(QC) of L. major with a N-terminal His-tag, the cloning was performed between 
the Ndel and the HindIll sites. The procedure was the same as before. The 
primers used for cloning of the full length QC were QCfor and QCrev. The 
primers used for cloning of the truncated QC were QCshortfor and QCrev The 
protein was expressed in the BL21(DE3) cells, by induction 4h with 1 mM IPTG 
at 15,25, or 37"C. 
2.3.1.2. In Pichia pastods 
2.3.1.2.1. Constitutive system 
The pGAPZaA vector (Invitrogen, Paisley) was chosen for constitutive 
expression. Constructs were designed for constitutive expression of the pro- 
mature cathepsin B with a C-terminal His-tag (using the primers pGAPCatBfor 
and pGAPCatBrev), and the pro-mature cathepsin B without a His-tag (using the 
primers pGAPCatBfor and pGAPCatBrev2), with subsequent release into the 
medium of the culture. The DNA fragments were cloned between the Xhol and 
Sacil sites. The final constructs and control empty vector were linearised with 
Avrll prior to transfection into the host Pichia pastoris cells X-33. Cells were 
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spread on plates selective for Zeocin resistance (100 jig/ml) and incubated 3 to 4 
days at 300C until colonies developed, as described in the Pichia expression kit 
manual (Invitrogen, Paisley). Insertions of the fragments were verified by PCR on 
genomic DNA extracted from positive clones as described in the Pichia 
expression kit manual, using the couples of PCR primers a-factor and TAOX1. 
One positive colony for each of the constructs was selected and tested for 
expression of the target protein as described in the manufacturer's manual (final 
volume of 50 ml of YPD medium). One ml aliquots were taken a regular time 
intervals, cells were separated from the supernatant of culture by centrifugation 
and samples of supernatant were used for analysis using gelatin SDS-PAGE, the 
azocasein assay, and either directly on Coomassie blue-stained SDS-PAGE gels 
and westem-blots, or after tricholoacetic acid (TCA) precipitation on Coomassie 
blue-stained SDS-PAGE gels and western-blots. The cells were resuspended in 
1 ml of 50 mM Tris pH 8.0 and analysed on Commassie blue-stained SDS-PAGE 
gels. Once the optimum time of growth had been determined, the cells were 
directly grown to that time point and harvested by centrifugation at 3000 g for 5 
min, and the supernatant and cells were stored at -2011C until further treatment 
and analysis. 
2.3.1.2.2. Inducible system 
A construct was designed for inducible expression of the pro-mature 
enzyme cathepsin B-like enzyme of E. tenella, with subsequent release into the 
culture medium. The pPIC9 vector (Invitrogen, Paisley) was used, and the DNA 
fragment was cloned between the SnaBl and Awil sites. The primers used for 
PCR were pPlC9CatBfor and pPlC9CatBrev. The final construct pPlC9catB and 
control empty vector were linearised with Sacl prior to transfection in the host 
Pichia pastoris cells KM71. As the KM71 strain contains a mutation in the 
endogenous AOXI gene (encoding the alcohol oxidase enzyme), only His' Muts 
phenotypes will be generated by successful recombination (His+ refers to 
histidine prototrophy, and Muts refers to "Methanol utilization slow" caused by the 
loss of the alcohol oxidase activity encoded by the AOX1 gene). Cells were 
spread on plates selective for histidine prototrophy (His+) and incubated 3 to 4 
days at 30"C until colonies developed, as described in the Pichla expression kit 
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manual (Invitrogen, Paisley). Insertions of the fragments were verified by PCR on 
genomic DNA extracted from positive clones as described in the Pichia 
expression kit manual, using the couples of PCR primers a-factor and TAOX1, or 
5'AOX1 and TAOX1. 
Positive colonies for each of the transfection were selected and tested for 
expression of the cathepsin B as described in the manufacturers manual. One 
positive colony for each of the transfection was selected, and used to inoculate 
100 ml of BMGY medium (1% (w/v) yeast extract, 2% (w/v) peptone, 100 mM 
potassium phosphate pH 6.0,1.34% (w/v) YNB, 4x 10-5% biotin (w/v), I% (v/v) 
glycerol). The culture was grown at 3011C shaking at 300 rpm, in a11 flask, until 
the culture reached an OD600 of 5-10 (24-48 h). The cells were then harvested by 
centrifugation at 3000 g for 5 min and resuspended in 20 ml of BMMY medium 
(1% (w/v) yeast extract, 2% (w/v) peptone, 100 mM potassium phosphate pH 6, 
1.34% (w/v) YNB, 4x 10-5 % biotin (w/v), 0.5% (v/v) methanol), placed in a 250 ml 
flask and the culture was grown again at 3011C shaking at 300 rpm. The cells 
were induced by addition of methanol to 0.5% (v/v, final concentration) every 24 
h, 0.5 ml aliquots were taken a regular time intervals and cells were separated 
from the supernatant of culture by centrifugation and samples of supernatant 
were analysed using gelatin SDS-PAGE, the azocasein assay, and either directly 
on Coomassie blue-stained SDS-PAGE gels, or after TCA precipitation on 
Coomassie blue-stained SDS-PAGE gels and western-blots. Once the optimum 
time of growth had been determined, cells were directly grown to that time point 
and harvested by centrifugation at 3000 g for 5 min, and the supernatant and 
cells were stored at -200C until further treatment and analysis. 
2.3.2. Protein defolding, refolding and activation procedures 
A summary of the conditions tested for unfolding, refolding, purification 
and activation of various preparations of recombinant cathepsin B of E. tenella is 
presented in Table 2.2. 
The N i-aga rose-pu rifled soluble pro-mature cathepsin B expressed in E. 
coli BL21 (DE3) or in HMS1 74(DE3) was treated as described in Sanderson et a/., 
2000, for unfolding and re-folding attempts of the enzyme. 
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The Ni-agarose-pu rifled soluble pro-mature cathepsin B expressed in E. 
coli BL21(DE3) was treated as described in Hellberg et a/., 2002, with a few 
modifications. The sample was diluted 1: 10 (v/v) in 8M urea or 6M guanidium, 
100 mM NaH2PO4,10 mM Tris/HCl pH 6.3 to unfold the protein. A fraction of this 
sample was then diluted dropwise 1: 100 (v/v) in a refolding buffer composed of 
50 mM Tris/HCl pH 6.8,300 mM NaCl, 5% glycerol (v/v), 0.1 mM EDTA, 0.5 mM 
oxidised glutathione, 3 mM reduced glutathione and the mixture was incubated 
overnight at 40C. Another fraction of the sample was directly dialysed against 100 
times its volume of 50 mM Tris pH 6.8 overnight at 40C. The diluted sample in 
refolding buffer was concentrated with a Centricon device through YM-10 
membrane (Amicon, Watford) from 11 to 3 ml to a final concentration of 100 
[tg/ml and dialysed over night against 500 ml of 50 mM Tris/HCI, pH 6.8 at 40C. 
The 2 samples treated separately with or without refolding by dilution were 
diluted 1: 1 (v/v) in 100 mM Tris/HCI, pH 8.8,0.08% SDS, 20 mM DTT at 37,16. 
Aliquots were taken at various time from 0 min to 1h and subsequently analysed. 
The inclusion bodies of pro-mature cathepsin B expressed in E. coli 
HMS174(DE3) were treated as described in Sanderson et al., 2000, and Sijwali 
et a/., 2001. 
Samples of Nickel-agarose purified truncated cathepsin B were diluted 
1: 1 (v/v) in 0.1 M sodium acetate buffer, pH 5.0 or 0.1 M Tris/HCl buffer, pH 8.0 
supplemented with 20 mM DTT and incubated at 37*C for 20 min, with or without 
the inhibitor E64 (final concentration of 300 ýtM). 
A sample of purified truncated cathepsin B was diluted 1: 4 (v/v) to a final 
concentration of about 100 pg/ml in 0.1 M Tris/HCl pH 8.0,8 M urea (total volume 
of 500 pl) and incubated 1h at 370C, to unfold the protein without rupturing the 
disulfide bonds. The sample was then dialysed for 2h at 40C against 500 ml of 
50 mM Tris/HCl, pH 8.0 and stored at -2011C for later analysis. 
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Table 2.2. Summary of the conditions tested for unfolding, refolding, purification and 
activation of various preparations of recombinant cathepsin B of E. tenella. BL21 and 
HMS 174 are E. coli strains used for expression. 
Sample Expressed in Expressed in HMS174 
Step Expressed in HMS174 at at 37"C/ Solubillsation 
o of f protei BL21/soluble 25"C/ Soluble of Inclusion bodies 
preparation fraction 
Unfolding/ 6M guanidium 
Sanderson et al., 2000 
solubilisation of 8M urea 
X Sijwali et al., 2001 
inclusion bodies 10 rnM DTT 
Dilution, pH 8.0, 
Refolding EDTA, DTT, X pH 8.0 GSSG/GSH, 40C 
12 h 
Purification of 
refolded protein 
Nickel-agarose X Anion-exchange 
370C 
3711C 371C pH 4.0 to 7.0 
Activation pH 4.0 to 7.0 pH 4.0 to 7.0 protein concentration 
(combinations 5 mM EDTA 5 mM EDTA from 50 to 500 pg/ml 
of the listed 10 mM DTT 10 mM DTT 5 mM EDTA 
components) 0.9 M NaCl 0.9 M NaCl 10 rnM DTT 
During 1 to 24 h During 1 to 6h 0.9 M NaCl 
During 1 to 7h 
2.3.3. Protein processing 
2.3.3.1. Non-specific 
The idea behind using non-specific peptidases in an attempt to cleave 
the pro-domain from the mature domain of the cathepsin B of E. tenella was that 
domains within a protein are tightly folded units (Richardson, 1981) and a 
correctly folded protein will have its loops and hinges most accessible to 
proteolytic cleavage. Using mild conditions, i. e. low enzyme/substrate (protein 
that requires cleavage) ratios and short incubation times might make it possible 
to separate domains by limiting the number of bonds cleaved and hopefully 
limiting processing to accessible bonds located in these loops between domains. 
Three commercially available peptidases were chosen: trypsin-TPCK from 
bovine pancreas (ref. T1426,12700 U/mg), cc-chymotrypsin-TLCK from bovine 
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pancreas (ref. C3142,57 U/mg) and subtilisin A from Bacillus ficheniformis (ref. 
P5380,10.6 U/mg) (all Sigma, Poole) for their broad substrate specificity and 
ease of use. A stock solution of each peptidase at a concentration of 1 mg1ml 
was prepared in 50 mM Tds/HCI, pH 8.0. The N i-agarose-pu rifled soluble pro- 
mature cathepsin B expressed in E. - coli BL21(DE3) was used as the substrate. 
To start with, enzyme/substrate ratios were fixed at 1: 50 and 1: 500 (w/w). 
Reactions were in 50 mM Tris/HCI, pH 8.0 and samples were incubated at 3711C 
for 2 min to 1 h. The reactions were terminated by dilution in an equal volume of 
2x SDS-PAGE loading buffer (0.1 M Tris/HCl pH 6.8,15% (v/v) glycerol, 3% (w/v) 
SIDS, 0.8% (v/v) P-mercaptoethanol, 0.0001% (w/v) Pyronin Y). Then ratios were 
adjusted if necessary (where there was too extensive cleavage) down to 1: 5000 
(W/W). 
2.3.3.2. Specific 
I 
A method to achieve specific cleavage at a particular location is to use a 
specific peptidase that will only cut bonds in this location. As no obvious specific 
cutting site could be detected within the region thought to make the link between 
pro- and mature domains of the cathepsin B of E. tenella, it was decided to 
engineer the specific cleavage sites for the Factor Xa and the TEV protease at 
that junction. 
Biotinylated Factor Xa from the Factor Xa Cleavage Capture Kit 
(Novagen, Nottingham), and recombinant TEV protease (Invitrogen, Paisley) 
were used. 
Digestions with Factor Xa used 10 to 50 [ig of nickel-agarose purified 
cathepsin B of E. tenella produced in E. coli and carrying the Factor Xa cleavage 
site, 5 ýtl of 1OX cleavage buffer, 1,0.2, or 0.01 U of Factor Xa in a final volume 
of 50 jd at 20 *C for various lengths of incubation. Non-specific cleavage on the 
purified pro-mature cathepsin B of E. tenella produced in E. coli not carrying the 
mutations for the Factor Xa cleavage site was also tested. 
Twenty jig of nickel-agarose purified cathepsin B of E. tenella produced 
in E coli and carrying the TEV cleavage site was incubated with 7.5 jil 20X 
cleavage buffer, 1.5 gi 0.1 M DTT, 10 U TEV in a final volume of 150 gl at 2011C 
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for various lengths of incubation. Non-specific cleavage on the purified pro- 
mature cathepsin B of E. tenella produced in E. coli not carrying the mutations for 
the TEV cleavage site was also tested. 
2.3.4. Determination of protein concentrations 
Protein concentrations were either determined spectrophotometrically at 
280 nm (provided the extinction coefficient P, of the protein was known), or using 
the BioRad protein assay, based on the Bradford method (Bradford, 1976) and 
using bovine serum albumin (BSA) as the protein standard. 
2.3.5. Protein precipitation 
To reduce quickly the volume of protein solution to analyse, one of the 
methods used was trichloroacetic acid (TCA) precipitation. This was used in 
particular prior to SDS-PAGE analysis. The disadvantage is that the protein will 
be irreversibly denatured. TCA was added to the protein sample at 10% (v/v) final 
concentration, and the mixture was incubated overnight at -200C. The sample 
was then centrifuged at 13000 g for 20 min at 40C, the pellet was washed in 1 ml 
100% ice-cold acetone, and resuspended usually in 10-30 pl 2x SDS-PAGE 
loading buffer (0.1 M Tris/HCl pH 6.8,15% (v/v) glycerol, 3% (w/v) SDS, 0.8% 
(v/v) P-mercaptoethanol, 0.0001 % (w/v) Pyronin Y). 
2.3.6. Protein concentration 
Devices used for protein concentration were YM-1 0 Centricon Centrifugal 
devices (Amicon, Watford), following the manufacturers instructions. 
2.3.7. Protein purification 
2.3.7.1. Nickel-agarose chromatography 
Soluble, or solubilised, recombinant N-terminal His-tagged cathepsin 13- 
like proteins of E tenella produced in E coli, as well as soluble recombinant N- 
terminal His-tagged PPI and PPI active site mutants of L. major produced in E. 
coli, were purified by gravity on a3 ml nickel-agarose column (Qiagen, Crawley) 
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following the manufacturer's instructions. The column was pre-equilibrated with 5 
volumes of 10 mM Tris/HCl, pH 8.0, the sample was applied, and the column was 
washed with 5 volumes of the same buffer, followed by a washing with 5 volumes 
of 10 mM Tris/HCl, pH 8.0, with 30 mM imidazole. Protein was eluted in 3 times 1 
ml of 10 mM Tris/HCI, pH 8.0, with 500 mM imidazole. Eluted fractions were 
dialysed against various buffers (see 2.3.2. for the cathepsin B-like proteins of E. 
tenella), or against 100 volumes of 50 mM HEPES pH 8.0,1 mM EDTA, 2 mM 
Tris(2-carboxyethyl)phosphorine hydrochloride (TCEP, Sigma, Poole) (for the 
PPI, and PPI active site mutants of L. major) overnight at 411C. 
2.3.7.2. Use of BioCAD 
The same proteins were also purified using the BioCAD 700 E 
workstation (PE Biosystems, Foster City, CA, US), with a 1.7 ml POROS MC 4.6 
mm column. The POROS beads were charged with nickel ions. The purification 
work was partially done by myself, and by Alan Scott (University of Glasgow). 
The column was equilibrated with 50 mM Tris/HCl, pH 8.0, and flow rate of 5-10 
ml/min. Sample was applied, flow-through was re-loaded, and the column was 
washed with 20 ml of 50 mM Tris/HCl, pH 8.0, and 15 ml of 50 mM Tris/HCI, pH 
8.0,30 mM imidazole. The protein was eluted with a gradient of 50-500 mM 
imidazole in the same Tris buffer, over 15 ml. Protein was detected by 
absorbance at 280 nm. Fractions containing the protein were pooled and treated 
as described 2.3.7.1. 
2.3.7.3. Ammonium sulfate saturation 
This method was used for the purification of the recombinant cathepsin B 
of E. tenella produced in P. pastoris. Different aliquots of supernatant of culture 
containing the released recombinant cathepsin B were incubated with various 
percentages of a saturating solution of ammonium sulphate for 2h at 40C with 
mild agitation to fractionate the proteins present in the culture supernatant 
according to their solubility at various concentrations of ammonium sulphate. The 
samples were then centrifuged for 15 min at 13000 9 at 40C and the pellet was 
resuspended in the same volume of 50 mM sodium acetate, pH 5.0. The samples 
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of resuspended pellets and supernatant were tested for enzyme activity and the 
protein profile was assessed by SDS-PAGE. 
2.3.8. Protein native molecular mass determination 
To determine the molecular mass of the recombinant pyroglutamyl 
peptidase I of L. major with a N-terminal His-tag, expressed in E. coli, and 
purified using a nickel-agarose column, gel-filtration analysis was performed. The 
column used was a high-resolution Sepharose 12 (1 cm diameter, 30 cm long), 
which was equilibrated in 50 mM Tris and 150 mM NaCl, pH 7.4, and run at 0.5 
ml/min. Calibration was with the following proteins: ribonuclease A (13.7 kDa), 
chymotrypsinogen (25 kDa), ovalbumin (43 kDa), BSA (67 kDa), alcohol 
dehydrogenase (1150 kDa) and P-amylase (200 kDa) (all Sigma, Poole). The pure 
soluble protein was provided to Dr. Helen Denton (University of Glasgow), who 
carried out the experiment. 
2.3.9. Protein deglycosylation 
Supernatant of P. pastoris culture containing the released recombinant 
cathepsin B of E. tenella was treated with 40% followed by 70% saturation of 
ammonium sulphate and aliquots (equivalent to about 20 pg of enzyme) were 
deglycosylated using 100 U of PGNase F (500000 U/ml, New England Biolabs, 
Hitchin) for 2.5 h at 370C. The reactions were terminated by freezing at -2011C. 
Deglycosylation was assessed by SDS-PAGE and western-blot analysis. 
2.3.10. SDS-PAGE 
Proteins analysed by SDS-PAGE included recombinant proteins, and 
Ecofi, P. pastotis and L. major lysates. The samples were mixed with equal 
volumes of 2X loading buffer and boiled for 5 min. Proteins were separated by 
SDS-PAGE according their molecular masses. The method was as described by 
Laemmli (1970). Gels used 12% (w/v) polyacrylamide (BioRad, Hemel 
Hempstead) and were run using a Mini-Protean 11 slab system (BioRad, Hemel 
Hempstead) according the manufacturers instructions. Gels were stained with 
0.25% (w/v) Coomassle Brilliant Blue R250 and destained with 10% (vIv) acetic 
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acid, 12.5% (v/v) methanol, or used for electro-blotting for specific protein 
analysis. 
2.3.11. Antibody production 
Full length, N-terminal His-tagged, n ickel-ag a rose-pu rifled recombinant 
cathepsin B-like enzyme of E tenella produced in E. coli was used to raise 
antiserum in a rabbit (done by Diagnostic Scotland, using standard methods). 
Full length, N-terminal His-tagged nickel-agarose purified recombinant 
pyroglutamyl peptidase I (PPI) of L. major produced in E. coli, and full length, N- 
terminal His-tagged nickel-agarose purified recombinant glutaminyl cyclase (QC) 
of L. major produced in E. coli were used to raise antiserum in a rat (done by 
Biological Services, University of Glasgow), by inoculation of 50 ýLg of protein 
diluted to a ratio of 1: 1 (v/v) in complete Freund's adjuvant (Sigma, Poole) in a 
total volume of 100 VI, followed by two other inoculations of 50 pg of protein 
diluted to a ratio of 1: 1 (v/v) in incomplete Freund's adjuvant (Sigma, Poole), with 
one month time separating each inoculation. 
2.3.12. Western-blot analysis 
Samples were in 1X loading buffer and proteins were separated on 12% 
(v/v) SDS-PAGE gels. Separated proteins were transferred to Hybond-C 
nitrocellulose membrane (Amersham, Chalfont St. Giles) by electroblotting in 
transfer buffer (20 mM Tris/HCI, 15 mM glycine, 20% (v/v) methanol) using a 
BioRad (Hemel Hempstead) mini transblot cell, at 411C for 1h at 100 V. Ponceau 
S staining allowed protein ladder visualization and labeling on the membrane. 
The membrane was then blocked for 1h at room temperature in 20 mM Tris/HCI 
pH 7.6,13.7 mM NaCl, 0.2% (v/v) Tween-20, and 5% (w/v) low fat dried milk. It 
was then incubated overnight with primary antibodies at 40C in 20 mM Tris/HCI 
pH 7.6,13.7 mM NaCl, 0.1% (v/v) Tween-20. Anti-cathepsin B of E. tenella 
antisera were used at a dilution 1: 8000 (v/v), anti-PPI of L. major antiserum was 
used at 1: 500 (v/v), and anti-His-tag antibody was used at 1: 2000 (v/v). Blots 
were washed 4 times for 30 min with 20 mM Tris/HCI pH 7.6,13.7 mM NaCl, 1% 
(w/v) low fat dried milk, and then incubated with secondary antibody for 2h at 
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room temperature in 200 mM Tris/HCl pH 7.6,137 mM NaCl, 1% (w/v) low fat 
dried milk. Secondary antibodies were anti-rabbit IgG-conjugated horseradish 
peroxidase (HRP) (Promega, Southampton) at 1: 5000 (v/v), anti-rat IgG- 
conjugated HRP (Pierce, Cramlington) at 1: 1500 (v/v), or anti-mouse IgG- 
conjugated HRP (Pierce, Cramlington) at 1: 2000 (v/v), depending on the primary 
antibody used. The membrane was washed 3 times for 30 min with 20 mM 
Tris/HCl pH 7.6,13.7 mM NaCl, 1% (w/v) low fat dried milk. Bound antibodies 
were detected by using the Supersignal Enhanced Chemiluminescence (ECL) 
reagents (Pierce, Cramlington) according the manufacturers instructions. 
Fluorescence was detected by autoradiography with reflexion autoradiography 
film (NEN Life Sciences, Boston, MA, US). 
2.3.13. Indirect immunofluorescence 
2.3.13.1. Analysis of the subcellular localisation of the cathepsin B-like 
enzyme in E. tenella 
The anti-cathepsin B of E. tenella antiserum raised in rabbit was sent to 
Professor David J. P. Ferguson (Oxford University, John Radcliffe Hospital, 
Oxford), who performed all of the cathepsin B localisation studies on various E. 
tenella stages of the life cycle. 
2.3.13.2. Analysis of the subcellular localisation of the pyroglutarnyl 
pepticlase I enzyme in L. major 
All steps were at room temperature. Stationary phase parasites were 
collected by centrifugation for 10 min at 1300 9, washed in PBS, and 
resuspended at 2x 107 cells/ml in PBS. An equal volume of 6% (w/v) 
paraformaldehyde in PBS was added and the mixture was incubated on ice for 1 
h. Five volumes of PBS were added and the cells were washed and harvested as 
above. Cells were resuspended at 2x 107 cells/ml in PBS. Slides were pre- 
treated with 200 jal of 0.01% (w/v) poly-L-lysine solution (Sigma, Poole), 
incubated for 5 min and then allowed to dry for 2 h. Then 200 pl of parasite 
suspension was applied to the slide and incubated 15 min. The cells were 
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permeabilised in 0.1% (v/v) Triton X-100 in PBS for 10 min (in a glass chamber), 
slides were washed 3 times in PBS for 5 min, and blocked for 1h with 20% (v/v) 
HIFCS in PBS. The primary antibody at a dilution 1: 25,1: 100 or 1: 500 (v/v) (anti- 
pyroglutamyl peptidase of L. major raised in rat) in PBS, with 20% (v/v) HIFCS 
was incubated on the slides for 1 h. The slides were washed 3 times for 5 min 
with PBS, and the secondary antibody at a dilution of 1: 500 (v/v) (Alexa Fluor@ 
568 goat anti-rat IgG [Molecular Probes, Paisley]) in PBS with 20% HIFCS was 
incubated for 1h at room temperature. The secondary antibody solution also 
contained the 4', 6-diamidino-2-phenylindole DAR staining (5 Pg/ml, final 
concentration). The slides were washed 3 times for 5 min with PBS and mounted 
with anti-quenching agent (MOWIOL-DABCO in 50% (v/v) PBS). The edges of 
the coverslips were sealed with varnish and the slides were stored at 40C in the 
dark until analysis. Fluorescence signals were visualized by UV fluorescence 
microscopy on a Zeiss Axioplan fluorescence microscope with a Hamamstsu 
Digital Camera using the OpenLab software (Improvision, University of Warwick). 
2.3.14. Enzyme activity measurements 
2.3.14.1. Substrate-gel electrophoresis 
Reducing gelatin SDS-PAGE was as described in Robertson et aL, 1990. 
Native gelatin SDS-PAGE was as described in Pandey et aL, 2003. All gelatin 
gels contained gelatin at 0.2% (w/v) final concentration. After electrophoresis, the 
gels were incubated for 1h in 2.5% (v/v) Triton X-100, and then in 0.1 M sodium 
acetate, pH 5.0, supplemented with 10 mM DTT at 3711C for 6-16 h before 
staining with Coomassie blue. 
2.3.14.2. Azocasein assay 
The proteolytic activity of various enzyme fractions towards azocasein 
(Sigma, Poole) was tested. Fifty ýtl of a 1% (w/v) azocasein solution in 1X PBS 
was mixed with 400 ltl of 0.1 M Tris/HCl pH 8.0 or 0.1 M sodium acetate pH 5.0 
with or without 10 mM DTT and/or 1 mM (2S, 3S)-3-(N-{(S)-1-[N-(4- 
guanidinobutyl)carbamoyl]3-methylbutyllcarbamoyl)oxirane-2-carboxylic acid 
(E64), and 50 gl of sample to test (about 5-10 pg of recombinant protein) and 
69 
Chapter 2: Material and Methods 
incubated at 3711C overnight. Controls without sample or with 25 jtg of a- 
chymotrypsin (Sigma, Poole, 57 U/mg) were also included. After incubation, 500 
ýtl of ice cold 1% TCA were added to the samples, incubated for 10 min on ice 
and centrifuged at 13000 g for 5 min at room temperature. The absorbance of the 
supernatant was measured at 400 nm. 
2.3.14.3. Spectrophotometric assays 
In all experiments, 1 unit of activity represents 1 Itmol of substrate 
hydrolysed per min. All measurements were in triplicate. 
The extinction coefficient at 410 nm for the substrate was measured using 
a standard curve of free chromogenic substituent in the buffer used for the 
assays. The extinction coefficient used for the paranitroanilide (pNA) substrates 
(all Bachem, St. Helens) was 9.5 x 103 1 /mol/cm in all buffer systems. The light 
path was 1 cm. 
2.3.14.3.1. Recombinant cathepsin B of E. tenella 
The assays using the chromogenic substrates benzyloxycarbonyl-Phe- 
Arg-pNA (Z-Phe-Arg-pNA) and Z-Arg-Arg-pNA consisted of 50 mM sodium 
acetate pH 5.0,2 mM EDTA, 10 mM DTT, with 333 ltM of chromogenic substrate 
in a total volume of 600 ld. The buffer was incubated at 3711C with the enzyme 
sample for 10 min and the reaction was started by addition of the substrate. The 
reaction was followed continuously for 10 min at 410 nm. 
2.3.14.3.2. Recombinant pyroglutamyl peptidase I of L. major 
The assays using the chromogenic substrates pGlu-pNA (Bachem, St. 
Helens) consisted of different buffers, with 2 mM of chromogenic substrate in a 
total volume of 1 mi. The buffer was incubated at 320C with the enzyme sample 
for 5 min and the reaction was started by addition of the substrate. The reaction 
was followed continuously for 10 min at 410 nm. 
The dependence on DTT was measured in 25 mM potassium phosphate 
buffer pH 8.0. The reaction was started by addition of 2 mM of substrate and 
measured continuously for 10 min. 
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The pH dependence was determined using 2 different methods. The first 
comprised assaying the activity in a mix of 4 buffers (25 mM acetic acid, 25 mM 
2-(N-morpholino) ethanesulphonic acid (MES), 75 mM Tris, 25 mM glycine) 
adjusted to the appropriate pH, with 10 mm DTT. The reaction was started by 
addition of 2 mM pGlu-pNA. The second method used a set of buffers, which was 
composed of "Good" buffers (Good et aL, 1966), as they are biologically and 
chemically non-reactive and their pK. show a minimum dependence on the 
temperature and the ionic strength. These were MES/NaOH (25 mM, pH 5.4 and 
6.5), piperazine-NN'-bis-2-ethanesulphonic acid (PIPES)/NaOH (25 mM, pH 6.3 
and 7), 3-(N-morpholino) propanesulphonic acid (MOPS)/ NaOH (25 mM, pH 6.5 
and 7.5), HEPES/NaOH (25 mM, pH 7.0 and 8.0), NN-bis (2-hydroxyethyl) 
glycine (BICINE)/NaOH (25 mM, pH 7.8 and 8.8), 2-(cyclohexylamino) 
ethanesulphonic acid (CHES)/NaOH (25 mM, pH 8.5,9.0,10.0 and 10.5), 3- 
(cyclohexylamino)-l-propanesulphonic acid (CAPSO)/NaOH (25 mM, pH 9.0,9.5 
and 10.0). Assays also included 10 mM DTT. The reaction was started by 
addition of 2 mM of pGlu-pNA. 
The effect of EDTA, and magnesium ions was measured in 50 mM 
HEPES pH 8.0,10 mM DTT using the substrate pGlu-pNA. The reaction was 
started by addition of 2 mM of substrate and measured continuously for 10 min. 
Enzyme stability was tested in 50 mM HEPES pH 8.0,2 mM Tris(2- 
carboxyethyl)phosphorine hydrochloride (TCEP), 1 mM EDTA with the substrate 
pGlu-pNA, at various time points. Enzyme stability was tested at -20,4, and 
370C. 
The measurement of the Km for hydrolysis of pGlu-pNA was performed 
using 10 ýN to 2 mM of substrate, in 50 mM HEPES pH 8.0,1 mM EDTA, 2 mM 
TCEP, at 32*C. 
For testing of inhibitors' effects, the inhibitor (or ion to test) was added to 
the buffer-enzyme mix and incubated for 10 min at 320C. Assays were in 50 mM 
HEPES pH 8.0,2 mM TCEP. The reaction was started with 200 liM of pGlu-pNA, 
and was then as described for the peptidase assay. 
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2.3.14.4. Fluorometric assays 
In all experiments, I unit of activity represents 1 Itmol of substrate 
hydrolysed per min. All measurements were in triplicate. 
The extinction coefficients for the different products of cleavage were 
measured using a standard curve of free fluorescent substituent. All substrates 
were from Bachem, St. Helens. The extinction coefficient for P-naphtylamine (P- 
NA) was found to be 2.6 x 109 I/mol/cm in all buffer systems (excitation 320/ 
emission 410 nm). The extinction coefficient for 7-amino-4-methylcoumarin 
(AMC) was found to be 5.8 x 109 I/mollcm in all buffer systems. The light path 
was 1 cm (excitation 380/ emission 465 nm). 
2.3.14.4.1. Recombinant cathepsin B of E tenella 
Peptidase activity was assessed using the fluorogenic substrates Z-Phe- 
Arg-AMC and Z-Arg-Arg-AMC at a concentration of 200 pM unless otherwise 
stated in 50 mM sodium acetate, pH 5.0,5 mM EDTA, and 10 mM DTT. 
Reactions were in a total volume of 1 ml, at 370C and started by addition of the 
substrate after a pre-incubation of the buffer-enzyme mix for 10 min at 3711C. The 
appearance of AMC was measured using excitation at 380 nm and emission at 
465 nm. Activities were calculated from the rate over the first 10 min. 
The dependence on DTT and on salt was measured using 10 gl of crude 
Pichia supernatant in 50 mM sodium acetate, pH 5.0, using the substrate Z-Phe- 
Arg-AMC. The reaction was started by addition of 50 gM of substrate and 
measured continuously for 5 min. 
The effect of EDTA was measured using 10 ýJ of crude Pichia supernatant in 
50 mM sodium acetate pH 5.0,10 mM DTT with the substrate Z-Phe-Arg-AMC. 
The reaction was started by addition of 30 ýM of substrate and measured 
continuously for 5 min (excitation 380 nm/emission 465 nm). 
The pH dependence was determined using 2 different methods. The first 
comprised assaying the activity in a mix of 4 buffers (25 mM acetic acid, 25 mM 
MES, 75 mM Tris, 25 mM glycine) adjusted to the appropriate pH, with 10 PI of 
crude Pichla supernatant and 10 mM DTT. The reaction was started by addition 
of 30 gM of Z-Phe-Arg-AMC. The second method involved using 3 different 
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buffers separately, depending on their pH range. These buffers were 0.1 M acetic 
acid, 0.1 M sodium acetate and 0.1 M potassium phosphate. Each assay used 2 
l. d of crude Pichia supernatant. All buffers were supplemented with 10 mM DTT. 
The reaction was started by addition of 30 gM of Z-Phe-Arg-AMC. 
Km measurements towards Z-Phe-Arg-AMC and Z-Arg-Arg-AMC used 0.5 
ýtg of enzyme per assay and were in 50 mM sodium acetate pH 5.0, 
supplemented with 10 mM DTT and 5 mM EDTA. The enzyme sample was 
incubated for 10 min at 370C in the assay buffer before start of the reaction by 
addition of the substrate (10 gM to 1.5 mM). The assays were continuous for 10 
min at 370C. 
For testing of inhibitors' effects, the inhibitor was added to the buffer-enzyme 
mix and incubated for 10 min at 370C. The reaction was then as described for Km 
measurements. 
2.3.14.4.2. Recombinant pyroglutamyl peptidase I of L. major 
All assays were at 320C in a total volume of 1 ml. The buffer was 
incubated at 320C with the enzyme sample for 5 min and the reaction was started 
by addition of the substrate. Excitation and emission wavelengths were, 
respectively, 320 and 410 nm for the P-NA fluorogenic substrates. 
The measurement of the Km for hydrolysis of pGlu-PNA and H-Glu-PNA 
was performed using 0.1 jiM to 1 mM of substrate, in 50 mM HEPES pH 8.0,1 
mM EDTA, 2 mM TCEP. All other assays against pGlu-PNA used 200 gM of this 
substrate. 
Assays against the H-Gln-PNA substrate were in 50 mM HEPES pH 8.0, 
I mM EDTA, 2 mM TCEP, with 200 gM of this substrate. 
2.3.14.4.3. Native pyroglutamyl peptidase I of L. major 
L. major promastigote cell lysis is described in 2.1.3. Typically 5-10 x 107 
L. major stationary phase promastigotes equivalent were tested per assay. The 
buffer consisted of 1 ml of 50 mM HEPES pH 8.0,1 mM EDTA, 2 mM TCEP, or 1 
ml of 50 mM Tris, pH 8.0. The buffer was pre-incubated at 320C for 5 min with 
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200 ýM of pGlu-PNA and the assay was started by addition of the cell extract to 
analyse. The measurements were continuous for 10 min. Excitation and emission 
wavelengths were, respectively, 320 and 410 nm. 
2.4. L. major infectivity 
2.4.1. In vitro infectivity in macrophages 
Peritoneal macrophages were extracted from peritoneal lavage of CD-1 
mice (work done by Susan Baillie, University of Glasgow). Macrophages were 
resuspended in RPMI medium (GibcoBRL, Paisley) with 10% (v/v) HIFCS at a 
concentration of 5x 105 cells/ml, 200 ýtl of this suspension was placed in each 
well of cavity slides (VWR, Lutterworth), incubated at 370C for 24 h in 5%CO2, 
95% air. Stationary phase L. major promastigotes or purified metacyclics of L. 
majorwere diluted in RPMl with 10% (v/v) HIFCS, and 200 ýLl were added to the 
macrophage suspension at a ratio of 2: 1 or 0.51 respectively, following the 
method described in Frame et a/., 2000. After 24 h in 5% C02v 95% air at 3711C, 
the L. major promastigotes were washed off and 400 ld of RPMI with 10% (v/v) 
HIFCS was added. After 3 days of further incubation at 370C the medium was 
removed and replaced by fresh medium and slides were further incubated for 3 
days at 370C. The cells were then fixed with methanol and stained with Giemsa 
stain, and the parasite loads were determined microscopically by counting 200 
macrophages. Each cell line of L. major being analysed was infected into 3 wells 
of the cavity slide. 
2.4.2. Infectivity in BALB/c mice 
Groups of 6 mice were inoculated in the footpad with 5x 105 stationary- 
phase L. major promastigotes, or 105 purified metacyclic promastigotes of L. 
major resuspended in 20 ýtl of PBS, pH 7.4. The thickness of the infected 
footpads was measured regularly over a 5-12 weeks period. 
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2.5. Bioinformatic analyses 
Vector NTI (v. 6.0) was used to analyse DNA and protein sequences 
(searching for open reading frames, restriction sites, design of oligonucleotides 
for PCR, construction of cloning and expression plasmids). Sequence alignments 
were studied with Align X (Clustal X) and ContigExpress was used to align 
overlapping sequences. For phylogenetic analyses, sequences were aligned 
using Align X (Vector NTI program), cut to the same amino acid length (166), and 
insertions were removed manually. The edited sequences were realigned using 
Align X. The unrooted phylogenetic tree was generated using the neighbour- 
joining method in the Molecular Evolutionary Genetics Analysis (MEGA) program, 
version 2.1 (Kumar et aL, 2001), with 1000 bootstrap replicates. 
The following web sources were used for database mining and analysis of 
DNA and protein sequences: 
TIGR databases: www. tigr. org 
The Sanger Institute: www. sanger. ac. uk 
GeneDB: www. genedb. org 
NCBI: www. ncbi. nim. nih. gov 
MEROPS: www. merops. sanger. ac. uk 
Protein domain predictions were with: 
SignalP (Nielsen et al., 1996): www. cbs. dtu. dk/services/SignalP 
Target Pv1.0: www. cbs. dtu. dk/services/TargetP 
TMpred: www. ch. embnet. org 
2.6. Statistical analyses 
Values were expressed either as mean ± standard deviation (SD) when 
the number of repetitions was more than 2, or mean ± standard error (SE) when 
the number of repetitions was 2. Levels of significance were calculated by 
unpaired t tests using the GraphPad Prism program (San Diego, CA, US). 
Differences were considered significant at P<0.05. 
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Chapter 3 
Expression'and characterisation of 
the recombinant cathepsin B of E. tenella 
3.1. Introduction 
Invasion of host cells by Eimeria, and other apicomplexan parasites, 
involves the regulated release of specialised secretory organelles; namely 
micronemes, rhoptries and dense granules, located at the anterior end of the 
parasite (Dubremetz, 1998) and forming the apical complex. Maturation, 
trafficking and secretion of many of the secretory organelles' proteins rely upon 
proteolytic processing (Soldati et a/., 1998; Carruthers et al., 2000; Reiss et a/., 
2001). After several cycles of asexual multiplication (schizogony or merogony), 
gametogony begins; macrogametocytes (female gamete) and microgametocytes 
(male) are formed, and fuse to form oocysts, that are released. The oocyst wall 
ensures the parasite survival in the external environment before finding the next 
host. The oocyst wall formation therefore constitutes an essential process for 
disease transmission. The wall is sequentially formed by the release of three 
macrogamete organelles structurally similar to the dense granules of the 
infectious stages (Ferguson et al., 2000); the veil forming bodies, the wall forming 
bodies type 1 (associated to the Golgi apparatus and located in the cytoplasm), 
and the wall forming bodies type 2 (associated to the endoplasmic reticulurn and 
found in vacuolar spaces) (Ferguson et al., 2003). Peptidases have been shown 
to be involved in the oocyst wall formation in Eimetia (Belli et a/., 2003a; Belli et 
al., 2003b), by maturation of precursor proteins found in the wall forming bodies. 
Some cysteine peptidases from apicomplexan parasites have been 
identified as important factors for invasion of host cells (Kim, 2004). These 
enzymes include the cathepsin B-like toxopain-1 in Toxoplasma gondii (Que et 
aL, 2002), and falcipain-1 in Plasmodium falciparum (Greenbaum et a/., 2002). 
Furthermore, parasite cysteine peptidases have attracted particular attention over 
the recent years because of their importance in parasite survival, interaction with 
the host cells and pathogenicity. Some of them seem to be promising targets for 
new selective inhibitors and anti-parasite agents (Selzer et al., 1997; Rosenthal, 
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1999). The well studied cathepsin L-like enzyme, CPB2.8, of Leishmania 
mexicana provides a good example (Mottram et a/., 1996; Coombs and Mottram, 
1997). 
Cathepsin B enzymes, which belong to the clan CA, family C1 of cysteine 
peptidases comprise a signal peptide, a pro-domain and a mature domain. The 
pro-domain, which might possess in some cases folding information (Pandey et 
al., 2004), has been shown to be a strong inhibitor of the catalytic domain (Sijwali 
et al., 2002), and so maintains the peptidase in an inactive form during trafficking 
to the lysosome. Activation of the enzyme is a regulated process involving the 
proteolytic cleavage (endogenous or exogenous) of the pro-peptide, facilitated by 
decreasing the pH (Turk et aL, 2000), which is favoured in the acidic pH 
environment of the lysosome. 
The ever-increasing number of gene sequences and EST data published 
in the public domain provides a great resource for analyses and potential 
identification of targets for therapeutics. Up to now, the anticoccidial drugs 
dominating the market for the treatment of avian Eimeria have been polyether 
ionophores, which perturb ion gradients in the parasite (Dutton et al., 1995). But 
because of problems of drug resistance and occurrence of mutant populations, 
toxicity and limited efficacy of current drugs, identification and evaluation of new 
drugs and new targets is constantly and urgently needed. 
The aim of this part of my work was to obtain active recombinant 
cathepsin B of E. tenella for biochemical characterisation, and drug screening. 
The difficulty of maintaining Eimeria species in-vitro somewhat limited the extent 
of the possible functional investigation in the parasite. Nonetheless, cysteine 
peptidase inhibitors have been shown to block sporozoite invasion (Samantha 
Brown, unpublished data), and to get an insight on what might be the role of the 
enzyme, immunolocalisation studies on invasive and sexual stages of Eimeria 
tenella were performed in collaboration with Prof David J. Ferguson, Oxford. 
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3.2. Results 
3.2.1. Cloning of the cathepsin B gene 
Database searches on the genomic database of E. tenella using the 
cathepsin B of Toxoplasma gondii (accession number AAL60053) as a query 
allowed detection of a 1535 bp open reading frame (Contig5436, 
www. geneDB. org). Amplification by PCR of the complete putative sequence 
coding for the cathepsin-B like protein (MEROPS clan CA, family C11) on both 
gDNA and cDNA gave a single product of the same size, about 1.6 kb, which 
corresponds to the predicted size for the amplification product using the specific 
primers designed (Fig. 3.1). The amplified fragments were sequenced and both 
fragments presented the same nucleotide sequences, confirming the absence of 
introns in the gene. The results of 5' RACE permitted detection of the presence of 
a mRNA comprising a 40 bp 5' untranslated region (5' UTR), confirming the start 
methionine (Fig. 3.2). Furthermore, the start methionine conforms to a Kozak 
eukaryotic consensus (Kozak, 1999) and the consensus assigned to protozoan 
parasites (Yamauchi, 1991) favouring the presence of a purine at position -3 and 
+4 of the start ATG. The complete ORF encodes a pre-pro-enzyme of 512 amino 
acids W, = 55,937). 
1.65 
1 
FIG. 3.1. PCR amplification of the cathepsin B-like gene of E. tenefia. Electrophoresis 
on 1% agarose gel of 10 lal of PCR products from the amplification on genomic DNA (lane 1) and 
cDNA (lanes 2 and 3) of the putative full sequence coding for the cathepsin B-like enzyme of E. 
tenella. Negative control PCR, representative of the amplification on genomic DNA present in the 
cDNA preparation after reverse transcription, is shown on lane 4. The marker used is the 1kb 
Plus. The size of fragments is indicated on the left of the figure in kb. 
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mRIGKLW 
1 TATTCGATTT CCACTTAGCT ACTACGCTTT GCATTCTGAG TTTGTGAAAA TGAGGATAGG GAAGCTGTGG 
ATAAGCTAAA GGTGAATCGA TGATGCGAAA CGTAAGACTC AAACACTTTT ACTCCTATCC CTTCGACACC 
ATLA Iss PLI FSCA mPS DDLGGAK 
71 GCCACCTTGG CCATTTCCAG CCCCCTGATC TTCAGTTGTG CGATGCCCTC CGATGATTTG GGCGGCGCTA 
CGGTGGAACC GGTAAAGGTC GGGGGACTAG AAGTCAACAC GCTACGGGAG GCTACTAAAC CCGCCGCGAT 
-EDL Qsv GNAI DAI FDR ILRDVEK 
141 AGGAAGATCT GCAGTCTGTG GGCAATGCCA TCGATGCCAT ATTCGACCGG ATTCTGCGAG ATGTAGAGAA 
TCCTTCTAGA CGTCAGACAC CCGTTACGGT AGCTACGGTA TAAGCTGGCC TAAGACGCTC TACATCTCTT 
-DIG HGKA LQA CGP SGSHT0GVEN 
211 GGATATTGGA CATGGCAAAG CCCTCCAAGC TTGCGGTCCC AGCGGTTCCC ACACGCAAGG TGTGGAGAAC 
CCTATAACCT GTACCGTTTC GGGAGGTTCG AACGCCAGGG TCGCCAAGGG TGTGCGTTCC ACACCTCTTG 
CRRVLKG EPD ESHE LLP YLLKDQE 
281 TGCAGGCGTG TGCTGAAAGG AGAGCCTGAC GAATCTCATG AGTTGCTGCC GTACCTGCTT AAGGACCAGG 
ACGTCCGCAC ACGACTTTCC TCTCGGACTG CTTAGAGTAC TCAACGACGG CATGGACGAA TTCCTGGTCC 
-AMR LWR DHFRRHV GEL VSSASEH 
351 AGGCCATGAG GTTGTGGCGG GATCACTTCC GTCGGCACGT GGGCGAGCTG GTATCCAGTG CATCGGAACA 
TCCGGTACTC CAACACCGCC CTAGTGAAGG CAGCCGTGCA CCCGCTCGAC CATAGGTCAC GTAGCCTTGT 
-SGA DTPLQGP VLK SLAESEFWGS 
421 TAGCGGGGCA GATACCCCCC TTCAGGGGCC GGTATTGAAA AGCCTCGCGG AAAGCGAATT CTGGGGAAGC 
ATCGCCCCGT CTATGGGGGG AAGTCCCCGG CCATAACTTT TCGGAGCGCC TTTCGCTTAA GACCCCTTCG 
RPAV SNG ALQ HLRV KMQ RLKLQAA 
491 CGGCCAGCTG TTAGCAACGG AGCTTTGCAG CACTTGAGGG TGAAGATGCA GCGGCTGAAG CTGCAAGCAG 
GCCGGTCGAC AATCGTTGCC TCGAAACGTC GTGAACTCCC ACTTCTACGT CGCCGACTTC GACGTTCGTC 
-EQG LDP EQAVTWE AEV SPRFKYH 
561 CTGAGCAGGG TCTAGACCCT GAACAGGCGG TGACGTGGGA AGCAGAAGTG TCTCCTCGTT TCAAATACCA 
GACTCGTCCC AGATCTGGGA CTTGTCCGCC ACTGCACCCT TCGTCTTCAC AGAGGAGCAA AGTTTATGGT 
.SIK DAKRHMG TYL SFYSDPDKPE 
631 CACCATCAAA GACGCGAAAA GGCATATGGG TACTTACCTT TCTTTCTATT CAGATCCAGA CAAGCCAGAG 
GTCGTAGTTT CTGCGCTTTT CCGTATACCC ATGAATGGAA AGAAAGATAA GTCTAGGTCT GTTCGGTCTC 
VPLGEPL PVK VFAETQQ VLETDKF 
701 GTGCCGCTTG GGGAGCCACT GCCTGTGAAG GTGTTTGCGG AGACGCAGCA GGTTCTGGAA ACTGACAACT 
CACGGCGAAC CCCTCGGTGA CGGACACTTC CACAAACGCC TCTGCGTCGT CCAAGACCTT TGACTGTTCA 
-DAR EAF PQCAEVI GHV RDQGDCG 
771 TTGACGCGAG GGAGGCCTTT CCTCAATGCG CAGAGGTGAT TGGCCATGTC CGAGACCAAG GCGACTGCGG 
AACTGCGCTC CCTCCGGAA. A GGAGTTACGC GTCTCCACTA ACCGGTACAG GCTCTGGTTC CGCTGACGCC 
.scw AFASTEA LND RFCIKSGGRH 
841 CTCGTGCTGG GCCTTTGCTA GCACAGAGGC CCTGAACGAC CGTTTCTGCA TCAAGTCAGG CGGCCGCCAT 
GAGCACGACC CGGAAACGAT CGTGTCTCCG GGACTTGCTG GCAAAGACGT AGTTCAGTCC GCCGGCGGTA 
REALsPQ HTT SCCDLLH CLSFGCS 
911 CGGGAGGCTC TGTCGCCGCA GCATACGACT TCATGCTGCG ACCTACTGCA CTGTTTGTCT TTTGGCTGCT 
GCCCTCCGAG ACAGCGGCGT CGTATGCTGA AGTACGACGC TGGATGACGT GACAAACAGA AAACCGACGA 
-GGQ PRM AWRWFSN DGV VTGGDYN 
981 CCGGGGGCCA GCCGAGGATG GCTTGGCGGT GGTTTTCGAA CGATGGGGTG GTAACCGGTG GTGACTACAA 
GGCCCCCGGT CGGCTCCTAC CGAACCGCCA CCAAAAGCTT GCTACCCCAC CATTGGCCAC CACTGATGTT 
-ELH TGKScwP yEI PFCRHHSEGP 
1051 CGAGCTGCAC ACGGGTAAAA GCTGCTGGCC TTACGAGATT CCCTTCTGCC GGCACCACTC GGAAGGGCCC 
GCTCGACGTG TGCCCATTTT CGACGACCGG AATGCTCTAA GGGAAGACGG CCGTGGTGAG CCTTCCCGGG 
YPKCEGP LPK APKCRKD CEEAEYT 
1121 TACCCAAAGT GTGAGGGGCC CTTGCCCAAG GCTCCGAAGT GCCGCAAGGA TTGTGAGGAA GCAGAGTACA 
ATGGGTTTCA CACTCCCCGG GAACGGGTTC CGAGGCTTCA CGGCGTTCCT AACACTCCTT CGTCTCATGT 
-SKV KPF KDD LHFA TSA YSVE0RD 
1191 CCAGCAAAGT GAAGCCATTC AAGGATGATC TACATTTCGC CACGAGTGCA TACAGTGTGG AAGGCCGGGA 
GGTCGTTTCA CTTCGGTAAG TTCCTACTAG ATGTAAAGCG GTGCTCACGT ATGTCACACC TTCCGGCCCT 
-QIK RELMENG TLT GAF LVYEDFL 
1261 CCAAATTAAA CGGGAACTTA TGGAAAATGG CACTCTCACT GGCGCTTTCC TCGTGTATGA GGACTTCCTG 
GGTTTAATTT GCCCTTGAAT ACCTTTTACC GTGAGAGTGA CCGCGAAAGG ACCACATACT CCTGAAGGAC 
LYKE GvY HHV TGMP MGG HAVKVIG 
1331 CTGTACAAGG AGGGGGTGTA TCACCACGTG ACAGGCATGC CCATGGGTGG TCACGCAGTG AAGGTGATTG 
GACATGTTCC TCCCCCACAT AGTGGTGCAC TGTCCGTACG GGTACCCACC AGTGCGTCAC TTCCACTAAC 
-FGN EDG RDYWLAV NSW NEYWGDK 
1401 GCTTCGGGAA CGAAGACGGG AGGGACTACT GGCTAGCTGT GAACAGCTGG AACGAATACT GGGGAGATAA 
CGAAGCCCTT GCTTCTGCCC TCCCTGATGA CCGATCGACA CTTGTCGACC TTGCTTATGA CCCCTCTATT 
-GTF KIEMGEA GID XEF CGGEPKV 
1471 AGGCACTTTC AAAATTGAAA TGGGAGAGGC AGGAATAGAT AAAGAATTCT GTGGAGGGGA GCCGAAAGTG 
TCCGTGAAAG TTTTAACTTT ACCCTCTCCG TCCTTATCTA TTTCTTAAGA CACCTCCCCT CGGCTTTCAC 
PND KNAS LLP SAQDL 
1541 CCCAATGACA AAAACGCCTC ATTGCTGCCG TCAGCGCAGG ACCTATGAAA CTAAAGGCGA TTCAAGGGC 
GGGTTACTGT TTTTGCGGAG TAACGACGGC AGTCGCGTCC TGGATACTTT GATTTCCGCT AAGTTCCCG 
FIG. 3.2. Complete sequence of the contig containing an open reading frame 
encoding a cathepsin B-like enzyme of E. tenella. The sequence of the 5' UTR obtained from 
5' RACE experiment is on grey background. The translation of the putative ORF is shown in bold. 
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The amino acid sequence was analysed with the SignalP algorithm (Nielsen 
et al., 1997) and a pre-peptide of 21 hydrophobic amino acids could be predicted. 
By comparison with cathepsins B from other organisms (Fig. 3.3), a pro-domain 
of 213 amino acids could be predicted as well. As a comparison, the cathepsin B- 
like enzyme of T. gondii (Que et al., 2002) has a pre-peptide of 34 amino acids, a 
pro-domain of 239 amino acids and the mature enzyme is composed of 296 
residues (Fig. 3.4). The cathepsin B-like enzyme of E. tenella has a long pro- 
domain very similar to the one from T. gondii. But both enzymes lack the ERFNIN 
motif, usually found in the pro-domain of cathepsins L- and H-like enzymes. The 
C-terminal end of the enzyme contains a potential site for asparagine-linked 
glycosylation (N-X-S/T) at position 502. The complete pre-pro-enzyme showed 
42% similarity with the T. gondii cathepsin B and the mature enzyme of 491 
amino acids showed good similarity to the human cathepsin B (45%), the 
cathepsin B of L. major (39%), T. gondii (57%), and S. mansoni (44%). The 
position of the catalytic cysteine, histidine and asparagine in the cathepsin B-like 
enzyme of E. tenella are respectively 263,445, and 465 (E. tenella cathepsin B 
numbering). The pro-enzyme contains 16 cysteine residues, which can possibly 
be involved in the formation of 8 disulfide bridges. The positions for 10 of the 
cysteine residues in the different enzymes of the different organisms compared 
were conserved. The occluding loop diagnostic of cathepsin B enzymes can also 
be identified at H iS352 and H iS353 . This loop might confer to the enzyme an 
exopeptidase activity in addition to the endopeptidase activity. By comparison to 
the human cathepsin B, a C-terminal extension of 8 amino acids can be detected. 
This short extension is similar to the one found for T. gondii (26 amino acids) but 
differs from the very long extensions found for some cathepsin L-like enzymes. 
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1 70 
Et (1) ------------- MRIGKLWATLAISSPLIFSCAMPSDDLGGAKEDLQSVGN --- AIDAIFDRILR--DV 
Tg (1) ME GRKSFRVLGTPLPFAALAAILLLGCMYTRAAGTPDDSLFPLSEDTSVDPRESFSAEDVLNAFVSPESV 
Sm (1) - -------------------------------------------------------------------- 
Lm (1) ---------------------------------------------------------------------- 
Hum (1) ---------------------------------------------------------------------- 
71 140 
Et (53) EKDIGHGKALQACGPSGSHTQGVENCRRVLK ---------- GEPDESHELLPYLLKDQEAMRLWRDHFRR 
Tg (71) ESLFDSIVAEQVVATSGNLTESAPRDRDSAPERRSDGGTLRGHPEDAGELLRLLLADSEDMELWKANFFR 
Sm (1) ---------------------------------------------------------------------- 
Lm (1) ---------------------------------------------------------------------- 
Hum (1) ---------------------------------------------------------------------- 
141 210 
Et (113) HVG ---------------- ELVSSASEHSGADTPLQGPVLKSLAESEFWGSRPAVSNGALQHLRVKMQRL 
Tg (141) HLTHSMRHIVRDSVLVSEKAFPSEQAGEAGRDPGDLKKALEETGEDVFWESRPASSNAAVALIKKKMEKQ 
Sm (1) --------------------------------- MNQYSCYLLQLYIIILLSYGTLNEIDARRHKRMYQPL 
Lm (1) --------------------------------- MALRAKSALCLVAVFALLLATTVSGLYAKPSDFPLLG 
Hum (1) -------------------------------------------- MWQLWASLCCLLVLANARSRPSFHPL 
211 280 
Et (167) KLQAAEQGLDPEQAVTWEAEVSPRFKYHSIKDAKRHMGTYLSFYSDPDKPEVPLGEPLPVKVFAETQQVL 
Tg (211) AGKTGEG ---- AG-HTWEPEVSLRFRYLSLKDAKKLMGTFLVN-TKVEGFPTPKGMPLPAKEFENATEPV 
Sm (38) SMELINFINY --- EANTTWKAAPTTRFRTVSDIRRMLGALPDP ---------- NGEQLETLCTGYISDEL 
Lm (38) KSFVAEVNSKAKGQWTASANNGYLVTGKSLGEVRKLMGVTDMS --------- TEAVPPRNFSVEELQQDL 
Hum (27) SDELVNYVN ---- KRNTTWQAGHNFYNVDMSYLKRLCGTFLG------------GPKPPQRVMFTEDLKL 
281 350 
Et (237) ETDKFDAREAFPQCAEVIGHVRDQGDCGSCWAFASTEALNDRFCIKSGGRHREALSPQHTTSCCDLLHCL 
Tg (275) P-AHFDARTAFPACKDVVGHVRDQGDCGSCWAFASTEAFNDRLCIRSQGKRLMPLSAQHTTSCCNAIHCA 
Sm (95) P-KSFDARVEWPHCPSIS-EIRDQSSCGSCWAFGAVEAMSDRICIKSKGKHKPFLSAENLVSCC --- SSC 
Lm (99) P-EFFDAAEHWPMCLTIS-EIRDQSNCGSCWAIAAVEAISDRYCTFG-GVPDRRMSTSNLLSCC --- FIC 
Hum (81) P-ASFDAREQWPQCPTIK-EIRDQGSCGSCWAFGAVEAISDRICIHTNAEVSVEVSAEDLLTCCG--SMC 
351 420 
Et (307) SFGCSGGQPRMAWRWFSNDGVVTGGDYNELHTGKSCWPYEIPFCRHHSEGP-YPKCEGPLP--KAPKCRK 
Tg (344) SFGCNGGQPGMAWRWFERKGVVTGGDFDALCKGTTCWPYEVPFCAHHAKAP-FPDCDATLVPRKTPKCRK 
Sm (160) GMGCNGGFPHSAWLYWKNQGIVTGDLYNTTNG --- CQPYEFPPCEHHVIGP-LPSCDGDVE---TPSCKT 
Lm (163) GLGCHGGIPTVAWLWWVWVGIAT ------- ED --- CQPYPFDPCSHHGNSEKYPPCPSTIYD--TPKCNT 
Hum (147) GDGCNGGYPAEAWNFWTRKGLVSGGLYESHVG --- CRPYSIPPCEHHVNGS-RPPCI'GEGD -q, PKCSK 
421 490 
Et (374) DCEEAEYTSKVKPFKDDLHFATSAYSVEG-RDQIKRELMENGTLTGAFLVYEDFLLYKEGVYIiHVTGMPM 
Tg (413) DCEEQAYADNVHPFDQDTHKATSAYSLRS-RDDVKRDMMTHGPVSGAFMVYEDFLSYKSGVYKHVSGLPV 
Sm (223) NCQPGYN ---- IPYEKDKWYGEKVYRIHSNPEAIMLELMRNGPVEVDFEVYADFPNYK. (, GVYQHVSGALL 
Lm (221) TCERNEM ------- DLVKYKGSTSYSVKG-EKELMIELMTNGPLELTMQVYSDFVGYKSGVYKHVLGDFL 
Hum (210) ICEPGYS ---- PTYKQDKHYGYNSYSVSNSEKDIMAEIYKNGPVEGAF'SVYSDFL, I, YKSGVYQHVTGEMM 
491* 560 
Et (443) GGHAVKVIGFGNEDGRDYWlýA%NSWNEYWGDKGTFKIEMG--EAGIDKEFCGGEPKVPNDKNASLLPSAQ 
Tg (482) GGRAIKIIGWGTENGEEYWHAVNSWNTYWGDGGQFKIAMG--QCGIDGEMVAGEAAWQETEGVVNGEEEL 
Sm (289) GGHAVRLLGWGEENNVPYWLIANSWNSDWGDKGYFKIVRGKNECGIESDVNAGIPKIKN ------------ 
Lm (283) GGHAVKLVGWGTQDGVPYWKVANSWNTDWGDKGYFLIQRGNNECKIESGGVAGIPAQE ------------ 
Hum (276) GGHAIRILGWGVENGTPYWLVANSWNTDWGDNGFFKILRGQDHCGIESEVVAGIPRTDQYWEKI ------ 
561 580 
Et (Sll) DL ------------------ 
Tg (550) PGQRAAGARAGAHAEEEREM 
Sm (348) -------------------- 
Lm (341) -------------------- 
Hum (340) -------------------- 
FIG. 3.3. Alignment of the cathepsin B of Eimeria tenelia with cathepsin B enzymes 
from different organisms. Numbering is based on the cathepsin B of Toxoplasma gondii. 
Dashes indicate gaps in the alignment. The predicted signal peptides are underlined. Active site 
residues are starred. Conserved residues are on grey background. The starts for the mature 
enzymes are in bold. Et, Eimeria tenella ; Tg, Toxoplasma gondii (accession number AAL60053, 
Que et al., 2002); Sm, Schistosoma mansoni (CAC8521 1, Klinkert et al., 1994); Lm, Leishmania 
major (AAB48119, Sakanari et al., 1997); Hum, human cathepsin B (NP 680093, Chan et al., 
1986). 
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Pre-0 Pro-O Mature 0 C-terminal 
21 213 270 8 
E. tenella [::::: 11 
34 239 2170 26 
.. 1 AM T. gondii 1: -: ": ýI 
S. mansoni 
22 71 255 
25 72 244 
major [::::: I11 
17 62 252 
Human 
FIG. 3.4. Schematic comparative representation of the different cathepsin B 
sequences. The sequences used are from the alignment in figure 3.3. The pre-, pro-, mature 
and C-terminal domains are represented as blocks and the size in amino acids for each domain is 
indicated on top of each block. 
3.2.2. The cathepsin B gene may be single copy in the E. tenella genome 
By Southern blotting of gDNA and hybridization with a probe specific to 
the cathepsin B gene, a single DNA fragment at about 1 kb was detected (Fig. 
3.5). Another DNA fragment at about 1.4 kb should be detected too, but the 
amount of DNA run on the gel was low, and as the intensity of the band depends 
on the length of hybridization, this band may not have been labeled enough for 
detection. The result obtained is indicative that the gene encoding a cathepsin B- 
like enzyme in E. tenella occurs in one copy in the genome. This result is 
supported by the sequence data from the Sanger database. 
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A 
1456 bp 1038 bp 7198 bp 
EcoRl EcoRl EcoRl E 
B 
2000 
1650 
1000 
850 
Contig5413 
FIG. 3.5. Southern blot analysis of E. tenella genornic DNA using the cathepsin B 
sequence as a probe. (A) Schematic representation of the cathepsin B gene on Contig5413 
(Eimeria assembly, Wellcome Trust Sanger Institute). The ORF is shown as an arrow. EcoRl 
sites are represented as well as the predicted sizes of the resulting digestion fragments. (B) 
Southern blot analysis. Two ýtg of genomic DNA were digested with EcoRl, separated on 1% 
agarose gel, blotted on nylon membrane and hybriclised with 32 P-labelled cathepsin B full gene. 
The blot was exposed for 6 days. The positions of the molecular size markers (bp) are shown on 
the left of the figure. The arrow indicates the band at about 1 kb. 
3.2.3. Expression of recombinant full-length cathepsin B in E. coli 
3.2.3.1. Expression in E. coli BL21(DE3) 
The sequence encoding the pro-mature cathepsin B was amplified from 
cDNA and cloned in the pET28a(+) vector for expression in E. coli with a N- 
terminal His-tag. The plasmid obtained and predicted protein are schernatised in 
Fig. 3.6. Expression in E. coli BL21(DE3) resulted in detection of an abundant 
protein at 56 kDa corresponding to the expected size for the pro-mature enzyme, 
and no protein corresponding to the size of the mature enzyme (around 30 kDa) 
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could be detected (Fig. 3.7). The vast majority of the protein was found to be in 
the soluble fraction of cell lysates, and about 20 mg of pure pro-mature cathepsin 
B could be obtained from 1 liter of E. coli culture. Western blot analysis using 
anti-His-tag antibody on the purified enzyme detected a single protein at 57 kDa 
(F i g. 3.8). 
The pure soluble enzyme did not present any activity against the substrates 
benzoyl-Phe-Arg-7-amino-4-methylcoumarin (Z-Phe-Arg-AMC) and Z-Arg-Arg- 
AMC. 
A 
Kar 
B 
His-tag (22) 
in B 
)96) 
(1272) 
11(1511) 
(1639) 
FIG. 3.6. Construct for expression of recombinant pro-cathepsin B of E. tenefla in 
E. coli. (A) Schematic representation of the plasmid resulting from the cloning of the pro-mature 
sequence of the cathepsin B of E. tenella in the pET28a(+) vector (Novagen) for expression of 
pro-mature cathepsin B with a N-terminal His-tag. Kan, kanamycin resistance gene; f1 origin, 
origin of replication of the phage fl; lacl, gene encoding the lac repressor protein. (B) Schematic 
representation of the protein expressed from the pETcatB plasmid. The size in amino acids of the 
different fragments is indicated between brackets. 
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1234M, 5 
50- 
20- 
4ý 
FIG. 3.7. Analysis of expression and purification of N-terminal His-tagged pro- 
mature cathepsin B of E. tenella expressed in E. coli BL21(DE3). Ten lLl samples were 
loaded on SDS-PAGE gel (12% acrylamide) and post-electrophoresis stained with Coomassie 
blue. Lane M, protein standards; lane 1, E. coli cell lysate prior to isopropyl [ý-D-thiogalactoside 
induction; lane 2, cell lysate after 4h induction at 37C; lane 3, E. coli whole cell lysate; lane 4, 
soluble fraction; lane 5, Nickel-agarose column load; lane 6, flow through; lane 7, elution fraction 
with 500 mM imidazole. 10-3 XMr is indicated on the left of the figure. 
Mr 1 
ý11' 
50- 
44MMW 
20 
FIG. 3.8. Detection of N-terminal His-tagged pro-mature cathepsin B of E. tenella 
expressed in E. coli BL21(DE3) using anti His-tag antibody. Membrane exposure of 2 min, 
anti-His-tag antibody dilution of 1: 2000 (v/v). Lane M, protein standards; lane 1,10 pI of 
recombinant protein expressed in BL21(DE3) and purified on nickel-agarose column. 10-3 X M, is 
indicated on the left of the figure. Arrow indicates the His-tagged pro-mature enzyme. 
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3.2.3.2. Expression in E. co/iJM109(DE3) and HMS174(DE3) 
Different E. coli strains were tested as the levels of soluble expression 
may vary from one strain to the other. Expression in JM109(DE3) and 
HIVIS1 74(DE3) strains of E. coli was evaluated at 150C, 2511C and 3711C, using 
0.5,1, or 1.5 mM IPTG for induction (Fig. 3.9). It revealed that at 370C the over- 
expressed protein was mainly found associated with the inclusion bodies and that 
the concentration in IPTG did not have any effect. At 1511C, the expression was 
considerably reduced and hardly detectable. As it seemed that the concentration 
in IPTG did not have an effect, it was fixed at 1 mM. Expression in both strains at 
250C with 1 mM IPTG resulted in over-expression of a protein of 57 kDa, 
occurring approximately equally in the soluble fraction of whole E. coli cell lysates 
and inclusion bodies (Fig. 3.10). As the expression pattern in the two strains was 
very similar, further analysis were performed on the HMS174(DE3) strain only 
(arbitrary choice). 
Inclusion bodies produced in E. coli HMS174(DE3) were solubilised (see 
Table 2.2, Chapter 2), and the purity of the enzyme could be increased using 
nickel-agarose column, though the purification was not complete (Fig. 3.11). 
Western blot analysis was performed using antibodies raised in rabbit against the 
purified recombinant enzyme produced in a soluble manner in E. coli BL21 (DE3). 
Analysis on the solubilised inclusion bodies generated via expression in 
HMS174(DE3) detected a major protein of 57 kDa corresponding to the pro- 
mature enzyme, plus other proteins, which could correspond to E. coli cross 
reacting proteins or, for the proteins with a molecular mass less than 57 kDa, to 
products of processing of the pro-enzyme (Fig. 3.11). Nevertheless, no protein at 
30 kDa that would correspond to the mature enzyme was detected. 
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JM109(DE3) 
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FIG. 3.9. Analysis of expression of the N-terminal His-tagged pro-mature cathepsin 
B of E. tenelia in E. coli JM109(DE3) and HMS174(DE3) at 371C and 15'C. Ten pl samples 
were loaded on SDS-PAGE gel (12% acrylamide)and post-electrophoresis stained with 
Coomassie blue. Lanes M, protein standards; lanes 1 to 12, JM109(DE3); lanes 13 to 24, 
HMS174(DE3). Above the lane numbers are indicated the concentrations in mM of IPTG used for 
induction, as well as the temperature of induction. Inductions were for 4 h. S: soluble fraction, 1: 
insoluble fraction. 10-3 X M, is indicated on the left of the figure. 
Mr 1234 
50- 
30- 
FIG. 3.10. Analysis of expression of the N-terminal His-tagged pro-mature 
cathepsin B of E. tenella in E. co/iJM109(DE3) and HMS174(DE3) at 25'C. Induction was with 
1 mM IPTG for 4 h. Ten ýd samples were loaded on SDS-PAGE gel (12% acrylamide) and post- 
electrophoresis stained with Coomassie blue. Lane M, protein standards; lane 1, JM109(DE3) 
soluble fraction; lane 2, JM109(DE3) inclusion bodies; lane 3, HMS174(DE3) soluble fraction; 
lane 4, HMS174(DE3) inclusion bodies. 10-3 XMr is indicated on the left of the figure. 
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FIG. 3.11. Solubilisation of N-terminal His-tagged pro-mature cathepsin B of E. 
tenella produced in E. coli HMS174(DE3) at 37'C and purification. Analysis on SDS-PAGE 
gel (12% acrylamide) stained with Coomassie blue. Lane M, protein standards; lane 1, soluble 
fraction of E. coli HMS174(DE3) lysate; lane 2, insoluble fraction; lane 3 and 4, inclusion bodies 
washes; lane 5, solubilised inclusion bodies before loading on anion-exchange column-, lane 6, 
eluted fraction. 10-3 XMr is indicated on the left of the figure. 10 pl samples were loaded. Arrow 
indicates the pro-mature enzyme. 
1 
50 
30- 
FIG. 3.12. Detection of N-terminal His-tagged pro-mature cathepsin B of E. tenella 
produced in E. coli HMS174(DE3) at 37'C using anti cathepsin B of E. tenella antibody 
raised in rabbit. Antibody was used at a dilution 1: 5000 (v/v). Membrane was exposed 15 
seconds. Lane 1,10 pl of solubilised inclusion bodies from expression in HMS 1 74(DE3). 10-3 X M, 
is indicated on the left of the figure. Arrow indicates pro-mature enzyme. 
3.2.4. Attempts to activate the pro-mature cathepsin B produced in E. coli 
Various sample of enzyme produced in a soluble manner in E. coli 
BL21(DE3) or HMS174(DE3), or as inclusion bodies in HMS174(DE3) were 
treated using methods and combinations of methods described in the literature 
for activation of cysteine peptidases. The summary of which samples were 
treated is presented in Table 2.2, chapter 2. The aim in all cases was to try to 
improve folding and disulfide bridge formation and so induce activation (removal 
of the pro-domain) and obtain mature active enzyme. The samples treated were 
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analysed on Coomassie blue-stained SDS-PAGE, western-blots, gelatin gels and 
assayed for activity using the azocasein assay and against the "typical" cathepsin 
B substrates Z-Phe-Arg-AMC and Z-Arg-Arg-AMC. Non-induced E. coli cell 
lysates treated in the same manner and no enzyme controls were included in the 
measurements of activity. 
In all cases, no maturation to the mature size enzyme (about 30 kDa) 
could be detected, and no activity against azocasein or gelatin could be detected 
(results not shown). The maximum activity observed among all the samples 
tested against the substrate Z-Phe-Arg-AMC was 30 mU/mg, but this may have 
been due to the pro-mature enzyme itself. 
3.2.5. Expression of recombinant truncated cathepsin B in E. coH 
The idea was to test if the removal of most of the pro-domain would 
facilitate the folding, processing and/or activation process of the enzyme in order 
to get a significant increase in activity (as has been the case for some other 
cysteine peptidases of Apicomplexa [Shenai et al., 2000; Sijwali et aL, 2001 ]). 
The sequence encoding the total mature domain of the cathepsin B and 
31 amino acids of the pro-domain was amplified from cDNA and cloned in the 
pET28a(+) vector for expression in E. coli BL21 (DE3) with a N-terminal His-tag. 
The plasmid obtained and predicted protein are schernatised in Fig. 3.13. Cells 
transformed with the construct were induced for either 4h at 370C with 1 or 0.5 
mM IPTG, or 4h at 20*C with 1 or 0.5 mM IPTG. An over-expressed protein of 
36 kDa, corresponding to the expected size for the truncated cathepsin B, could 
be detected in all cases, but it was found in the insoluble fraction of E. coli lysates 
if expressed at 37"C (results not shown). The highest rate of expression in a 
soluble manner was obtained by induction at 200C with 0.5 mM IPTG, and the 
soluble protein produced was purified using Ni-agarose affinity chromatography 
(Fig. 3.14). 
89 
Chapter 3: Expression and characterisation 
of the recombinant cathepsin B of E. tenella 
A 
Kar 
B 
His-tag (22) 
On B 
(1096) 
ol(1154) 
FIG. 3.13. Construct for expression in E. coli BL21(DE3) of recombinant cathepsin 
B of E. tenella with 31 amino acids of pro-domain. (A) Schematic representation of the 
plasmid resulting from the cloning of the sequence of the cathepsin B of E. tenella with 31 amino 
acids of the pro-domain in the pET28a(+) vector (Novagen) for expression of mature cathepsin B 
with a N-terminal His-tag and 31 amino acids of pro-domain. Kan, kanamycin resistance gene; f1 
origin, origin of replication of the phage fl; lacl, gene encoding the lac repressor protein. (B) 
Schematic representation of the protein expressed from the pETcatB plasmid. The size in amino 
acids of the different fragments is indicated between brackets. 
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1 
FIG. 3.14. Expression in E. coli BL21(DE3) at 201C of recombinant cathepsin B of E. 
tenella with a truncated pro-domain. Lane M, protein standards; lane 1, E. coli cell lysate after 
isopropyl P-D-thiogalactoside induction, soluble fraction; lane 2, elution fraction 1 from Nickel- 
agarose column with 500 mM imiclazole; lane 3, elution fraction 2; lane 4, elution fraction 3.10-3 X 
M, is indicated on the left of the figure. 10 ýtl samples were loaded. 
3.2.6. Attempts to activate the truncated cathepsin B produced in E. coli 
Unfolding and folding attempts of the truncated cathepsin B were as 
described in Table 2.2. Samples of Nickel-agarose purified truncated cathepsin B 
diluted 1: 1 (v/v) in 0.1 M sodium acetate buffer pH 5.0 or 0.1 M Tris/HCl buffer pH 
8.0 supplemented with 20 mM DTT and incubated at 370C for 20 min showed a 
shift in size of about 2 kDa (Fig. 3.15). Precipitation was observed in the samples 
incubated at pH 5.0, which resulted in lower amount of protein being visible on 
the gel. The shift was not inhibited when the samples were incubated in the 
presence of 300 ýM of E64 (Fig. 3.15). 
Analysis on western blot using anti-cathepsin B antibodies detected a 
single protein of 34 kDa, 2 kDa short compared to the truncated cathepsin B 
sample not incubated in the described conditions (Fig. 3.16). Using anti-His-tag 
antibodies, the protein at 34 kDa could still be detected (Fig. 3.17), suggesting 
some processing of the protein, but not at the N-terminus. The samples 
incubated at pH 5.0 or pH 8.0 were loaded onto gelatin gels and post- 
electrophoresis and washing the gels were incubated at pH 5.0 and pH 8.0 with 
DTT, but no activity could be detected. The same samples were assayed at pH 
5.0 or 8.0 with 10 mM DTT against Z-Phe-Arg-pNA, but no activity was detected. 
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FIG. 3.15. Analysis of the processing of the truncated cathepsin B of E. tenelia 
expressed in E. coli. SDS-PAGE gel (12% acrylamide) stained with Coomassie blue. Lane M', 
protein standards; lane 1,10 pg of purified protein; lane 2,3 pg of the purified protein; lane 3,10 
ýig of purified protein left 18 In at 40C after purification; lane 4,10 pg of purified truncated 
cathepsin B incubated in 0.1 M Tris/HCl pH 8.0,10 mM DTT at 37C for 20 min; lane 5,10 pg of 
purified truncated cathepsin B incubated in 0.1 M Tris/HCI pH 8.0,10 mM DTT at 37"C for 20 min 
with 300 pM E64 . 
10-3 X M, is indicated on the left of the figure. 
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FIG. 3.16. Detection of the truncated cathepsin B of E. tenella expressed in E. coli 
with anti-cathepsin B antibodies. Antibody dilution of 1: 5000 (v/v). Membrane was exposed 30 
seconds. Lane 1,10 pg of purified protein; lane 2,10 pg of purified truncated cathepsin B 
incubated in 0.1 M Tris/HCI pH 8.0,10 mM DTT at 370C for 20 min, 10-3 XMr is indicated on the 
left of the figure. 
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FIG. 3.17. Detection of the truncated cathepsin B of E. tenella expressed in E. coli 
with anti-His-tag antibodies. Antibody was used at a dilution of 1: 2000 (v/v). Membrane was 
exposed 30 seconds. Lane 1,10 pg of purified protein; lane 2,10 Vg of purified truncated 
cathepsin B incubated in 0.1 M Tris/HCI pH 8.0,10 mM DTT at 371)C for 20 min. 10-3 X Mr is 
indicated on the left of the figure. 
Truncated cathepsin B purified on Ni-agarose was directly assayed at pH 
4.0,5.0,6.0 or 7.0 in the presence of 5 mM EDTA, 10 mM DTT and 0.9 M NaCl 
against Z-Phe-Arg-AMC, but no activity could be detected. The protein fell out of 
solution rapidly at pH 4.0,5.0 and 6.0. The same sample was then assayed at pH 
5 or 7 with or without 5 mM EDTA and with or without 10 mM DTT, to test the 
influence of these components, against Z-Phe-Arg-AMC or Z-Arg-Arg-AMC. The 
protein fell out of solution and no activity could be detected. 
The soluble truncated cathepsin B obtained was also treated to unfold and 
slowly refold the protein, to try to improve the folding and disulfide bridge 
formation. The unfolded and dialysed truncated cathepsin B (Sanderson et al., 
2000) was assayed at pH 5.0 or 8.0 with 10 mM DTT against Z-Phe-Arg-AMC, 
but no activity could be detected. 
3.2.7. Non-specific processing of the soluble recombinant pro-mature 
cathepsin B expressed in E. coli BL21 (DE3) 
The idea of this approach was that a correctly folded protein will have 
primarily its loops and hinges accessible to proteolytic cleavage in mild 
conditions. Using low enzyme/substrate ratio and short incubation time- 
digestions with enzymes of wide substrate specificity might allow the separation 
of different domains; i. e. the separation of the pro-domain from the mature 
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domain of the enzyme. Based on the structure of the human cathepsin B (Fig. 
3.18), the domain at the junction between the pro- and the mature domains 
seems accessible to the solvent. Provided the folding might be similar in the 
cathepsin B of E. tenella, cleavage might be possible at that junction. 
FIG. 3.18. Crystal structure of human procathepsin B at 3.3 Angstrom resolution 
(Turk et al., 1996). a-helixes are in orange, P-sheets are in pink and strands are in grey. 
Residues at the N-, and C-termini and at the start of the mature domain are in yellow and marked 
by arrows. 
An analysis using SDS-PAGE of a trypsin digest of the partially purified 
(on Ni-agarose) pro-mature cathepsin B using enzyme/substrate ratios of 1-500 
or 1: 5000 is shown on Fig. 3.19A. The pro-mature cathepsin B seems to be 
reasonably quickly degraded into fragments. In particular fragments at 31,29,20 
and 16 kDa seemed to increase in amount over time. The sample corresponding 
to 30 min incubation with a 1: 5000 ratio of trypsin seemed to yield a good 
representation of these fragments and was therefore chosen for further analyses. 
A chymotrypsin digest analysis at ratios of 1: 500 and 1: 5000 is shown on 
Fig. 3.19B. The ratio of 1: 5000 seemed to be again adequate for analysis as 
several fragments (at 34,28,18,16 kDa, for example) seemed to increase in 
amount over time in a sensible time for analysis. 
In the case of the use of subtilisin, the ratio had to be adjusted to 1-50000, 
as at a ratio of 1: 5000, practically all cathepsin B was degraded within 2 min of 
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incubation (Fig. 3.19C). Analysis of a digest at ratio 1: 50000 is presented on Fig. 
3.19D. Within 30 to 60 min of incubation, 2 major fragments at 42 and 28 kDa 
seemed to clearly increase in amount. 
Samples of cathepsin B incubated either with trypsin 1: 5000 for 30 min, 
chymotrypsin 1: 5000 for 60 min, or subtilisin 1: 50000 for 45 min were analysed 
using gelatin SDS-PAGE, but no activity could be detected when gels were 
incubated at pH 5.0 or 8.0 with 20 mM DTT. The same samples were tested for 
activity against Z-Phe-Arg-pNA at pH 5.0,7.0 or 8.0 +/- 5 mM EDTA, +/- 10 mM 
DTT. No activity could be detected except in the samples with trypsin at pH 7.0 or 
8.0. This activity was not E64 inhibited (11 mM) but could be inhibited with TLCK 
(0.1 mg/ml), an inhibitor of serine peptidases, at pH 7.0 but not 8.0. Knowing 
TLCK is not stable at pH above 7.5, it can be concluded that the activity detected 
was due to trypsin. 
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FIG. 3.19. Analysis of the non-specific cleavage of the recombinant N-terminal His- 
tagged cathepsin B of E. tenella produced in E. coli. 40 pg of cathepsin B were used per test. 
Cleavages were at room temperature and analysed using SIDS-PAGE (12% acrylamide) and 
staining with Coomassie blue. Lane M, protein standards. Arrows mark bands appearing with 
time. 10-3 X M, is indicated on the left of the figure. (A) Cleavage with trypsin. Trypsin ratio was of 
1: 500 (w/w) (lanes I to 5) or 1: 5000 (w/w) (lanes 6 to 9). Lane 1, incubation 0 min; lanes 2 and 6, 
2 min; lanes 3 and 7,15 min; lanes 4 and 8,30 min; lanes 6 and 9,11 h. (B) Cleavage with 
chymotrypsin. Same labelling as in (A). (C) Cleavage with subtilisin. Same labelling as in (A). (D) 
Cleavage with subtilisin, ratio 1: 50000. Lane 1, incubation of 0 min; lane 2,2 min; lane 3,15 min; 
lane 4,30 min; lane 5,1 h. Samples marked with a star were further analysed by gelatin SDS- 
PAGE and tested for activity. 
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3.2.8. Specific processing of the recombinant pro-mature cathepsin B 
The idea of this approach was to introduce various very specific cleavage 
sites for commercially available enzymes at the limit between the predicted pro- 
and mature domains, predictions based on the domains of the T. gondii 
cathepsin B (Que et A, 2002). This would be done by site-directed mutagenesis 
on the existing complete cathepsin B expression construct in pET28a(+). The 
hypothesis was that it might allow for easy removal of the pro-domain and 
activation of the enzyme, provided the soluble enzyme was properly folded. 
Thrombin and enterokinase did cleave the non-mutated cathepsin B, 
whereas the Factor Xa and the TEV protease did not, and mutagenesis to 
introduce the specific cleavages sites for these 2 peptidases was performed. The 
resulting proteins were expressed in a soluble manner in E. coli BL21(DE3) at 
250C and purified on nickel-agarose column. A scheme of the method used and 
the results of cleavage of the mutated proteins by the Factor Xa or the TEV are 
shown on Fig. 3.20 and Fig. 3.21, respectively. In case of cutting with the TEV, 
two protein fragments could be detected, at the predicted sizes for the pro- 
domain (-26 kDa) and the mature domain (31 kDa). In case of cleavage with the 
Factor Xa, an additional protein was detected 2 kDa smaller than the pro-domain, 
which could correspond to the size of the pro-domain without the His-tag, or a 
product of unspecific cleavage. This was tested by western-blotting, using anti 
His4ag antibodies (Fig. 3.20D). A single protein at the expected size for the pro- 
domain (-26 kDa) was detected in both cleaved samples. The additional protein 
fragment resulting from the Factor Xa cleavage does not correspond to a His- 
tagged protein. 
The cleaved samples were analysed using gelatin SIDS-PAGE with 
incubation at pH 5.0 or 8.0, but no activity could be detected. Based on the 
possibility that the enzyme might get inactivated irreversibly during the 
electrophoresis, the azocasein assay was used. The activity was tested at pH 5.0 
or 8.0 with 24 h incubation at 3711C. From the measurements taken, no real 
positive cleavage of the azocasein occurred compared to the negative control 
(unprocessed recombinant cathepsin B of E. tenella) (results not shown). The 
same samples were also tested for activity continuously for 30 min against Z- 
Phe-Arg-AMC but no cleavage of the substrate could be detected. 
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FIG. 3.20. Mutagenesis for specific cleavage by the Factor Xa at the predicted 
junction between the pro- and the mature domains of the recombinant cathepsin B of E. 
tenella expressed in E. coli. (A) Schematic representation of the method used. Amino acids are 
represented by the single letter code. Sizes of fragments are not to scale. (B) Expression of 
recombinant N-terminal His-tagged protein carrying the mutation for the Factor Xa cleavage site. 
Lane M, protein standards; lane 1, E. coli cell lysate after IPTG induction 4h at 250C, insoluble 
fraction; lane 2, E coli cell lysate, soluble fraction; lane 3, elution fraction 1 from Nickel-agarose 
column; lane 4, elution fraction 2; lane 5, elution fraction 3.10-3 X Mr is indicated on the left of the 
figure. 10 ýd samples were loaded. (C) Analysis of cleavage (overnight) of recombinant cathepsin 
B (40 Vg) with Factor Xa (1 Unit) at room temperature using SDS-PAGE (12% acrylamide) and 
staining with Coomassie blue. Lane 1, non-mutated cathepsin; lane 2, mutated cathepsin B. (D) 
Detection of His-tagged proteins on gel on figure C. Anti His-tag antibody dilution of 1: 2000 (v/v). 
Membrane exposure of 1 min. Lane 1, non-mutated cathepsin; lane 2, mutated cathepsin B. 
97 
Chapter 3: Expression and characterisation 
of the recombinant cathepsin B of E. tenella 
His-tag 
Predicted pro-domain 
Predicted mature domain 
Cathepsin B 
expressed in 
E. coli 
56.8 kDa 
56.8 kDa 
Cleavage by 
TEV protease 
II... 
-EN 25.8 kDa 
I+ 
-7-::: 
] 
31 kDa 
Bc 
M, 12345M, 12 
50- 50- 50- 
20- 
25- 
20- 
FIG. 3.21. Mutagenesis for specific cleavage by the TEV (Tabacco etch virus) Nla 
protease at the predicted junction between the pro- and the mature domains of the 
recombinant cathepsin B of E. tenella expressed in E. coli. (A) Schematic representation of 
the method used. Amino acids are represented by the single letter code. Sizes of fragments are 
not to scale. (B) Expression of recombinant N-terminal His-tagged protein carrying the mutation 
for the TEV protease cleavage site. Lane M, protein standards; lane 1, E. coli cell lysate after 
IPTG induction 4h at 250C, insoluble fraction; lane 2, E. coli cell lysate, soluble fraction; lane 3, 
elution fraction 1 from Nickel-agarose column; lane 4, elution fraction 2; lane 5, elution fraction 3. 
10-3 x M, is indicated on the left of the figure. 10 pl samples were loaded. (C) Analysis of cleavage 
(overnight) of recombinant cathepsin B (40 pg) with TEV protease (10 Units) at room temperature 
using SDS-PAGE (12% acrylamide) and staining with Coomassie blue. Lane 1, non-mutated 
cathepsin B; lane 2, mutated cathepsin B. (D) Detection of His-tagged proteins on gel on figure C. 
Anti His-tag antibody dilution of 1: 2000 (v/v). Membrane was exposed 1 min. Lane 1, non- 
mutated cathepsin B; lane 2, mutated cathepsin B. 
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3.2.9. Expression of recombinant full-length cathepsin B in Pichia pastoris 
The idea behind trying to express the enzyme in the Pichia system was 
that, by expressing in a eukaryotic system, the protein may be glycosylated, 
which might be necessary for the enzyme activity. Moreover, the release into the 
supernatant of culture may provide potentially easy purification. Both constitutive 
and inducible expressions were tested. The constitutive system is easier to use, 
but in some cases inducible expression may be more successful, as it involves 
reaching a high cell density before starting of the induction. 
3.2.9.1. Constitutive system 
The sequence encoding the pro-mature cathepsin B was amplified from 
cDNA and cloned in the pGAPZaA vector for expression in a constitutive manner 
and release of the recombinant enzyme without or with a C-terminal His-tag into 
the supernatant of culture of P. pastoris X-33 cells. The plasmids obtained and 
predicted proteins are schematised in Fig. 3.22 and Fig. 3.23, respectively. 
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FIG. 3.22. Construct for expression of recombinant pro-cathepsin B of E. tenelia in 
Pichia pastoris, constitutive system. (A) Schematic representation of the plasmid resulting 
from the cloning of the pro-mature sequence of the cathepsin B of E. tenella in the pGAPZCt 
vector for constitutive expression of pro-mature cathepsin B in the supernatant of culture. (B) 
Schematic representation of the protein expressed from the pGAPcatB plasmid. The size in 
amino acids of the different fragments is indicated between brackets. 
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FIG. 3.23. Construct for expression of recombinant pro-cathepsin B of E. tenefla 
with a C-terminal His-tag in Pichia pastoris, constitutive system. (A) Schematic 
representation of the plasmid resulting from the cloning of the pro-mature sequence of the 
cathepsin B of E. tenella in the pGAPZct vector for constitutive expression of pro-mature 
cathepsin B in the supernatant of culture. (B) Schematic representation of the protein expressed 
from the pGAPcatB plasmid. The size in amino acids of the different fragments is indicated 
between brackets. 
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3.2.9.1.1. Confirmation of transformants 
Transformants were selected on Zeocin plates (100 pglml), and 
insertions of the fragments were verified by PCR on genomic DNA extracted from 
positive clones, using the PCR primers a-factor and TAOX1. Results are shown 
in Fig 3.24. Analysis of transformants by PCR showed integration for all three 
plasmids transfected. A DNA fragment between 200 and 300 bp was amplified on 
the genomic DNA extracted from cells transfected with the empty vector, which 
corresponds to the predicted size of 295 bp. On the genomic DNA extracted from 
the cells transfected with the pGAPHisCatB plasmid and the pGAPCatB plasmid, 
the size of the predicted amplified fragments was about 1800 bp. Two positive 
clones were therefore detected for the former plasmid (Fig. 3.24A) and all the 
clones tested for the latter plasmid seemed to be positive (Fig. 3.24B), as a DNA 
fragment between 1650 and 2000 bp was amplified. 
3.2.9.1.2. Analysis of expression 
One positive colony for each of the constructs was selected and tested for 
expression of the target protein as described in the manufacturers manual (final 
volume of 50 ml of YPD media). One ml aliquots were taken a regular time 
intervals, cells were separated from the supernatant of culture by centrifugation 
and samples of supernatant and cell lysates were used for analysis using gelatin 
SDS-PAGE, the azocasein assay, and either with Coomassie blue-stained SDS- 
PAGE or western blot analysis. 
Analysis of the supernatant of culture of the Pichia cells having integrated 
the empty vector or the pGAPHisCatB or pGAPCatB plasmids showed in all 
cases the presence of a faint single protein between 40 and 50 kDa after 24 to 48 
h of culture (results not shown). This protein is unlikely to be related to the protein 
of interest, as it is expressed in the negative control cells that had integrated the 
empty vector. No protein at the expected size for the pro-mature cathepsin B 
(55.4 kDa) could be detected in crude supernatant or in the cell extracts by SDS- 
PAGE (results not shown). By western-blot analysis, a protein corresponding to 
the expected size for the pro-mature cathepsin B at about 55 kDa could be 
detected in the crude supernatant of culture and the cell extracts of the Pichia 
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cells transfected with the pGAPCatB and pGAPHisCatB plasmids but not in the 
control cells transfected with the empty vector (Fig. 3.25). Signs of processing 
could also be detected as smaller bands could be visualised, especially in the 
supernatant of culture of the cells transfected with the pGAPCatB plasmid. The 
proteins trapped inside the cells were of less interest, as purification would be 
more difficult. 
By TCA precipitation of a small volume of supernatant of culture of Pichia 
cells transfected with the pGAPHisCatB and the pGAPCatB plasmids, the protein 
between 40 and 50 kDa was more easily detected by SDS-PAGE (Fig. 3.26). 
However, it does not seem to be related to the cathepsin B, as it was not 
recognised with anti-cathepsin B antibodies (Fig. 3.25). An additional protein at 
about 55 kDa, corresponding to the expected size for the pro-mature cathepsin B 
could also faintly be detected after 48 to 72 h of culture (Fig. 3.26), and the 
expression seemed stable for at least 8 days (results not shown). By western-blot 
analysis of the TCA-precipitated supernatant of culture of Pichia cells transfected 
with the pGAPHisCatB plasmid and the pGAPCatB plasmid, the results obtained 
by SDS-PAGE were confirmed. That is, a 55 kDa band corresponding to the 
predicted size for the pro-mature cathepsin B could be detected after 48 h of 
culture (Fig. 3.27). Moreover, signs of processing of the protein could be 
observed in the supernatant of cells transfected with the pGAPCatB plasmid (Fig. 
3.27). 
Aliquots of supernatant of the cultures described above were analysed 
using gelatin SDS-PAGE with incubation at pH 5.0 and pH 8.0 for 24 h at 37*C, 
but no difference in activity could be detected between the cathespin 13- 
expressing cells and the negative control cells. The same pattern of proteins was 
detected in all cases (proteins were in high molecular weight range, above 50 
kDa). 50 ýLl of supernatant of culture were tested as well for activity using the 
azocasein assay, but no activity could specifically be detected compared to the 
control cells supernatant. The activity detected on azocasein was in all cases 
DTT inhibited and not E64 inhibited (the activity was probably due to the release 
of a peptidase into the supernatant of culture not related to the cathepsin B) 
(Table 3.1). This peptidase activity did degrade the cathepsin B. 
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FIG. 3.24. Verification of insertion of the pGAPHiscatB and pGAPcatB constructs in 
the Pichia X-33 genome. PCR analysis of Pichia transformants, using1% agarose gel and 
ethidium bromide staining. (A) Cells transfected with the pGAPZ(IA empty vector (lanes 1 to 4), or 
with the pGAPHiscatB plasmid (lanes 5 to 8). (B) Cells transfected with the pGAPcatB plasmid. 
Size in bp is indicated on the left of the figure. M, corresponds to molecular mass in kDa. 
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FIG. 3.25. Analysis of expression of the cathepsin B of Eimeria tenelia in Pichia 
pastoris X-33, constitutive system. Analysis by western blot (1: 8000 dilution of last bleed anti 
cathepsin B antiserum; 1: 5000 dilution of anti-rabbit antibody; 2 min exposure) of the supernatant 
of culture (lanes 1,3 and 5) and the Pichia cell extracts (lanes 2,4 and 6) transfected with the 
pGAPZccA vector (lanes 1 and 2), the pGAPcatB plasmid (lanes 3 and 4) and the pGAPHiscatB 
plasmid (lanes 5 and 6) at t= 72 h. 10 pl of suspension were loaded. M, corresponds to molecular 
mass in kDa. 
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FIG. 3.26. Analysis of expression of the cathepsin B of Eimeria tenefia in Pichia 
pastoris X-33, constitutive system, by TCA precipitation of the supernatant of cultures. 
Analysis on post-el ectroph ores is Coomassie blue-stained 12% (w/v) SDS-PAGE gel of the 
equivalent of 0.2 ml of TCA-precipitated supernatant of culture of Pichia cells transfected with the 
pGAPHisCatB plasmid (lanes 1 to 5) and the pGAPCatB plasmid (lanes 6 to 9). Lane 1,24 h; 
lane 2,48 h; lane 3,72 h; lane 4,96 h; lane 5,168 h; lane 6,24 h; lane 7,48 h; lane 8,72 h; lane 
9,96 h. The arrow indicates the 55 kDa protein. M, corresponds to molecular mass in kDa. 
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FIG. 3.27. Detection of the cathepsin B of Eirneria tenella expressed and released by 
Pichia pastoris X-33, constitutive system, in TCA-precipitated supernatant of cultures. 
Analysis by western blot (1: 8000 dilution of last bleed anti cathepsin B antiserum; 1: 5000 dilution 
of anti-rabbit antibody; 2.5 min exposure) of the equivalent of 0.2 ml of TCA-precipitated 
supernatant of culture of Pichia cells transfected with the pGAPHisCatB plasmid (lanes 1 to 5) 
and the pGAPCatB plasmid (lanes 6 to 9). Lane 1,24 h; lane 2,48 h; lane 3,72 h; lane 4,96 h; 
lane 5,168 h; lane 6,24 h; lane 7,48 h; lane 8,72 h; lane 9,96 h. M, corresponds to molecular 
mass in kDa. 
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Table 3.1. Azocaseln assay on Pichia culture supernatant after 192 h of culture. Fifty 
l. d of a 1% (w/v) azocasein was mixed with 400 pl 50 mM sodium acetate pH 5.0 and 50 l. Ll of 
sample to test (about 10 pg of recombinant protein) and incubated at 37"C overnight. The 
absorbance of the supernatant was measured at 400 nm. 
Sample Absorbance (400 nm) 
Control without protein 0.09 
pPlC9catB supernatant 0.948 
pPlC9catB supernatant 0 464 10 mM DTT, 1 mM E64 . 
pPIC9catB supernatant 0.975 
1 mM E64 
pPIC9catB supernatant 0.471 
10 mM DTT 
pPIC9 supernatant 0.861 
pPIC9 supernatant 0.921 
1 mM E64 
pPIC9 supernatant 0.459 
10 mM DTT 
3.2.9.2. Inducible system 
The sequence encoding the pro-mature cathepsin B was amplified from 
cDNA and cloned in the pPIC9 vector for expression in an inducible manner and 
secretion into the supernatant of culture of P. pastoris KM71 cells of the 
recombinant enzyme without a His-tag. The plasmid obtained and predicted 
protein are schernatised in Fig. 3.28. 
3.2.9.2.1. Confirmation of transformants 
Insertions of the fragments were verified by PCR on genomic DNA 
extracted from positive clones, using the pairs of PCR primers a-factor and 
XAOX1, or 5'AOX1 and 3'AOX1 (see Table 2.1, chapter 2). Results of PCRs on 
genomic DNA extracted from KM71 His' Muts are shown on Fig. 3.29. By PCR 
using the (x-factor/3'AOX1 primers, a DNA fragment of 1661 bp is predicted to be 
amplified on the genomic DNA from KM71 cells transfected with the pPlC9catB 
plasmid, and a DNA fragment of 195 bp is predicted to be amplified on the 
genomic DNA from KM71 cells transfected with the pPIC9 empty vector. Using 
the 5'AOX1/3'AOX1 primers, a DNA fragment at 3.6 kb corresponding to the 
amplification from the endogenous mutated AOXII gene should be detected in all 
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His"' Muts cells. The amplification of the inserted fragment from the pPIC9catB 
construct would yield a product at 1968 bp and the amplification of the inserted 
fragment from the pPIC9 empty vector would yield a product at 492 bp. 
Therefore, from the results on Fig. 3.29, the clone selected for each transfection 
seems to correspond to a positive clone. 
3.2.9.2.2. Analysis of expression 
One positive colony for each of the transfections was selected and tested 
for expression of the target protein. Cells were induced with 0.5 % methanol (v/v, 
final concentration) every 24 h and 0.5 ml aliquots were taken a regular time 
intervals. Cells were separated from the supernatant of culture by centrifugation 
and samples of supernatant were used for analysis using gelatin SDS-PAGE, the 
azocasein assay, and, either directly or after TCA-precipitation, Coomassie blue- 
stained SDS-PAGE and western blot analysis. The control strain transfected with 
the empty vector was induced and its supernatant of culture was also analysed 
after TCA-precipitation. 
Time course analysis of expression showed that the recombinant protein 
was already present about 24 h after the start of induction, that the amount of 
protein increased slightly until 96 h after induction and then remained stable until 
at least 192 h after induction (data not shown). The cells were routinely harvested 
192 h after the start of induction. Analysis of expression showed a major protein 
at about 30 kDa on Coomassie blue-stained SIDS-PAGE gels in the supernatant 
of cells transfected with the pPIC9catI3 plasmid, but not in the supernatant of the 
cells transfected with the empty pPIC9 vector (Fig. 3.30). This corresponds to the 
size expected for the mature cathepsin B-like enzyme. Using specific anti-pro- 
cathepsin B antiserum, a major protein at about 30 kDa (Fig. 3.30, lane 6), the 
size expected for the mature enzyme, was found in the supernatant of culture of 
the KM71 Pichia cells transfected with the pPIC9CatB plasmid for inducible 
expression. Based on Coomassie blue-stained SIDS-PAGE analysis, the 
expression was estimated to be about 100 mg of protein per litre of culture. In the 
TCA-precipitated supernatant of culture at the time of harvest, 2 major proteins 
were detected using specific anti-pro-cathepsin B antiserum (Fig. 3.30, lane 7). 
One band was the protein at 30 kDa, the other was slightly larger (about 32 kDa). 
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Fainter proteins at about 54 kDa and 22 kDa could also be detected, which could 
correspond, respectively, to the pro-mature enzyme and the pro-domain. 
By western blot analysis of the cell extracts of Pichia cells transfected with 
the pPlC9catB plasmid and the empty vector, only traces of the 54 kDa protein 
could be detected in the cell extracts of the cells transfected with the pPIC9catB 
plasmid but not the empty vector, suggesting that most of the protein expressed 
was released into the medium (results not shown). 
Supernatants of cultures of both the cathepsin B-expressing and control 
cells were tested for activity against the Z-Phe-Arg-AMC substrate and there was 
significantly greater activity (3000-fold) in the supernatant of culture of cells 
expressing a processed protein recognised by anti-cathepsin B antiserum, 
compared to the same volume of supernatant of culture of cells transfected with 
the empty vector. The culture supernatant containing the active enzyme was 
analysed immediately or stored at -200C for later analysis. 
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FIG. 3.28. Construct for expression of recombinant pro-cathepsin B of E. tenefla in 
Pichia pastoris, inducible system. (A) Schematic representation of the plasmid resulting from 
the cloning of the pro-mature sequence of the cathepsin B of E tenella in the pPIC9 vector for 
inducible expression of pro-mature cathepsin B in the supernatant of culture. Amp, ampicillin 
resistance gene; CoIE1, origin of replication; AOX1, alcohol dehydrogenase gene; HIS4; histidine 
prototrophy gene. (B) Schematic representation of the protein expressed from the pPIC9catB 
plasmid. The size in amino acids of the different fragments is indicated between brackets. 
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FIG. 3.29. Verification of insertion of the pPlC9catB construct in the Pichia KM71 
genome. (A) Schematic representation of the position of the different primers used for PCR and 
their position. (x, cc-factor sequence; AOX1, alcohol dehydrogenase gene; ARG4, gene for 
arginine prototrophy. (B) PCR analysis of Pichia transformants using 1% agarose gel and 
ethidium bromide staining. Ten jal of reactions were loaded. PCRs used the primers C(- 
factor/3'AOX1 (lanes 1 and 2), and 5'AOX1/3'AOX1 (lanes 3 and 4). Genomic DNA from KM71 
cells transfected with the pPIC9catB plasmid was analysed on lanes 1 and 3. Genomic DNA from 
KM71 cells transfected with the pPIC9 empty vector was analysed on lanes 2 and 4. Size in bp is 
indicated on the left of the figure. 
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FIG. 3.30. Analysis of expression of the cathepsin B of Eimeria tenelia in Pichia 
pastoris KM71, inducible system. Fifteen pl of supernatant of culture of Pichia cells transfected 
with the pPIC9catB plasmid (lanes 2 and 6) and the empty pPIC9 vector (lanes 1 and 5) were 
analysed using Coomassie blue-stained 12% (w/v) SIDS/PAGE (lanes 1 and 2) and by western 
blot analysis (lanes 3 and 4; 1: 8000 dilution of last bleed anti-cathepsin B antiserum; 1: 5000 
dilution of anti-rabbit antibody; 5 min exposure). The equivalent to 0.5 ml of supernatant of culture 
of Pichia cells transfected with the pPIC9catB plasmid (lanes 3 and 7) and the empty pPIC9 
vector (lanes 4 and 8) after TCA-precipitation were analysed using Coomassie blue-stained 12% 
(w/v) SDS/PAGE (lanes 3 and 4) and by western blot analysis (lanes 7 and 8; 1: 8000 dilution of 
last bleed anti-cathepsin B antibody; 1: 5000 dilution of anti-rabbit antibody; 2 min exposure). 
3.2.10. Purification of recombinant full-length cathepsin B expressed and 
secreted by Pichia pastoris 
The enzyme was purified from the supernatant of culture by ammonium 
sulfate precipitation. The enzyme was found to precipitate mainly between 40 
and 70 % ammonium sulfate saturation (Fig. 3.31). The protein appeared to be 
slightly purer using 70% rather than 80% saturation precipitation and the smear 
apparent in the low molecular mass range of the gels with crude extract 
disappeared (Fig. 3.32, lane 1). In addition, the yellow-brown colour of the culture 
supernatant (due to the abundant polysaccharides present) also was less in the 
pellet resuspensions compared with the crude extract. Thus, ammonium sulfate 
precipitation improved the purity of the enzyme significantly. A 40 % saturation 
precipitation followed by a 70 % saturation precipitation on the supernatant of 
precipitation resulted in the presence of 2 proteins at about 30 and 32 kDa on 
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Coomassie blue-stained gels (Fig. 3.32, lane 2), specifically recognised by anti- 
pro-cathepsin B antiserum (Fig. 3.32, lane 4). 
I 
> 
Ammonium sulfate saturation (%) 
FIG. 3.31. Ammonium sulfate precipitation of the cathepsin B of Eimeria tenella 
produced by Pichia pastoris KIVI71, Inducible system. Aliquots of supernatant of culture of 
Pichia cells expressing the cathepsin B were incubated for 2h at 4"C with gentle agitation In the 
presence of increasing ammonium sulfate saturation concentrations. The precipitated proteins 
were pelleted for 15 min at 13000 g, 4"C and resuspended in the Initial volume of 50 mM sodium 
acetate, pH 5.0. The activity was measured and compared to the non-treated sample. The activity 
present in the pellet was expressed as a percentage of the initial activity. 
3.2.11. Deglycosylation of recombinant full-length cathepsin B expressed In 
Pichia pastoris 
After treatment with the PGNase F for deglycosylation, a single protein at 
30 kDa corresponding to the mature cathepsin B could be detected on 
Coomassie blue-stained SDS-PAGE gel (Fig. 3.32, lane 3), specifically 
recognised by anti-pro-cathepsin B antibodies (Fig. 3.32, lane 5). 
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FIG. 3.32. Deglycosylation of the cathepsin B of Eimeria tenefla produced and 
released by Pichia pastoris KM71, inducible systern. The supernatant of culture of cathepsin 
B-expressing Pichia cells (lane 1) was treated with 40% ammonium sulfate for 2h at 4'C with 
gentle agitation; the supernatant of this treatment was then incubated in the presence of 70% 
ammonium sulfate for 2h at 40C with gentle agitation, and the precipitated fraction after this step 
was resuspended and analysed on a Coomassie blue-stained 12% (w/v) SDS-PAGE gel (lane 2) 
and by western blot analysis (lane 4,1: 8000 dilution of last bleed anti-cathepsin B antiserum; 
1: 5000 dilution of anti-rabbit antibody; 3 min exposure). The purified enzyme was treated with 
PGNAse F (0.5 U, 1h at 37'C) and analysed on a SDS-PAGE gel (lane 3) and by western-blot 
(lane 5) as described for the non-deglycosylated sample. Fifteen pl of each sample were loaded 
on the gels. 
3.2.12. Characterisation of the active recombinant cathepsin B expressed in 
Pichia pastoris 
An activity of about 0.6 U/ml towards the substrate Z-Phe-Arg-pNA (333 
pM) in 50 mM sodium acetate pH 5.0,2 mM EDTA, 10 mM DTT, could be 
detected in the sample of crude culture supernatant (concentration of 100 pg 
protein/ml), whereas the crude supernatant of culture of Pichia cells transfected 
with the empty pPIC9 vector showed a maximum of activity of 0.2 mU/ml against 
the same substrate. The Km for Z-Phe-Arg-pNA could not be measured as the 
substrate was falling out of solution at higher concentrations. No activity towards 
100 [, M of Z-Arg-Arg-pNA could be detected under the conditions used. Higher 
concentrations of substrate provoked its precipitation in the assay buffer. From 
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the alignment on Fig. 3.3, it can be predicted that the Eimeria cathepsin B should 
be able to cleave Arg at the P2 position, as it possesses Glu-325 (human 
cathepsin B numbering), allowing the enzyme to accommodate Arg at the P2 site 
like the human cathepsin B (Hasnain et al., 1993; Chan et al., 1999). But it is also 
known that the human cathepsin B has a 7-fold preference for Phe over Arg at 
the P2 position (Hasnain et al., 1993), so the concentration of Z-Arg-Arg-pNA 
may not be sufficient for detection of activity. 
3.2.12.1. Dependence on DTT and EDTA 
The enzyme activity was strictly dependent on the presence of DTT, 10 
mM being the minimum required for maximum activity. EDTA seemed to have a 
beneficial effect on the activity, with 5 mM being the minimum required for 
observation of maximum activity (Fig. 3.33). 
EDTA 
DTT 
> 
0 
Concentration (mM) 
FIG. 3.33. Dependence of the activity of the recombinant cathepsIn B of Eimeria 
tenefla on DTT and EDTA- Enzyme activity was tested for dependence on DTT and EDTA, and 
measured in 50 mM sodium acetate pH 5.0, using the substrate Z-Phe-Arg-AMC, In a total 
volume of 0.6 mi. 30 til of crude Pichia supernatant were used for each assay. The reaction was 
started by addition of 50 pM of substrate and measured continuously for 5 min at 37"C 
(Excitation: 380 nm/Emission: 465 nm). Dependence of the activity on DTT was measured in the 
absence of EDTA, and dependence of the activity on EDTA was measured in the presence of 10 
mM DTT. Activity towards Z-Phe-Arg-AMC in the control supernatants (from Pichia transfected 
with the empty plasmid) was negligible under these conditions. 
114 
05 10 15 20 
Chapter 3: Expression and characterisation 
of the recombinant cathepsin B of E. tenella 
3.2.12.2. Dependence on salt 
Sodium chloride, which may in some cases stabilise enzyme activity, did 
not seem to have any beneficial effect at concentrations up to 200 mM; on the 
contrary, above 200 mM it seemed to be slightly detrimental, reducing the activity 
by 20% (Fig. 3.34). Sodium chloride was omitted from all subsequent assays. 
101 
81 
6 
.ý 
2 
NaCl (mM) 
FIG. 3.34. Dependence of the activity of the recombinant cathepsin B of Eirneria 
tenella on salt. Enzyme activity was tested for dependence on NaCl, and measured in 50 mM 
sodium acetate pH 5.0, using the substrate Z-Phe-Arg-AMC, in a total volume of 0.6 ml. 30 I. Ll of 
crude Pichia supernatant were used for each assay. The reaction was started by addition of 50 
I. tM of substrate and measured continuously for 5 min at 3711C (Excitation: 380 nm/Emission: 465 
nm). 
3.2.12.3. pH optimum 
In terms of pH dependence, the activity was close to zero when the pH 
was under 4.0 or above 9.0 and seemed to present 2 maxima, at pH 5.0 and pH 
8.0, in the mix of buffers (Fig. 3.35A). The reason why the activity seems to drop 
at pH 5.5 and 6.0 is unclear at present, but might be due to changes in ionic 
strength in the buffer. Using individual buffers, the activity dropped drastically 
when the pH was under 4.0 or above 9.0. The activity seemed to present 2 peaks 
in these conditions, one between pH 4.0 and 5.5, one at pH 7.5. The activity 
decreased rapidly or slightly (depending on the buffer) between pH 5.5 and 6.5 
(Fig. 3.35B). 
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FIG. 3.35. Dependence of the activity of the recombinant cathepsin B of Elmeria 
tenella on pH. (A) The pH dependence was determined using a mix of 4 buffers (25 mM acetic 
acid, 25 mM MES, 75 mM Tris, 25 mM glycine) adjusted to the appropriate pH, with 2 ý11 of crude 
Pichia supernatant and 10 mM DTT. The reaction was started by addition of 30 IaM of Z-Phe-Arg- 
AMC. (B) Three different buffers were used separately, depending on their pH range. These 
buffers were 0.1 M acetic acid, 0.1 M sodium acetate and 0.1 M potassium phosphate. All buffers 
were supplemented with 10 mM DTT. The reaction was started by addition of 30 ýLM of Z-Phe- 
Arg-AMC. Reactions used 10 ýd of crude Pichla supernatant and were measured continuously for 
5 min at 370C (Excitation: 380 nm/Emission: 465 nm). Results are the means ± SID from 3 
independent measurements. 
3.2.12.4. K .. s against Z-Phe-Arg-AMC and Z-Arg-Arg-AMC 
Purified enzyme was active against the substrates Z-Phe-Arg-AMC and Z- 
Arg-Arg-AMC; activity was 20-fold higher against Z-Phe-Arg-AMC than against Z- 
Arg-Arg-AMC (Fig. 3.36A). The strong preference for a phenylalanine residue at 
the P2 site compared to arginine is a characteristic for this class of enzymes. The 
Km and specific activities were respectively 168 ± 33 ýN and 6 U/mg protein 
against Z-Phe-Arg-AMC; and 1.40 ± 0.25 mM and 0.3 U/mg protein against Z- 
Arg-Arg-AMC (Fig. 3.36B). The purified enzyme had very comparable 
characteristics to the purified and deglycosylated enzyme, with a variation of Kms 
lower than 8% and variation of activity lower than 10%. The use of culture 
supernatant from control cultures (Pichia with the empty vector) showed that it 
contained no detectable activity towards Z-Phe-Arg-AMC (< 0.2 mU/ml). 
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FIG. 3.36. Analysis of the activity of the non-deglycosylated and deglycosylated 
cathepsin B of Eimeria tenella produced in Pichia pastoris against the synthetic 
fluorogenic substrates Z-Phe-Arg-AMC and Z-Arg-Arg-AMC. Bars indicate the standard 
deviation around the mean, based on 3 repetitions of each measurement. 0.5 ýIg of enzyme was 
used per assay. (A) Representation of the activity (U/mg protein) of the different enzyme fractions 
against the 2 substrates Z-Phe-Arg-AMC and Z-Arg-Arg-AMC. Enzyme samples were tested for 
activity in a final volume of 1 mi. The enzyme sample was incubated for 10 min at 370C in the 
assay buffer before start of the reaction by addition of the substrate (200 plM, unless for K, 
determination were 10 pM to 1.5 mM were used). Excitation and emission wavelengths were 
respectively 380 and 465 nm. The assays were continuous for 10 min at 370C. (B) 
Representation of the Km (pM) of the different enzyme fractions against the 2 substrates Z-Phe- 
Arg-AMC and Z-Arg-Arg-AMC. Results are the means ± SID from 3 independent measurements. 
3.2.12.5. Inhibitors 
Various peptidase inhibitors were tested on both the non-deglycosylated 
and deglycosylated enzymes (Tables 3.1A and B). As expected, the cysteine 
peptidases inhibitors (2S, 3S)-3-(N-{(S)-l-[N-(4-guanidinobutyl)carbamoyl]3- 
m ethyl butyllca rba moyl)oxi ra ne-2-ca rboxyl ic acid (E64), N-methyl-piperazine- 
Phe-homoPhe-vinylsulfone-phenyl (K1 1777), Z-Phe-Arg-d iazomethyl ketone 
(ZFRDMK), leupeptin and N-tosyl-L-lysine-chloromethyl ketone (TLCK) strongly 
inhibited the enzymes. The sulfhydryl-blocking agent, iodoacetamide, showed 
strong inhibition too, while N-ethyl maleimide (NEM) did not. The 
metal lopeptidase inhibitor 1,10-phenanthroline, the serine peptidase inhibitors 
phenylmethylsulphonyl fluoride (PMSF) and benzamidine, and the aspartyl 
peptidase inhibitor pepstatin A did not show any affect unless used at very high 
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concentrations. This might be due to interfering interactions with other amino 
acids involved in the catalytic reaction. 
Table 3.2. Testing of various inhibitors on the purified recombinant cathepsin B of 
Eimeria tenella. For testing the effect of inhibitors, the inhibitor was added to the buffer-enzyme 
mix and incubated for 10 min at 370C. The reaction was started by addition of 200 i. LM of the 
substrate Z-Phe-Arg-AMC and monitored continously for 5 min (excitation: 380 nm/Emission: 
465 nm). The activity remaining, relative to the maximum activity measured without inhibitor, is 
indicated in percentage, as well as the standard deviation based on 3 repeats of each 
measurement. E64: (2S, 3S)-3-(N-{(S)-1 -[N-(4-guanidinobutyl)carbamoyl]3- 
methýbutyl)carbamoyl)oxirane-2-carboxylic acid; K1 1777: N-methyl-piperazine-Phe-homoPhe- 
vinylsulfone-phenyl; ZFRDMK: Z-Phe-kg-diazomethylketone; TLCK: N-tosyl-L-lysine- 
chloromethyl ketone; PMSF: phenylmethylsulphonyl fluoride; NEM: N-ethyl maleimide. (A)The 
purified enzyme was used (0.5 jig per assay). (B) The purified deglycosylated enzyme was used 
(0.5 pg per assay). 
A 
Inhibitor Concentration (gM) Activity 
E64 100 0 
10 2±0.2 
1 7±2.4 
Kl 1777 10 0 
1 1.3 ± 0.3 
ZFRDMK 100 0 
10 1.8 ± 0.3 
Leupeptin 100 0.4 ± 0.1 
10 3.3 ± 0.2 
TLCK 100 1.3 0.2 
10 4.3 0.6 
lodoacetamide 100 0.7 0.1 
10 14 2.5 
Bestatin 100 3 0.2 
10 59 ±5 
1,10-phenanthroline 1000 50 ±8 
100 97 ±5 
PMSF 1000 66.8 ±4 
100 99 7 
Benzamidine 1000 72.1 ±6 
100 98 6 
Pepstatin A 10 99 ± 1.5 
1 100 5 
NEM 100 86 3 
10 91 2 
2-pyrrolidinone 100 95 3 
10 100 0.5 
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B 
Inhibitor Concentration (ýM) Activity 
E64 100 0 
10 0 
1 4±1.5 
Kl 1777 10 0.2 ± 0.1 
1 1.6 ± 0.3 
ZFRDMK 100 0 
10 2.1 ± 0.1 
Leupeptin 100 0 
10 2.1 ± 0.8 
TLCK 100 0.6 ± 0.4 
10 5.6 ± 0.9 
3.2.10.6. Gelatin and azocasein are not substrates for the enzyme 
Samples of purified and deglycosylated, or not, cathepsin B produced and 
released by P. pastoris were analysed on gelatin SDS/PAGE. No activity could 
be detected in the conditions tested on either reducing or native gels. 
Samples of purified and deglycosylated, or not, cathepsin B produced and 
released by P. pastoris were analysed using the azocasein assay. The activity 
detected on azocasein was in all cases close to the control without enzyme 
(absorbance of -0.1, see Table 3.1). 
3.2.13. The cathepsin B enzyme Is expressed in E. tenella oocysts and 
sporozoites 
The analysis by western-blot of total protein content of sporulated oocysts 
and sporozoites with specific anti-cathepsin B antibodies detected a protein at 
-30 kDa, which may correspond to the mature cathepsin B. Faint proteins at just 
above 50 kDa and about 20 kDa may correspond to the pro-mature protein and 
the pro-domain, respectively (Fig. 3.37). 
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FIG. 3.37. Immuno-detection of the cathepsin B of Eimeria tenella on sporozoite 
and oocyst extracts. Detection using the anti-cathepsin B of E. tenella antibodies raised in rabbit 
(1: 1000), followed by HRP-conjugated anti-rabbit antibodies (1: 2000). Membrane exposure of 2.5 
min. Lane 1, total protein from -105 oocysts equivalent; lane 2, total protein from _106 
sporozoites. Molecular mass standards are indicated on the left of the figure. The full arrow 
indicates the expected size for the mature cathepsin B enzyme (31 kDa), and the hollow arrow 
indicates the size expected for the pro-cathepsin B (57 kDa). 
3.2.14. Localisation of the cathepsin B in the asexual stages of the life cycle 
In sporozoites, it was shown that the anti-cathepsin B antibodies were 
detecting proteins at the sizes of the pro-mature and mature enzymes (Fig. 3.37). 
The antibody was also tested against purified organelles from E. tenella 
sporozoites, on fractions thought to correspond to micronernes and rhoptries 
(samples extracted and purified on sucrose gradient by Dr Fiona Tomley's group, 
Institute of Animal Health, Compton). In the lane corresponding to sporozoites, 2 
proteins were detected at respectively about 55 kDa and 30 kDa, which 
correspond to the expected sizes for the pro-mature and mature cathepsin B, 
respectively 57 and 31 kDa (Fig. 3.38). The same 2 proteins were also detected 
in the fraction thought to correspond to micronemes, as well as an additional 
protein at about 100 kDa of unknown origin. The same bands could not be 
detected in the fraction thought to correspond to rhoptries (Fig. 3.38B, lane 3). 
Two proteins at respectively 45 and 70 kDa were detected though it is unknown 
what these proteins may be (Fig. 3.38, lane 3). 
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FIG. 3.38. SDS-PAGE and western-blot analysis of Eimeria tenella sporozoite, 
micronerne and rhoptry preparations. Lane 1, total protein from -10 6 sporozoites equivalent; 
lane 2, total microneme proteins from -4 x 106 sporozoites equivalent; lane 3, total rhoptry 
proteins from -4 x 10 6 sporozoites equivalent. Molecular weight standards are indicated on the 
left of the figure. (A) Coomassie blue-stained gel. (B) Detection using the anti-cathepsin B of E. 
tenella antiserum raised in rabbit (1: 750), followed by HRP-conjugated anti-rabbit antibodies 
(1: 5000). Membrane exposure of 30 sec. The full arrow indicates the expected size for the mature 
cathepsin B enzyme (31 kDa), and the hollow arrow indicates the size expected for the pro- 
cathepsin B (57 kDa). 
The immunolocalisation study of the cathepsin B in the asexual stages of 
E. tenella was done by Prof David Ferguson (Oxford). The antibody against the 
cathepsin B was used to stain sections of the caecum of chickens infected with E. 
tenella, or on purified sporozoites. In purified sporozoites, the staining was 
localised to the anterior end of the parasite using the anti-cathepsin B antibodies, 
and the staining pattern was very similar to the one obtained with the anti-MIC2 
antibodies (Fig. 3.39A). MIC2 is an adhesive E. tenella microneme protein 
(Bromley et al., 2003). The apparent microneme staining using anti-cathepsin B 
antibodies is consistent with the results obtained by western blot analysis on 
sporozoites organelle preparations (Fig. 3.38). During schizogony, a discrete 
zone at the periphery of the schizont was strongly stained (Fig. 3.40). The nature 
of the structure stained was unclear. Very little signal was detected from the 
merozoites. However, it was possible to identify a single small spherical structure 
positively stained within the merozoite cytoplasm (Fig. 3.40). But the signal was 
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very faint, and it is unclear if the signal detected was real and what these 
structures might be. No specific apical staining could be detected compared to 
the anti-MIC2 staining in the mature schizonts (Fig. 3.39B), and the cathepsin B 
might therefore be cytoplasmic in fully formed merozoites. 
FIG. 3.39. Immunollocallisation of the cathepsin B in sporozoites (A) and merozoites 
(B) of E. teneila. Blue colour corresponds to DAPI staining of DNA. Red colour corresponds to 
auto-fluorescence of the posterior refractile body in A, and staining of a perinuclear structure in B. 
CatB: anti-cathepsin B antibodies. MIC2: anti-MIC2 antibodies. Sections of the caecum of 
chickens infected for 112 h were used in B. 
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FIG. 3.40. Immunolocalisation of the cathepsin B in mature schizonts of E. tenella. 
Sections of the caecum of chickens infected for 96 h were used. (A) and (B) are the same 
photographs, the signal being increased in photograph (B). Long arrows indicate staining on the 
periphery of the early schizont, short arrows indicate staining at the tip of mature merozoites. 
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3.2.15. Localisation of the cathopsin B In the sexual stages of the life cycle 
of E. tenella 
This work was done by Prof David Ferguson (Oxford). In the sexual 
stages, no staining could be found in the microgametes (male), and there was a 
light staining of the cytoplasm of early macrogametocytes (Fig. 3.41). However, 
in the mature macrogametocyte, granules at the periphery of the cells were 
stained, and more specifically, the periphery of these granules was stained (Fig 
3.41 and 3.42). The size and location of the granules would be consistent with 
being wall-forming bodies (Fig. 3.43), probably of type 1, due to their location and 
appearance in the mature macrogametes (Vieira et al., 1997; Mouafo et al., 
2002). In early oocysts within epithelial cells and in the gut's lumen, there was a 
strong staining of the cytoplasm, as well as some staining of cytoplasmic 
structures probably related to wall forming bodies (Fig. 3.44). 
FIG. 3.41. Immunolocalleation of the cathopsin B In the sexual stages of E. tenella. 
Sections of the caecurn of chickens infected for 96 h were used. Mi: microgamete; eMa: early 
macrogamete; Ma: macrogamete; WFB: wall forming bodies. 
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FIG. 3.42. Immunolocallsation of the cathepsin B In the sexual stages of E. tensile. 
Sections of the caecum of chickens infected for 96 h were used. M: merozoites; MI: microgamete; 
Ma: macrogamete; WFB: wall forming bodies. Arrows indicate the staining at the tip of the 
merozoites. 
Jim 
.. _1M&_ 
FIG. 3,43. Phase microscopy of sexual stages of E. tenella. Sections of the caecurn of 
chickens infected for 96 h stained with azure A were used. Mi: microgamete; Ma: macrogamete; 
WFB: wall forming bodies. 
125 
Chapter 3: Expression and characterisation 
of the recombinant cathepsin B of E. tenella 
FIG. 3.44. Immunolocallsation of the cathepsin B In oocysts of E. tenefla. Sections 
of the caecum of chickens infected for 136 h were used. Blue staining corresponds to DAPI 
staining of DNA. Red staining corresponds to staining of a perinuclear structure. Ma: 
macrogamete; 0: oocyst. Arrows indicate structures that may be wall forming bodies. 
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3.3. Discussion 
Peptidases have been shown to take part in essential events of the life 
cycle in Eimeria, such as the formation of the oocyst wall (Belli et. a/, 2003a; Belli 
et. al, 2003b) and host cell invasion (Fullet and McDougald, 1990). By database 
mining using the cathepsin B sequence of T. gondii (Que et aL, 2002), a single 
complete sequence coding for a cathepsin B-like enzyme was identified in the 
Eimeria tenella EST database. The sequence was amplified on gDNA and cDNA 
and this showed that no introns are present. The gene was shown to be single 
copy. The predicted enzyme contained the cysteine, asparagine, histidine 
catalytic triad and showed good similarity with the cathepsin B of T. gondii (42%) 
and other cathepsin Bs from different organisms (Fig. 3.3). 
Soluble recombinant pro-cathepsin B could be successfully expressed in 
various E. coli cell lines, but no maturation to a mature size protein with 
significant activity against the substrate Z-Phe-Arg-AMC, which has been shown 
to be a substrate for cathepsin B enzymes (Caffrey et aL, 2002), could be 
observed, despite the numerous conditions tested for unfolding, refolding and 
activation. This may suggest that the enzyme did not self-activate, or that the 
enzyme did not properly fold, and conditions for proper folding and self-activation 
were not obtained. 
Expression of the cathepsin B-like enzyme without the full pro-domain may 
have been favourable for folding and/or activation. In this case, however it does 
not seem to have had a beneficial effect. No activity towards gelatin or Z-Phe- 
Arg-AIVIC could be detected in any of the conditions tested. Incubation at 370C 
with 10 mM DTT seemed to yield some processing but the western blot analysis 
suggested that it did not happen at the N-terminal end, which would be where a 
cleavage would be expected in case of removal of the pro-region and activation. 
This may suggest again that the protein does not self-activate. The fact that the 
protein fell out of solution in the assays at pH below 6 tends to indicate a sub- 
optimal folding. As cathepsins usually fold around the pro-domain (Wiederanders, 
2000; Cappetta et aL, 2002), this would not be unexpected. There has been proof 
though, that some cathepsins can fold and be active when expressed without 
their pro-domain (Sijwali et aL, 2001, Pandey et aL, 2004), hence the reason for 
testing this possibility. 
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It has recently been shown that the cathepsin B of Schistosoma mansoni 
that the activation process is not autocatalytic, rather it can be processed and 
activated using the endogenous asparaginyl endopeptidase (Sajid et a/., 2003). 
This is consistent with the conclusions we drew from our attempts to activate the 
E. tenella cathepsin B-like enzymes expressed in Ecoli. Whether or not there is 
an asparaginyl endopeptidase in E. tenella that activates the cathepsin B-like 
enzyme is not known as yet (although no asparaginyl endopeptidase gene in the 
genome database of Eimetia could be identified). A variety of commercially 
available peptidases were tested for their ability to activate the soluble cathepsin 
B from E. tenella produced in E. coli. Although processing could be detected, 
there was no indication that any of the cleaved fragments corresponded to the 
mature cathepsin B, and no activity could be detected in any of the methods 
tested. Non-specific peptidases would in theory preferentially cut in the most 
accessible domains of a protein, that is to say, in accessible hinges and loops. By 
looking at the three dimensional structure of the human cathepsin B, one could 
expect that the Smeria peptidase, provided it folds into a comparable structure, 
would not be cut in multiple places, as it looks like a rather compact globular 
protein. Nevertheless this method did not generate any active protein. 
As no active peptidase could be generated by non-specific cleavage of 
the pro-mature protein, the idea came to introduce a cleavage site for specific 
peptidases commercially available, by mutagenesis at the predicted junction 
between mature and pro-domains. Specific cleavage using Factor Xa and TEV 
protease generated a protein the size of the mature cathepsin B. The mature 
fragment produced did not show activity in the conditions tested, even when 
assayed at a pH that would promote the dissociation of the pro-domain that might 
stay bound and act as an inhibitor (Carmona et aL, 1996). The fact that still no 
active enzyme could be produced might be due to the fact that some proteins 
expressed in E. coli do not get fully their native conformation even if expressed in 
a soluble manner (Jean et aL, 2000). It also might be due to the fact that the 
expression in E. coli lacks the typical eukaryotic phenomenon of glycosylation 
and the peptidase might need them to be active, as it is the case for the human 
glutamate carboxypeptidase 11 (Barinka et a/., 2004). This is why three Pichia 
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systems were tested, in order to get soluble, released and active Eimeria 
cathepsin B. 
Pro-mature cathepsin B could successfully be produced in the constitutive 
Pichia expression system, and the protein seemed to be successfully released 
into the culture medium. Furthermore, the suppression of the C-terminal His-tag 
seemed to favour processing of the pro-mature protein. No signs of processing 
could be detected in the supernatant of culture of the cells transfected with the 
plasmid encoding for the pro-mature cathepsin B C-terminal His-tagged, though 
some apparent processing was observed in the cell extracts. It is unknown why 
no complete processing and no significant activity against Z-Phe-Arg-AMC 
compared to the control cells could be detected in these cases. 
Active mature recombinant cathepsin B of Eimeria tenella was 
successfully produced in the Pichia pastoris inducible system (Fig. 3.30). The 
enzyme was released in the supernatant of culture at a concentration of about 
100 gg/ml, and was readily purified by sequential ammonium sulfate precipitation 
(Fig. 3.31). The characteristics of the enzyme conform to what is expected for a 
cathepsin B; it is strictly dependant on reducing agents (Fig. 3.33), it cleaves 
Phe-Arg and Arg-Arg substrates with a preference for Phe-Arg (Fig. 3.36), it is 
inhibited strongly by general cysteine peptidase inhibitors like E64 and 
iodoacetamide, as well as by the specific inhibitor K11777 (Table 3.1). 
Interestingly, it is active over a wide spectrum of pHs (Fig. 3.35), whereas most 
cathepsin Bs are mostly active at acidic pH. This might reflect a broad distribution 
of the enzyme in various locations in the cell. 
The reason why the soluble enzyme produced in E. coli was not active 
remains unclear. Glycosylations, which do not occur in bacterial expression 
systems, did not seem to play an important role in the enzyme activity. It is still 
unknown if the cathepsin B of Eimeria tenefia is capable of cis-maturation by 
autocatalytically removing its pro-domain, as it seems to be the case for the 
cathepsin B of T gondii (Que et aL, 2002) and has been reported for other 
cysteine peptidases of the same family (Turk et aL, 2001), or if it requires an 
heterologous enzyme for processing, which may be provided in this case by the 
expressing host. If, indeed, a host enzyme is required for maturation, this may 
explain why different sorts of maturation patterns were observed in different 
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Pichia host cell lines. Recombinant expression in the Pichia inducible system of a 
version of the cathepsin B carrying mutations at the active site residues would 
allow determining if there is indeed cis- or trans-activation. 
Immuno-blotting using anti-cathepsin B of Eirneria tenella polyclonal 
antibodies allowed detection of the enzyme in sporozoite and oocyst extracts 
(Fig. 3.37). The enzyme seems therefore to be expressed at these stages of the 
life cycle. The pro- and mature enzyme could also be detected in the fraction 
thought to correspond to microneme proteins, but not rhoptry proteins (Fig. 3.38). 
The absence of specific anti-microneme protein or anti-rhoptry protein antibodies 
of E. tenella does not allow to give a definite proof of the specificity of the anti- 
cathepsin B antibody binding, and other contaminating proteins could be 
detected in these fractions. Also, the organelle fractions are not completely pure, 
although preparations appear clean by observation by electron microscopy 
(Bromley et al., 2003). 
Immunolocalisation studies of the cathepsin B, on various E. tenella stages 
of the life cycle, were done by Prof David Ferguson (Oxford). The enzyme 
showed an anterior end localisation in sporozoites, similar to the pattern found for 
MIC2, a microneme protein of E. tenella. In merozoites, the enzyme seemed to 
localise to a single dot at one tip, but the signal was very faint and might be not 
real. The signal was diffuse in the cytoplasm and no apical localisation could be 
detected like with the anti-MIC2 antibodies. So the cathepsin B may localise to 
micronernes in sporozoites, but may not in merozoites. This might reflect a stage 
specific expression of the cathepsin B. But a cytoplasmic localisation in 
sporozoites might still be possible, as it cannot be excluded that microneme 
preparations might be contaminated by cytoplasmic material. Nevertheless, there 
was reasonable evidence that the cathepsin B of E. tenella did not localise to 
rhoptries. This is in contrast to the results obtained for toxopain of T. gondd (Que 
et aL, 2000), which was reported to, localise to rhoptries, but could reflect a 
different role for the enzyme. Cysteine peptidases from E. tenella appear to have 
a role in host cell invasion, as invasion can be inhibited by cysteine peptidase 
inhibitors (Samantha Brown, PhD thesis); the sequencing of the genome of E. 
tenella will provide a good tool for investigation of the parasite's cysteine 
peptidase repertoire, though the presence of introns in most genes and lack of 
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definite intron prediction system makes protein prediction still problematic. In 
sporozoites, the cathepsin B seemed to be found in microneme preparations. In 
the sexual stages of the parasite, the enzyme is located in mature macrogametes 
and early oocysts to granules, the size and location of which would be consistent 
with being wall-forming bodies. With formation of the oocyst wall, the localisation 
in the oocysts spread to the entire cytoplasm. Peptidases had previously been 
reported to be involved in the oocyst wall formation in Eimeria (Belli et a/., 
2003a), by maturation of precursor proteins found in the wall forming bodies, but 
this is the first a time a cysteine peptidase has actually been shown to localise to 
such formations. Similar roles for cysteine peptidases have been suggested in 
Giardia. Three cathepsin B-like cysteine proteases, CP1, CP2 and CP3, were 
purified from G. lamblia (Ward et a/., 1997). CP2 might be involved in excystation 
of trophozoites as excystation is inhibited in the presence of C132 specific inhibitor 
(Ward et al., 1997), though this has not been definitely established. Another 
stage regulated cathepsin B-like cysteine protease known as ESCP has been 
reported to process a cyst wall protein and may therefore be involved in the 
parasite's encystation (Touz et aL, 2002). The oocyst wall formation being an 
essential process for parasite's survival in the external environment and 
propagation of the disease, these may be exciting findings. The enzyme is now 
available for drug screening, and provided specific inhibitors can be obtained, the 
cathepsin B of E. tenella might present a good new drug target. 
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4.1. Introduction 
Pyroglutamyl peptidase (also referred to as pyrrolidonecarboxylate 
peptidase, pyroglutamate aminopeptidase, pyrrolidonecarboxylyl peptidase, 5- 
oxoprolyl peptidase, pyroglutamyl aminopeptidase and pyroglutamyl peptide 
hydrolyse) belongs to the class of omega peptidases (EC 3.4.19. -) and 
hydrolyses N-terminal L-pyroglutamate residues (L-pGlu) from peptides and 
proteins containing this modification (Browne and O'Cuinn, 1983; Cummins and 
O'Connor, 1996). Pyroglutamyl peptidase activity was first detected in 
Pseudomonas fluorescens (Doolittle and Armentrout, 1968) and has been since 
described in tissues from mammals (Dando et aL, 2003; Cummins and O'Connor, 
1996), bacteria (Ito et aL, 2001; Ogasahara et a/., 2001), birds (Tsuru et a/., 
1982), fish, reptiles (Prasad et aL, 1982) and plants (Kembhavi et aL, 1993). 
They are divided into two classes, the cysteine peptidase pyroglutamyl peptidase 
I (EC 3.4.19.3., MEROPS C15 [180]), and the metallopeptidase pyroglutamyl 
peptidase 11 (EC 3.4.19.6., MEROPS M1 [181]). Pyroglutamyl peptidase I is a 
soluble, intracellular enzyme (Cummins and O'Connor, 1998), whereas 
pyroglutamyl peptidase 11 is membrane-bound (O'Connor and O'Cuinn, 1984). 
4.1.1. Pyroglutarnyl metabolism in human 
4.1.1.1. Pyroglutamyl peptidase I 
Pyroglutamyl peptidase I (PPI) occurs as a monomeric enzyme of 
relatively low molecular mass (- 25 kDa) and with a pH optimum from 6.5 to 8.5, 
that is located in the cytosol in mammals (Mantle et aL, 1991; Cummins and 
O'Connor, 1996; Dando et aL, 2003). PPI activity exhibits a strict requirement for 
reducing environment (Dando et aL, 2003). It has broad substrate specificity in 
that it can hydrolyse a variety of natural or synthetic peptides containing L-pGlu 
at the N-terminal position (Cummins and O'Connor, 1996; Dando et a/., 2003). 
The rate of hydrolysis of the various peptides depends on the amino acid residue 
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following the pGlu in the sequence and it has been shown that mammalian PPI 
does not cleave pGlu-Pro bonds (Browne and O'Cuinn, 1983). Although PPI has 
been shown to have broad substrate specificity, it also has a strong specificity for 
pGlu residues and will not cleave modified pGlu residues (Capecchl and Loudon, 
1985). A schematic representation of the catalytic reaction is shown on Fig. 4.1. 
0/H 
N0 
11-: 
--NH-CH-CO- 
H20 0/H 
N0 
11-OH 
pGlu 
H2N-CH-CO---- 
I 
K 
FIG. 4.1. Schematic representation of the reaction catalysed by PPI. The dotted 
arrow represents the cleavage site by PPI. The dashes at the C-terminus represent the 
continuation of the amino acid chain. The reaction releases free pyroglutarnate (pGlu) and the 
amino acid chain. R: variable side group of the amino acid. 
The catalytic triad of the PPI was found to be composed of Glu-81, Cys- 
144 and His-I 68 (Bacillus amylotumetaciens numbering, Yoshimoto et al., 1993). 
These residues are conserved in the human and the mouse enzymes (Dando et 
aL, 2003). 
Due to the nature of the active site and the requirement of the catalytic 
cysteine, sulfhydryl-blocking agents (iodoacetate, iodocetamide) are potent 
inhibitors (Dando et aL, 2003). Metallic ions such as CU2+, Zn 
2+ 
and Ni2+ were 
also shown to be strong inhibitors, reversible by addition of a chelating agent in 
excess or by dialysis (Dando et aL, 2003). PPI was not inhibited by serine 
peptidase inhibitors, such as phenyimethylsulphonyl fluoride (PMSF) or cysteine 
peptidase (family Cl) inhibitors, such as (2S, 3S)-3-(N-{(S)-l -[N-(4- 
guanidinobutyl)carbamoyl]3-methylbutyl}carbamoyl)oxirane-2-carboxylic acid 
(E64). Among active site specific inhibitors, chloromethyl ketone derivatives of 
pGlu are irreversible, potent inhibitors (Fujiwara et aL, 1982). Other specific 
inhibitors include aldehyde analogues of pGlu, natural compounds isolated from 
Streptomyces, and the pyroglutamyl analogue 2-pyrrolidone, also used to 
stabilise PPI activity during storage (Cummins and O'Connor, 1998). 
133 
Chapter 4: Expression and charactedsation of recombinant 
pyroglutamyl peptidase / of L. major 
The biological activity of some peptides is regulated via modifications such 
as cyclisation of N4erminal glutamine to L-pGlu, acetylation of the Werminal 
residue or amidation of the carboxy terminal residue. The pyroglutamyl group 
confers a relative stability towards aminopeptidase degradation to these 
peptides. In fact, 12.3% of proteins with signal peptides are initiated with Gln 
once the signal peptide is removed (Liao et al., 2003). Also, removal of the N- 
terminal translation initiator methionine is often crucial for the function and 
stability of proteins (Hirel et al., 1989; Liao et al., 2003), and pGlu-modified 
peptides can then occur if the second amino acid is a Gln, though this is not 
systematic (Predel et al., 1999). Many of the naturally occurring peptides 
containing the pGlu modification are substrates for PPI (see Table 4.1). Among 
them are neuropeptides. Neuropeptides are up to 40 amino acid-long peptides 
released to allow inter-cellular communication, and regulate processes such as 
differentiation, growth and metabolism in mammals (Cummins and O'Connor, 
1998). In addition to giving resistance to aminopeptidase cleavage, the pGlu 
modification has also been shown to be essential to the bioactivity of some 
peptides. For instance, the chernotactic protein-2 activity in human is dependent 
on its pGlu modification, as receptor recognition involves the N-terminal part of 
the molecule (Van Coillie et a/., 1998). In human, free pGlu has been shown to 
improve learning and to help prevent age-associated memory loss (Grioli et al., 
1990). 
As the L-pGlu N-terminal modification can be determinant in biological 
activity of peptides (Perlman et a/., 1994), PPI has been attributed a role of 
neuropeptide regulation and metabolism in mammalian systems, though the lack 
of its release from the cells still causes doubts regarding its function (Salers et 
a/., 1991). PPI may participate in the protein metabolism (Lauffart and Mantle, 
1988) and increased levels of PPI have been observed in the spinal cord of 
patients with motor neurone disease (Mantle et al., 1995). However, only very 
few mammalian PPIs have been fully characterised so far and a definite 
physiological role still has to be attributed. 
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Table 4.1. Some natural bloactive compounds cleaved by mammalian PPI. TRH, 
thyrotropin-releasing hormone; LHRH, luteinizing hormone-releasing hormone; ACE, angiotensin 
converting enzyme. [1], Fujiwara et al., 1979; [2], Cummin and O'Connor, 1996; [3], Dando et al., 
2003. 
Protein/peptide N-terminal cleavage site Organism Reference 
TRH pGlu-His Human [1,2] 
LHRH pGlu-His Human [1,2,3] 
Bombesin pGlu-Gln Frog [2,3] 
Bradykinin pGlu-Gly Human [1,3] 
potentiator B 
ACE inhibitor pGlu-Trp Human [3] 
Leukopyrokinin pGlu-Thr Human [3] 
Neurotensin pGlu-Leu Human [1,2,3] 
Litorin pG[u-Gln Frog [11 
4.1.1.2. Pyroglutamyl peptidase 11 
A distinct PP activity membrane-bound and inhibited by reducing and 
chelating agents was demonstrated in several mammals (Friedman et al., 1986; 
Gallagher et al., 1997). Compared to PPI, PPII has a relatively high molecular 
mass (- 230 kDa) and is not inhibited by PPI inhibitors (Friedman et aL, 1985). 
PPII purified from rat and porcine brain showed a dimeric architecture 
characteristic of membrane-bound peptidases (Bauer, 1994). The activity of this 
metal lo peptida se is mainly located in the central nervous system (CNS) in 
mammals, where it is found mainly associated with neurons (Bauer et al., 1990; 
Cruz et aI., 1991b). A characteristic of PPII is that it is highly specific for 
thyrotropin-releasing hormone (TRH) and TRH-like peptides (Elmore et aL, 
1990), which stimulate the release of thyroid-stimulating hormones. The 
increased release of thyroid hormones increases the metabolic rate, glucose 
absorption, blood pressure and heart rate, decreases the cholesterol level in 
plasma, stimulates growth hormone production, and regulates the CNS 
development (Cummins and O'Connor, 1998). PPII is therefore thought to be an 
important regulatory element that influences the activity of TRH at target sites 
(Schomburg and Bauer, 1995). PPII expression and activity is indeed regulated 
by TRH (Joseph-Bravo et aI., 1998). The only site-specific inhibitor of PPIl known 
to date is CPHNA (N-[l(RS)-carboxy-2-phenylethyl]-N-imidazole benzyl-histidyl 
p-naphthylamide) (Chadi et al., 1989). 
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A third PP activity was isolated from serum and its narrow specificity for 
TRH-like peptides lead to the name "serum thyroliberinase" (Bauer and Nowak, 
1979). However, given its high resemblance to the PPII activity, it is possible, but 
not yet known, that it is a product of the same gene. There has been recent 
evidence that the thyroliberinase activity results from the cleavage of the PPII 
liver enzyme (Schmitmeier et aL, 2002). 
4.1.1.3. Glutaminyl cyclase 
Glutaminyl cyclase (QC), or glutaminyl-peptide cyclotransferase (EC 
2.3.2.5., MEROPS clan MH, family M28), is the enzyme involved in cyclisation of 
N-terminal glutamine, which is unmasked by proteolytic processing of precursor 
proteins by, for example, prohormone convertases (Seidah et al., 1998). Peptides 
modified by a QC are constitutively secreted in humans, and tissue-specific forms 
of the enzyme may exist (Sykes et al., 1999). The enzyme localises to the 
secretory pathway (Pohl et al., 1991). The cyclisation of glutamine can occur 
spontaneously, especially under the catalytic influence of phosphate ions 
(Chikuma et al., 2004), but previous studies have demonstrated that the 
formation of pGlu residues in cells must be enzymatically catalysed because the 
non-enzymatic conversion is slow under physiological conditions (Consalvo et al., 
1988). QCs have also been identified in various mammals (Busby et aL, 1987) 
and plants (Oberg et aL, 1998). It was previously proposed the mammalian QC 
has some features in common with zinc aminopeptidases, and human pituitary 
glutaminyl cyclase and bacterial zinc aminopeptidase share a common fold and 
active site residues. In contrast to the aminopeptidase, however, QC does not 
appear to require zinc for enzymatic activity (Booth et aL, 2004). The human QC 
possesses 6 key active site residues: histidines 140 and 330, glutamates 201 
and 202, and aspartates 159 and 248 (Bateman et al., 2001), although the 2 
aspartates have no catalytic role. Little is known about the biological role of QC at 
present. Researchers have suggested that QC is responsible for modification of 
storage proteins during seed germination in plants (Gololobov et al., 1996), as 
well as in vivo modification of bioactive peptides in mammals (Hinke et al., 2000). 
These findings support the view that pGlu modification might be important for 
protection of the N-terminus of bioactive peptides against exopeptidases. 
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Moreover, this enzymatically catalysed N-terminal formation of the pyroglutamic 
acid residue could be important in developing the proper receptor-binding 
conformation of such peptides (Ziegler et aL, 1998). 
4.1.2. Pyroglutamyl peptidase activity in bacteria 
Most bacterial PPs examined so far are soluble, have broad substrate 
specificity, require a reducing environment and occur as multimers (Fujiwara et 
al., 1979; Awade et aL, 1992a; Awade et aL, 1992b). In terms of substrate 
specificity, catalytic residues and inhibitors, they resemble the mammalian PPI 
enzymes. Structures for the PPs of Thennococcus litoralis and Bacillus 
amylotumefaciens are known (Protein Data Bank [PDB] identification numbers 
1A2Z and 1AUG, respectively). The known PPs bacterial genes are single copy, 
and are characterised by inverted repeats of the gene found upstream and 
downstream of the ORFs, suggesting transcriptional control (Cummins and 
O'Connor, 1998). The expression of the PP gene of Pseudomonas fluorescens is 
regulated by the intracellular levels of pyroglutamic acid and iron (Le Saux and 
Robert-Baudouy, 1997). Like for the mammalian PPIs, a definite function still has 
to be attributed. It has been suggested they may play a role in intracellular 
protein metabolism (Lazdunski, 1989), though the presence of PP activity is not 
ubiquitous among the bacterial kingdom. 
The only indication of the presence of a QC in bacteria was presented by 
Cook and Russell in 1991. They suggested the glutamine cyclase reaction of 
Streptococcus bovis was a mechanism of deriving energy from non-oxidative and 
non-reductive deamination. 
4.1.3. Bioactive peptides containing pGlu 
Aside from neuropeptides, various bioactive peptides possess a N- 
terminal L-pGlu modification and can be synthesised by various organisms. As 
examples, a variety of anti-microbial peptides have been isolated from mammals 
(Tang et al., 2002; Boman, 2003), insects (Rabel et al., 2004), shrimp 
(Destournieux et al., 1997), spider (Silva et al., 2000), and scorpions (Cociancich 
et al., 1993). The widespread occurrence of these compounds suggests they 
may play a role in innate immunity against microorganisms and other pathogens 
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(Selsted and Ouellette, 1995; Ganz and Lehrer, 1999). Gomesin, an 18 amino 
acid N-terminal pGlu-modified peptide isolated from a spider (Silva et a/., 2000) 
showed strong bacterial growth inhibition, affected development of filamentous 
fungi and yeast, as well as the viability of the parasite Leishmania amazonensis. 
The mechanism of inhibition of growth is unknown. However, this observation 
might support a need for bacteria and other pathogens, such as parasites, to 
possess a PIP activity, for degradation of such bioactive compounds. There is 
some evidence that the innate immune response of humans involves various lytic 
factors, including antibacterial peptides. These peptides are classified in different 
families, depending on their structure. Humans possess 2 classes of defensins, 
a- and P-defensins, which are cationic 15-45 amino acid long peptides with a 
pattern of disulfide bridges essential to the activity (Torres and Kuchel, 2004). 
Defensins are produced in the phagolysosomes of neutrophils and macrophages 
as well as in epithelial cells (Selsted and Ouellette, 1995) and play a role in 
innate immunity acting as anti-microbial agents and chemokines (Hoover et al, 
2001; Schibli et aL, 2002). Some of the P-defensins have a pGlu modification at 
the N-terminus (Selsted et aL, 1993). Another family of anti-microbial peptides in 
humans, the cathelicidins, are produced in epithelial cells as pre-pro-proteins. 
The pro-protein possesses a N-terminal pGlu (Andersson et aL, 2002), and upon 
maturation, the mature C-terminal domain acts as a potent anti-microbial agent 
(Isogai et aL, 2003). In insects, various homologues of the defensins exist, 
namely the cecropins (Cornet et aL, 1995). The only reported proofs of action of 
human anti-microbial peptides on parasitic protozoa are that resistance in 
humans against Trypanosoma bruce! brucei can occur as the parasite is killed by 
lytic factors (anti-microbial peptides) found in the serum (Lugli et a/., 2004), and 
that the enteric parasite Giardia lamblia can be killed by cationic neutrophil 
peptides produced by the intestine epithelium (Aley et aL, 1994). In Drosophila, 
an anti-microbial peptide with a N-terminal pGlu has been identified (Rabel et a/., 
2004). So there is some evidence that pGlu-modified peptides with anti-microbial 
activity exist in human and insects, the two hosts of Leishmania. 
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4.1.4. Pyroglutamyl peptidase in parasites 
The sequence for a PP with resemblance to mammalian PPI was 
identified in the genomes of L. major, L. intantum, T. brucei and T. cruzi. 
Interestingly, no sequence with identity to the human PPI could be identified in 
the genomes of P. falciparum, P. yoeffl, T. gondii, E. tenella, E. histolytica, S. 
mansoni, or T. vaginalis. It is still unclear if the presence of a PPI may be specific 
to kinetoplastids, as the sequencing and annotation of most of the genomes cited 
are uncompleted. The sequence for a possible glutaminyl cyclase, the enzyme 
responsible for the cyclisation of Gin residues to pGlu, and sequences 
homologous to the mammalian PPII enzyme were also identified in the genomes 
of L. major, L. intantum, T. brucei and T. cruzi. No studies have previously been 
reported on PP activity in parasites and it is unknown what role it may play. But 
one hypothesis we considered is that it might be involved in bioactive peptide 
inactivation in the mammalian host or in the insect vector. As these parasite PPs 
seem to resemble mammalian PPIs, it may be predicted that they may have a 
broad substrate specificity and be able to cleave various regulatory and anti- 
microbial factors. 
This study focused on the PPI of L. major. The aim was to express 
recombinant active PPI for biochemical characterisation in order to get an insight 
on which of the eukaryotic or prokaryotic enzymes it is the most closely related 
to, in terms of oligomerisation, substrate specificity, kinetic features and 
inhibitors. A second aim was to try to obtain recombinant glutaminyl cyclase, for 
characterisation and antibody production, in order to investigate the occurrence 
and possible role of the enzyme in the parasite. 
4.2. Results 
4.2.1. Cloning of the pyroglutamyl peptidase I gene of L. major 
Database searches on the genomic database of L. major using the 
human PPI as a query (accession number NP 060182, 
www. ncbi. nim. nih. org/entrez/) detected a 834 bp open reading frame (Fig. 4.1) 
translating into a 277 amino acid protein (LmjF34.2000, www. genedb. org) with 
the PPI features, although it was annotated as a hypothetical protein of unknown 
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function. No other sequence with PPI features could be detected in the L. major 
database (now totally sequenced), which indicates the PPI is a single copy gene 
in L. major. The amino acid sequence was analysed with the SignalP algorithm 
(Nielsen et al., 1997), and TMpred (Hofmann and Stoffel, 1992), and no signal 
peptide or trans-membrane domain were predicted. 
5' RACE on total cDNA was performed using a 5' primer with a sequence 
complementary to the splice leader (SL primer) and a 3' primer with a sequence 
complementary to a sequence downstream of the predicted start ATG. The PCR 
product obtained was used as a template for a semi-nested PCR using the SL 
and the PPrace2 primers (see Table 2.1). The results of the 5' RACE showed the 
presence of a mRNA comprising a 49 bp 5' untranslated region (UTR), and 
confirming the start methionine attributed in LmjF34.2000 (Fig. 4.2). 
1 GTCCTCAGCA CTGAAAGGGA ATCATCCTCC ACCTTCCCTC CCCAACCA((' A('r(, ('A('A('(, 
CAGGAGTCGT GACTTTCCCT TAITAGGA3G TO(ýAACCGA(l, 
71 GATCAATGTC TCACTATTGC AA--CGGCCTT CTACGAGCAC ACAGGGCTCC TCGCAGTTCC GCJkCCGCTTA 
CTAGTTACAG AGTGATAACG TTCGCCGGAA GATGCTCGTG TGTCCCGAGG AGCGTCAAGG CGTGGCGAAT 
MLHSXAGIVVFITGYGPFATVKV 
141 AAATGCTGCA CTCCAAGGCG GGCATCGTCG TGTTCATCAC GGGCTACGGG CCCT'I'CGC('A C'PGI'GAA(; (! 'I' 
TTTACGACGT GAGGTTCCGC CCGTAGCAGC ACAAGTAGTG CCCGATGCCC GGGAAGCGGT GACAC711CCA 
-NPSSDIALRVAEGLKRHPDVAEV 
211 GAACCCCAGC TCCGACATTG CCCTTCGTGT CGCGGAGGGC CTGAAGCGCC ACCCCGACGT CGCGGAGGTG 
CTTGGGGTCG AGGCTGTAAC GGGAAGCACA GCGCCTCCCG GA=CGCGG TGGGGCTGCA GCGCCTCCAC 
RYTELDVSVTSVAAYFEKVERDTA 
281 CGCTACACGG AGCTGGATGT CAGCGTGACC AGCGTCGCAG CGTACTTTGA GAAGGTGGAA AGGGACACTG 
GCGATGTGCC TCGACC7rACA GTCGCACTGG TCGCAGCGTC GCATGAAACT CrTCCACCTT TCCCTGTGAC 
-DIIAEHGAGVKILLCHLGVHND 
351 CCGACATCAT CGCCGAACAC GGCGCCGGCC AGGTGAAGAT CCTTCTCTGC CACCTAGGTG TTCACAATGA 
GGCTGTAGTA GCGGCTTGTG CCGCGGCCGG TCCACTTCTA GGAAGAGACG GTGGATCCAC AAGTGTTAC-l' 
-TTGLICVEvQGCN9LFSsvPDVD 
421 CACAACGGGG CTCAT(: 7rGCG TTGAGGTGCA GGGCTGCAAC GAGCTCTTTT CTAGCGTCCC TGACGTGGAC 
GTGTTGCCCC GAGTAGACGC AACTCCACGT CCCGACGTTG CrCGAGAAAA GATCGCAGGG ACTGCACCTG 
GKVLNHEPIvPEDGAIEVFHESWF 
491 GGTAAGGTGC TCAACCACGA GCCCATTGTA CCGGAGGACG GCGCCATTGA AGTATTTCAC GAGAGCTGGT 
CCATTCCACG AGTTGGTGCT CGGGTAACAT GGCCTCCTGC CGCGGTAACT TCATAAAGTG CTCTCGAC'CA 
-GKEGSPQLEKLERLIQQVNDTVA 
561 TCGGCAAGGA GGGCTCGCCG CAGCTCGAGA AGCTGGAGCG CTTGATTCAA CAGGTAAACG ACACCGTTGC 
AGCCGTTCCT CCCGAGCGGC GTCGAGCTCT TCGACCTCGC GAACTAAGTT GTCCATTTGC TGTGGCAAC(, 
-ESWHHWVTGAVTNN9VTSADTDR 
631 CGAGTCATGG CATCACTGGG TGACGGGTGC CGTGACCAAC AATGAGGTGA CATCGGCGGA CACAGACAGA 
GCTCAGTACC GTAGTGACCC ACTGCCCACG GCACTGGTTG TTACTCCACT GTAGCCGCCT GTGTCTGTCT 
KDMAMPTFQAPSSAISRNAGRYLC 
701 AAGGACATGG CGATGCCAAC GTTTCAGGCG CCGAGCTCrG CAATTTCGCG CAACGCAGGG CGCTACCTG'r 
TTCCTGTACC GCTACGGTTG CAAAGTCCGC GGCTCGAGAC GTTAAAGCGC GTTGCGTCCC GCGATGGACA 
-NCALYHALRLQEKNPGVVYGIFv 
771 GCAACrGCGC CCTCTACCAC GCACTTCGAC TTCAGGAAAA GAACCCGGGT GTCGTCTATG GCATCTTCGT 
CGTrGACGCG GGAGATGGTG CGTGAAGCTG AAGTCCTTTT CTTGGGCCCA CAGCAGATAC CCTAGAAGCA 
-HVVDPIRGKTEIEGGPIVAYNpp 
841 TCACGTTGTC GATCCGATTC GCGGCAAGAC GGAGATCGAG GGCGGTCCCA TTGTGGCTTA CAACCCACCG 
AGTGCAACAG CTAGGCTAAG CGCCGTTCTG CCTCTAGCTC CCGCCAGGGT AACACCGAAT GTTGGGTGGC 
TIVsvQv0cLMHGLLSLXTm 
911 ACGATCGTAC AGTCGGTGCA AGTGCAGTGT CTCATGCACG GCCTGCTGTC TTTGATGACC ATGTGACGAA 
TGCTAGCATG TCAGCCACGT TCACGTCACA GAGTACGTGC CGGACGACAG AAACTACTGG TACACTGCTT 
981 GACATCGTTC GCAGCGA 
CTGTAGCAAG CGTCGCT 
FIG. 4.2. Complete sequence encoding a PPI enzyme in L. major. The sequence of 
the 5' UTR obtained from the 5' RACE experiment is shown with a grey background. The 
translation of the putative ORF is shown in bold (single letter amino acid code). Dots indicate 
codons that are split over the line break. 
140 
Chapter 4: Expression and characterisation of recombinant 
pyroglutamyl peptidase / of L. major 
The 834 bp ORF translating into a 277 amino acid protein with PPI 
features was located on chromosome 34 of L. ma r. The protein was aligned jo 
with known PPIs from mammals, plant and bacteria (Fig. 4.3) and the 
corresponding identity table is presented in Table 4.2. The L. major protein 
showed little similarity with the various PPIs, but the catalytic residues Glu-81, 
Cys-144 and His-168 were conserved in all the sequences (Thermococcus 
litoralis numbering), placing the L. major enzyme in the C15 family of cysteine 
peptidase (Barrett and Rawlings, 2001). Only 13 residues were fully conserved in 
the 5 sequences. The L. major enzyme also has a large insertion (position 145- 
199) of unknown function. 
1 50 
AthPPI (1) MGSEGPTGVT-- o ! &Fý ý rl]HGVAEMPTEKMANNLKEYLAKNCVSKDVNLG 
BamPPI (1) ------ MEKKVý i jEF'PUGGETVMPSWEAVKRLNGAAEGP --------- 
TlitPPI (1) ------- MKKV:, IjjZF; ý POGGDSKIPTEQIAKYFDRKQIGN --------- 
HsPPI (1) --- MEQPRKAV, ", JEF, -3P[IGEHTVMASWIAVQELEKLGLGDS -------- 
LmPPI (1) -MLHSKAGIVVFI[BYGPIIATVK-IPSSDIALRVAEGLKRHPDVAEVR-- 
51 100 
AthPPI (51) SCTVLETAGQGALASLYQLLQSAVNTKESESLTGKTIWVHFIIVNSGAT-K 
BamPPI (36) ------- ASIVSEQVPTVFYKSLAVLREAIKKHQPDIIICVIQAGGRM-Q 
TlitPPI (3s) ------- AMVYGRVLPVSVKRATIELKRYLEEIKPEIVINIII, AIITYS-N 
HsPPI (40) ------- VDLHVYEIPVEYQTVQRLIPALWEKHSPQLVVHVIVSCMAT-T 
LmPPI (48) YTELDVSVTSVAAYFEKVERDTADIIAEHGAGQVKILLCHIIVIiNDTTGL 
101- 150 
AthPPI (100) FAIOQQAVMEATFRCPDELGWKPQNLPIVPSDGPISTVRK'I'NLPVEE --- 
BamPPI (78) ITPlRVAIMLNEARIPDNEGNQPVGEDIS-QGGPAA--YWTGLPIKIZ --- 
TlitPPI (77) ITV§RIAVMIIDARIPDNDGYQPIDEKIE-EDAPLA--YMATLPVRA --- 
HsPPI (82) VTLOKCC3HMKGYKGLDNCR-FCPGSQCCV-EDGPES--IDSIIDMDA --- 
LmPPI (98) ICVIIVQGC71ELFSSVPDVDGKVLNHEPIVPEDGAIEVFHESWFGKEGSPQ 
151 200 
AthPPI (147) ---------------------- ITKALEKN ------------------ GF 
BamPPI (122) ---------------------- IVEEIKKE ------------------ Gl 
TlitPPI (121) ---------------------- ITKTLRDN ------------------ GI 
HsPPI (125) ---------------------- VCKRVTTLGL ---------------- DV 
LmPPI (148) LEKLERLIQQVNDTVAESWHHWVTGAVTNNEVTSADTDRKDMAMPTFQAP 
201 250 
AthPPI (157) EVITrDýFýINYVYYHSLRFAEQNKT--RSIOVMVPLFVAVDEET-- 
BamPPI (132) PAAVM': ": ZTFýJINHLFYGLMDEISRHHPHIRC, (II I MI PYI PEQTL --- Q 
TlitPPI (131) PATIM': '. -Ze: --YLSIYVMFKTLHFSKIEGYPLKA(, 
g i IBVPYTPDQVVNKFF 
HsPPI (137) SVTIM-: -'MRYLJDFTYYTSLYQS ----- 
HGR-lýAGMPPI, (3KPYNADQL 
LmPPI (198) SSAIMRNýYLIINCALYHALRLQEKNPGVVYGISMIWDPIRGKTEIEG 
251 292 
AthPPI (203) ---------------- QMRFTVSLLEVLASICK --------- 
BamPPI (179) KS --- APSLSLDHITKALKIAAVTAAVHEDDIETGGGELH-- 
TlitPPI (181) LLGKNTPSMCLEAEIKAIELAVKVSLDYLEKDRDDIKIPL-- 
HsPPI (182) G -------------- RALRAIIEEMLDLLEQSEGKINYCHKH 
LmPPI (248) GP ------------ IVAYNPPTIVQSVQVQCLMHGLLSLMTM 
FIG. 4.3. Alignment of the pyroglutamyl peptidase I (PPI) of L. major with various 
known PPIs from different organisms. Dashes indicate gaps in the alignment. The catalytic 
triad residues are starred. Identical residues are on black background. Conservative residues are 
on grey background Ath, Arabidopsis thaliana; (GenBank Accession No.: NP 173758); Barn, 
Bacillus amyloliquefaciens (JX0244); Tlit, Thermococcus litoralis (CAA74299); Hs, Homo sapiens 
(NP 060182), Lm, L. major, PPI, pyroglutamyl peptidase 1. 
141 
Chapter 4: Expression and characterisation of recombinant 
pyroglutamyl peptidase / of L. major 
Table 4.2. Similarity table of the L. major PPI with various PPls. Numbers represent 
percentage of identity. ArabTh : Arabldopsis thaliana; Bamyl : Bacillus amyloliquefaciens; Tlit 
Thermococcus fitoralis; Hum: Homo sapiens; Lm : L. major. 
AthPPI BamPPI TlitPPI HsPPI LmPPI 
AthPPI 100 32 33 33 23 
BarnPPI 100 49 38 15 
TlitPPI 100 37 15 
HsPPI 100 20 
LmPPI 100 
Using the human PPI as a query (accession number NP 060182, 
www. ncbi. nlm. nih. org/entrez/) also allowed detection of PPIs in the genomic 
databases of other parasites. For instance, a PPI-like sequence was detected in 
the genome of L. infantum, Trypanosoma brucei and T. cruzi. These sequences 
were aligned as before (Fig. 4.4) and a somewhat higher similarity was detected 
among them (Table 4.3). T. brucei and T. cruzi PPs are quite similar to each 
other, as are the L. infantum and L. major PPs. Interestingly, the L. major PP was 
only just under 30% homologous to the PPs of the 2 Trypanosoma species, 
which is the percentage of similarity between the human and the bacterial 
enzymes (Dando et al., 2003). 
To study the structure that the L. major PP might have, it was sent to 
SwissModel for structure prediction, using the PPs from T. fitorafis and B. 
amylotumefaciens (PDB 1A2Z and 1AUG, respectively) as templates. Only the 
residues 5 to 41 and 193 to 240 could be assigned a structural prediction by 
superposition to residues 1 to 36 of the B. amylotumefaciens PP or residues 128 
to 171 of T. fitoralis, respectively. The rest of the sequence did not show sufficient 
similarity for three-dimensional structure prediction. 
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i 50 
LiPPI (1) MLHSKAGIVV FIEt: 'M -'-'VK-'JMSE)BALRkIVENLKRHPDVAEMRYTE 
LmPPI (1) MLHSKAGIV-VFIEI' M' ", ';. -VMýý, DBALPkIAECLKRHPDVAEVRYTE 
TbPPI (1) --MKPTKPLLYIEe- 
M '-'ýý3M-,: 'UAQ, 'ýBAE(: )VRQS-GEADVIIHET 
TcPPI (1) --MRRSNLQLYM&C: 
M KPMMED - SELQVHYEK 
51 99 
LiPPI (51) MVTTU&:, AMEK7. ERE IADI IAEHGAGKVKIECHIJMBN - DTTGLIR 
LmPPI (51) "TS', 'TSjA. AMEK, ERDTADI IAEHGAGQVKIECHLEVMN - DTTGLIC 
TbPPI (48) jWLEATUSýýRLNESVTAELEATHPEN- RVEVN-VJI, MSRFKEKVLR 
TcPPI (48) l--'&--, LEAUTSAJZID'-LEGALAQHMEDNPDG- - CVMLHIMI jSRE1-: EGKMR 
1-19 
LiPPI (100) ýIVJQGYMFASVPDVDGKVL14HEPIVPEDGTIEVI-'HEMWF(, KAGSPQLE 
LmPPI (100) '. ZQG-'MMFSSVPDVDGKVLNHEPIVPEDGAIEVIý'H F(; KEGSPQLE 
TbPPI (97) LMRAF-13MEGNP ------------- IDDELPLSTCKfFVK(, CKLE 
TcPPI (96) LMCGYMEGSP ------------- IDESI PMDVCLEjMLVRDGCI)I-: ý; K 
iso I ()() 
LiPPI (150) KLERMIQQVMDTIAESWHHSVTGAVTKNEVTPSDADRKDMAMPAFQASSW 
LmPPI (150) KLERMQQ', IZDTVAESWHHWVTGAVTNNEVTSADTDRKDMAMP'I'FQAOS. 13 
TbPPI (132) TTTANIEE:, IAIERN ------------------------- GSDIHIPFIliý1W 
TcPPI (133) ATAENEELJZAAISK --------- RGR ------------- RE("DPQQjHW 
249 
LiPPI (200' . -ýIER', 
=: ýECAMIHALRISEKNPGIJYGVlTMVVDPIRGKTEIEGGP 
LmPPI (200) ýý, "=LECAýALPIgEKNPGVIYGIUMEVVDPIRGKTEIEGGP 
TbPPI (157) IMYDMYEYqllRGVKMEEALNSIZUTIý'AVIIM I VASTVVC 
TcPPI (161) IJORDMYEYTERSLKI. C* KKWRGRJIFAVIMANPFTCN ------- 
ýýc 283 
LiPPI (250) IVAYNPTTMVSSIIWRFMH(41LSLMT ------ 
LmPPI (250) IVAYNPPTIVESVEIQCLMHGMLSLMTM ----- 
TbPPI (200) ------- MEERVAUJRMLVSHlLKHMEAVE --- 
TcPPI (204) ---- NPSLEERTAELSLVSClVRIVRNKHIV- 
FIG. 4.4. Alignment of the pyroglutamyl peptidase I (PPI) of L. major with various 
predicted PPIs in different trypanosomatids. Dashes indicate gaps in the alignment. The 
catalytic triad residues are starred. Identical residues are on black background; conservative 
residues are on grey background. Li, Leishmania infantum (GeneDB CDS: LinJ34.1440); Tb, 
Tfypanosoma brucei (GeneDB CDS: Tb04.11-119.1350); Tc, Trypanosoma cruzi (GeneDB CDS: 
TcOO. 1047053506635.60); Lm, L. major (GeneDB CDS: LmjF34.2000); PPI, pyroglutamyl 
peptidase 1. 
Table 4.3. Similarity table of the L. major PPI with various parasites' PIRls. 
Numbers represent percentage of identity. Li : L. infantum; Lm : L. major, Tb : T. brucei; Tc : T. 
cruzi. 
UPPI LmPPI TbPPI TcPPI 
UPPI 100 78 26 27 
LmPPI 100 27 28 
TbPPI 100 56 
TcPPI 100 
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4.2.2. Expression of recombinant L. major PPI in E. coli 
The full open reading frame (ORF) for the PPI of L. major was cloned in 
the pET28a(+) vector (Novagen) for expression of PPI with a N-terminal His-tag. 
The resulting pETLmPP plasmid is represented on Fig. 4.5. Cells transformed 
with the pETLmPP plasmid were induced either for 4h at 370C with 1 mM IPTG, 
or for 4h at 200C with 1 mM IPTG. An over-expressed protein of about 32 kDa, 
corresponding to the expected size for N-terminal His-tagged protein, could be 
detected in all cases, but it was found in the insoluble fraction of E. coli lysates if 
expressed at 370C. The highest rate of expression in a soluble manner was 
obtained by induction at 200C with 1 mM IPTG, and the soluble protein produced 
was purified on Ni-agarose column (Fig. 4.6). The BioCAD purification on Ni- 
agarose column resulted in a protein above 95% pure, although a few 
contaminating E. coli proteins remained. From a1 liter induced culture, about 4 
mg of enzyme were routinely purified. As a control, non-transformed BL21 (DE3) 
E. coli cells were treated in the same manner and both the insoluble and soluble 
fractions were analysed using Coomassie-blue stained SDS-PAGE. No over- 
expressed protein could be observed in any of the fractions (results not shown). 
The soluble fraction was kept as a control for the analysis of the enzyme activity. 
Xho 1 (159) 
fl origin HindIII (174) 
Sal 1 (180) 
Sma 1 (345) 
Ka(n Xhol (573) 
Sma 1 (5080 LmPAPI 
Clal (4897) Ndel (1018) 
p Ncol (1076) pE LmPP 
p 6 IL48 b, p 
FIG. 4.5. Construct for expression of recombinant pyroglutamyl pepticlase I (PPI) of 
L. major in E. coli. Schematic representation of the plasmid resulting from the cloning of the 
sequence of the PPI of L. major in the pET28a(+) vector (Novagen) for expression of PPI with a 
N-terminal His-tag. Kan, kanamycin resistance gene; fl origin, origin of replication of the phage 
fl; lacl, gene encoding the lac repressor protein. 
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M, 123456789 
mom -- 
50 
20- 
FIG. 4.6. Analysis of expression and purification of the L. major PPI expressed in E. 
coli BL21(DE3). A SIDS-PAGE gel (12% acrylamide) stained with Coomassie blue. Lane M, 
protein standards; lane 1, E. coli cell lysate after IPTG induction, crude lysate; lane 2, load for Ni- 
agarose column; lane 3, flow-through; lane 4,30 mM imidazole wash; lanes 5 to 9, elution 
fractions from Ni-agarose column with 500 mM imidazole. 10-3 XMr is indicated on the left of the 
figure. 10 lal samples were loaded. 
Active site mutants of the PPI of L. majorwere generated by site-directed 
mutagenesis. Based on the work of Le Saux and co-workers (Le Saux et al., 
1996), cysteine-210 was mutated to alanine, histidine-234 to serine, glutamic 
acid-101 to glutamine and glutamic acid-107 to glutamine (L. major PPI 
numbering). The mutated L. major PPIs were all partially soluble when induced at 
200C, and were purified as the native recombinant PPI with similar yields (results 
not shown). 
4.2.3. Biochemical characteristics of the recombinant PPI of L. major 
For all investigations, controls without enzyme were carried out, and it 
was confirmed that there was no spontaneous hydrolysis of the substrates used. 
Control assays using crude soluble fraction from non-transformed E. coli did not 
show any activity towards pGlu-pNA (less than 0.1 mU/ml), whereas the same 
extract of cells expressing the L. major PPI showed a significant activity (-1 
U/ml). 
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4.2.3.1. Dependence on reducing conditions, EDTA and magnesium Ion 
The recombinant PPI from L. major showed a strong dependence on 
reducing agents, as expected for a cysteine peptidase and as reported for other 
PPIs (Cummins and O'Connor, 1998; Dando et aL, 2003). The presence in the 
assay buffer of at least 10 mM DTT or 0.5 mM TCEP was required to observe full 
activity (Fig. 4.7). 
IE 
4- 
0 I- 
E 
9 
FIG. 4.7. Dependence of L. major PPI activity on DTT. Assays used 10.6 pg enzyme, 
2 mM pGlu-pNA and were in 25 mM potassium phosphate buffer, pH 8.0. Results are the means 
± SID from 3 independent measurements. 
As for the human PPI, no stabilising effect was observed in the presence 
of EDTA (Dando et aL, 2003) for the L. major recombinant enzyme (Fig. 4.8), but 
I mM EDTA was routinely included in the assay buffer to chelate ions like Ni2+, 
which may be present in traces due to Nickel-agarose purification and have been 
shown to be inhibitory on PPI enzymes (Dando et aL, 2003, section 4.2.3.6. ). 
> 
U 
0 
0 It 
FIG. 4.8. Effect of EDTA on L. major PPI activity. Experiments used 11.4 Vg enzyme, 
2 mM pGlu-pNA and were in 50 mM HEPES buffer, pH 8.0, with 10 mM DTT- Results are the 
means ± SD from 3 independent measurements. 
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The effect of Mg2+ ions, which would be chelated by the EDTA included 
in the buffer and might be beneficial to enzyme activity, was investigated. No 
beneficial effect was observed (Fig. 4.9), and therefore Mg2+ was not added to 
the assays. ' 
E 
4- 
0 
0. 
E 
0 
E 
MgSO4(MM) 
FIG. 4.9. Effect of Mg2+ on L. major PPI activity. Experiments used 11.4 pg enzyme, 
2 mM pGlu-pNA and were in 50 mM HEPES buffer, pH 8.0, with 10 mM DTT. Results are the 
means ± SD from 3 independent measurements. 
4.2.3.2. pH optimum 
Activity towards the synthetic substrate pGlu-pNA was observed over a 
wide spectrum of pHs, with maximum activity being between pH 8.8 and 10.5 
(Fig. 4.10). This is slightly higher than has been reported for other PPIs (Awade 
et aL, 1992a, Dando et aL, 2003), but confirms an alkali optimum for the enzyme. 
The activity decreased rapidly below pH 8.0. Though the observed pH optimum 
was above 8, assays were performed at pH 8.0, for biological significance. 
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FIG. 4.10. Effect of pH on L. major PPI activity. (A) Experiments used 11.4 pg enzyme 
and were in the mix of buffers (25 mM acetic acid, 25 mM MES, 75 mM Tris-base, 25 mM 
Glycine), supplemented with I mM EDTA, 10 mM DTT, 2 mM pGlu-pNA. (B) Experiments used 
11.4 pg enzyme and were in the buffers indicated in the legend, supplemented with I mM EDTA, 
10 mM DTT, 2 mM pGlu-pNA. Results are the means ± SD from 3 Independent measurements. 
4.2.3.3. Storage and stability 
The recombinant L. major PPI was found to be stable for at least 3 
months at -200C in 50 mM HEPES pH 8.0,1 mM EDTA, 2 mM TCEP, and 3h at 
370C but lost almost all activity in 6 days storage at 40C in the same suspension 
buffer (Fig. 4.11). The enzyme was thus routinely stored at -20, DC, and fresh 
aliquots were defrosted immediately prior to analysis. 
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FIG. 4.11. Stability of L. major PPI, stored In 50 mM HEIRES pH 8.0,2 rnM TCEP, I 
rnM EDTA. Experiments used 10.5 pg enzyme, 2 mM pGlu-pNA and were In 50 mM HEPES pH 
8.0, supplemented with 2 mM TCEP and I mM EDTA. 
4.2.3.4. L. major PPI is a monomer 
Gel filtration analysis showed that the active recombinant enzyme has a 
molecular mass of about 36 kDa (Fig. 4.12). The predicted molecular mass for a 
monomer of the enzyme is 32.5 kDa. The fraction containing the protein showed 
significant activity towards pGlu-PNA (1 U/mg protein). Mammalian PPIs are also 
monomers (Dando et aL, 2003). 
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FIG. 4.12. Determination of the molecular mass of the recombinant L. major PPI by 
gel-filtration analysis. The enzyme was produced in E. coli with a N-terminal His-tag. The 
purified PPI was applied to a Sepharose 12 10 x 300mm gel-filtration column, which had been 
calibrated with the following proteins: 1, ribonuclease A; 2, chymotrypsinogen; 3, ovalbumin; 4, 
BSA; 5, alcohol dehydrogenase; 6,0-amyiase. The broken line indicates the ratio V. (elution 
volume) to V. (void volume) of recombinant, active L. major PPI and the arrow head Indicates the 
inferred molecular mass (36 kDa). 
4.2.3.5. Activity towards pGlu-, H-Glu- and H-Gln- substrates 
Purified enzyme was active towards the substrates pGlu-pNA, pGlu-PNA, 
H-Glu-PNA, with a strong preference for the pGlu substrates (20-fold greater 
activity) (Fig. 4.13). The enzyme did not present any activity towards H-Gly-PNA. 
Other PPIs have been reported not to cleave Glu at the N-terminus (Dando et a/., 
2003). The activity towards H-Glu-PNA being low, it cannot be excluded that this 
activity might be due to cleavage of pGlu-PNA present at a low concentration in 
the H-Glu-PNA substrate, and resulting from spontaneous cyclisation of the H- 
Glu-PNA substrate. The Kms and specific activities were, respectively, 4.5 ± 0.5 
jiM and 1.02 ± 200 mU/mg protein towards pGlu-PNA; 33.5 ± 2.5 l. N and 904 ± 
310 mU/mg against pGlu-pNA; 85 ± 18 ýt! Vl and 50 ± 12 mU/mg protein towards 
H-Glu-PNA. This falls within the range of expected Km values reported for 
mammalian PPIs towards pGlu-pNA (20 to 80 ýLM) (Mantle et al., 1995; Cummins 
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and O'Connor, 1998; Dando et al., 2003), and not the range for the bacterial 
enzymes (180 to 250 VM) (Le Saux et al., 1996; Ito et al., 2001). 
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FIG. 4.13. Analysis of the activity of the PPI of L. major produced in E. coli against 
the synthetic substrates pGlu-PNA, pGlu-pNA, and H-Glu-PNA. (A) K, s (JIM) of the 3 
substrates. (B) Activities (U/mg protein) of the enzyme against the 3 substrates. Enzyme samples 
were tested for activity in a final volume of 1 ml. The enzyme sample was incubated for 5 min at 
320C in 50 mM HEPES pH 8.0 buffer, supplemented with 2 mM TCEP and 1 mM EDTA, before 
start of the reaction by addition of the substrate (200 pM, unless for K, determination 0.1 plM to 1 
mM were used). Excitation and emission wavelengths were respectively 320 and 410 nm for the 
DNA fluorogenic substrates. Reading wavelength was 410 nm for the pNA chromogenic 
substrate. The assays were continuous for 10 min at 320C. Results are the means 1 SID from 3 
independent measurements. 
Activity towards H-Gln-PNA was also investigated, but the results were 
more difficult to analyse. There was an initial low rate for about 5 min, which 
quickly accelerated to reach the rate that occurred towards the pGIu-pNA 
substrate (Fig. 4.14). The initial rate only was observed when there was no pre- 
incubation of the substrate in the assay buffer at 320C. If pre-incubation was 
used, the rate detected was immediately the same as maximum rate towards 
pGlu-PNA. It was concluded that a small proportion of the H-GIn-IMA substrate 
was quickly converting to pGlu-PNA. The Km towards pGlu-1-INA is about 4 pM, 
thus a spontaneous cyclisation of only about 5% of the 200 pM of H-GIn-IMA 
used in the assay would result in the maximum rate towards the pGlu-[MA 
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substrate. It had previously been shown that up to 6% of H-Gln-PNA could 
convert spontaneously to pGlu-PNA when incubated at 3711C for 2h (Chikuma et 
aL, 2004). Lower concentrations of H-Gln-PNA were also investigated but the 
initial rate then was at the limit of detection and precise measurements were not 
possible. It is therefore not certain if PPI presents some activity towards H-GIn- 
PNA, as the very low activity detected could be due to a very small fraction of 
pGlu-PNA already present in the H-Gln-PNA substrate. The PPI has an apparent 
activity of 10 mU/mg protein towards 200 ltM of H-Gln-PNA and it seems likely 
that PPI may not have any activity at all against this substrate. 
200 tiM pGlu-PNA B 200 gM H-Gln-PNA 500-1 1 
400 
Secondary III 
rate 
Initial Accele 
200- rate 
100- 
0 10 120' 30 r0 50 60 
TIMO (s) 
FIG. 4.14. Typical traces obtained with 0.2 mU of recombinant PPI of L. major 
produced In E. coil, and the substrates 200 liM pGlu-PNA (A), and 200 plVI H-Gln-ONA (B). 
Assays were in 50 mM HEPES pH 8.0,2 mM TCEP, 1 mM EDTA, at 32"C. In both A and B, the 
buffer was pre-incubated for 5 min at 320C, and the reaction was started by simultaneous addition 
of PPI and substrate. Measurements were continuous (excitation 320 nm, emission 410 nm). AU. 
arbitrary fluorescence units; s, seconds. 
4.2.3.6. Inhibitors 
The human PPI had been reported to be inhibited by transition metal ions 
(Dando et aL, 2003). Various ions were tested on the recombinant PPI of L. 
major (Table 4.4). Nickel, copper and zinc ions showed strong inhibition of the 
enzyme; nickel almost completely inhibited the enzyme when at 1 mM. As 
expected, calcium, magnesium, sodium and lithium ions did not have any effect. 
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Table 4.4. The effects of various Ions on the activity of the purified recombinant PPI of 
L. major. Assays were in 50 mM HEPES pH 8.0,2 mM TCEP. The ions were added to the 
buffer-enzyme mix and incubated for 10 min at 3211C. The reaction was then started by addition of 
200 pM pGlu-pNA and monitored continuously for 5 min at 410 nm. The activity remaining Is 
indicated as a percentage of the activity of the non-treated enzyme In the same conditions. 
Values correspond to mean ± SID from 3 measurements. 
Ion Concentration (mM) Activitv M 
Ni` 1 1.0 0.3 
Ni> 0.1 52 1.0 
Mg : 94 2.1 
Na+ 100 2.5 
Ca 2+ 1 88 ±I. 6 
CU: 1 8.7 0.3 
Li+ 1 92 0.7 
Zn 2+ 1 19.8 ± 0.4 
Other inhibitors were tested, but only sulfhydryl blocking agents such as 
iodoacetamide, iodoacetic acid and N-ethyl maleimide (NEM) showed strong 
inhibition of the enzyme (Table 4.5). Though the PPI is a cysteine peptidase, the 
common cysteine peptidase inhibitor (2S, 3S)-3-(N-((S)-1 -[N-(4- 
guanidinobutyl)carbamoyl]3-methylbutyl)carbamoyl)oxirane-2-carboxylic acid (E64) 
did not inhibit the enzyme's activity. This reflects the very different catalytic 
mechanism of PPI compared with clan CA, family C1 peptidases, such as papain. 
This is consistent to what was found for the human enzyme (Dando et a/., 2003). 
Surprisingly, the serine peptidase inhibitor phenylmethylsulphonyl fluoride (PMSF) 
showed some inhibition, but only at the mM range, and the pGlu analogue 2- 
pyrrolidinone, reported to be an inhibitor for the bacterial enzymes (Cummins and 
O'Connor, 1998), inhibited only when at I mM. 
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Table 4.5. The effects of various Inhibitors on the activity of the purified recombinant 
PPI of L. major. Assays were in 50 mM HEPES pH 8.0,2 mM TCEP. Inhibitors were added to 
the buffer-enzyme mix and incubated for 10 min at 3211C. The reaction was then started by 
addition of 200 pM pGlu-pNA and monitored continuously for 5 min at 410 nm. The activity 
remaining is indicated as a percentage of the activity of the non-treated enzyme In the same 
conditions, with the standard deviation based on 3 repeats of each measurement. PMSF: 
phenylmethylsulphonyl fluoride; NEM: Wethyl maleimide. 
Inhibitor Concentration (pM) Activity (%) 
E64 100 79 ± 1.2 
10 91.8 ± 2.1 
Pepstatin A 10 93 ± 1.6 
1 A4 A+IA 
PMSF 
lodoacetamide 
lodoacetic acid 
1,10-phenanthroline 
1000 46.6 0.8 
100 101 1.0 
100 1.7 0.3 
10 7.4 0.8 
100 0 
10 1.2 0.4 
1000 98.2 0.7 
100 98.8 1.9 
Benzamidine 1000 96 2.2 
100 100 1.2 
Bestatin 10 101 1.7 
NEM 100 1.9 0.4 
10 3.1 0.3 
2-pyrrolidinone 1000 66 2.5 
100 86.7 3.0 
10 99 ± 2.8 
4.2.4. Biochemical analysis of active site mutants of the recombinant PPI of 
L. major 
As expected for a pyroglutamyl peptidase I (Dando et a/., 2003), the 
active site cysteine and histidine predicted for the PPI of L. ma r, at respectively Vo 
positions 210 and 234 (PPI of L. major numbering), from the alignment with PPI 
from different organisms (Fig. 4.3 and 4.4) were found to be essential for the 
enzyme's activity. Mutants lacking the active site cysteine (C210A) or histidine 
(H234S) had practically no activity (Table 4.6). The E101Q mutated enzyme had 
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about 2% of activity compared with the unmutated recombinant enzyme, with a 
Km for pGlu-pNA about 30 times higher than that of the unmutated enzyme. In 
contrast, the E107Q mutated enzyme still had 50% of the activity of the native 
enzyme and the Km was only 2.5 fold higher. These results confirmed that 
glutamic acid 101 is part of the active site, whereas glutamic acid 107 probably 
plays a minor role in the catalytic reaction. 
Table. 4.6. Biochemical analysis of the recombinant PPI active site mutants of L. 
major expressed In E. coH and purified on Nickel-agarose column. The amino acids are 
represented using the single letter code. Numbering refers to the native PPI of L. major. Activity is 
expressed as a percentage of the activity of the recombinant non-mutated PPI of L. major In the 
same conditions. Assays were in 50 mM HEPES pH 8.0.1 mM EDTA, 2 mM TCEP, 200 PM 
pGlu-pNA, at 3211C and measured continuously for 10 min at 410 nm. The K,, of the different 
enzymes was measured for the substrate pGlu-PNA. N/A: non applicable. 
Mutant Activity remaining Km (pGlu-pNA) 
C21 OA <0.5% N/A 
H234S <0.3% N/A 
E101Q 2% 936 ±5 gM 
E107Q 50% 88 ± 26 pM 
4.2.5. Cloning of the glutaminyl cyclase gene of L. major 
Database searches on the genomic database of L. major using the 
human glutaminyl cyclase (QC) as a query (GenBank accession number NP 
036545) detected a 2724 bp open reading frame translating into a 907 amino 
acid protein (GeneDB; LmjF05.0950) with QC features, and which was annotated 
as a putative glutaminyl cyclase. No other sequence with QC features could be 
detected in the L. major database (now totally sequenced), which suggested that 
the putative QC is a single copy gene in L. major, localised on chromosome 5. 
The amino acid sequence was analysed with the SignalP algorithm (Nielsen et 
al., 1997), and TMpred (Hofmann and Stoffel, 1992), and a trans-membrane 
domain was predicted near the N-terminus (position 120-144 on the predicted 
protein). 
0 
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The results of the 5' RACE showed a mRNA comprising a 108 bp 5' 
untranslated region (UTR), confirming the start methionine attributed (Fig. 4.15). 
101 CTGCCTTTTC TTTTCTGATG CAACATCAAT 
GACGGAAAAG AAAAGACTAC GTTGTAGTTA 
FIG. 4.15. L. major QC 5' untranslated region (UTR) determined by 5' RACE. 5' UTR 
is on grey background. The predicted start ATG is underlined. 
The protein was aligned with the human QC (Fig. 4.16). A schematic 
representation of the alignment is shown in Fig. 4.17. The complete L. major 
protein and the L. major QC protein fragment from position 408 to 907 showed 
little overall sequence identity with to the human QC (11% and 16% identity, 
respectively). However, blocks of sequence identity were observed around the 
active site residues of the human QC. It has a very long N-terminal extension of 
407 amino acids, which contains a trans-membrane domain, whereas the human 
enzyme possesses a signal peptidase for localisation in the secretory system. 
This suggests a different location for the L. major QC. From the 6 key catalytic 
residues in the human QC, 5 were conserved in L. major QC: His-140, Glu-201, 
Glu-202, Asp-248 and His-330 (human enzyme numbering). The Asp-159 was 
not conserved, but in the human QC the Asp residues are not thought to be 
involved in the catalytic reaction (Bateman et al., 2001). The L. major QC has a 
long insertion from positions 733-757 (L. major QC numbering) of unknown 
function. By computational analysis, it is unclear if the L. major QC may be 
functional, but it possesses the necessary residues for activity. 
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1 80 
HsQC (1) --------------------------------------------------------------------- -------- -- 
LmQC (1) MQHQSLAARRRGRRLARRGESAFWCSLLKRCLPCLPLRWKSVHATSRTRRILMGILLCLITTLIFLIGLLVCLTWKSNRS 
81 160 
HsQC (1) ------------------------------------------------------------------------------- 
LmQC (81) NTPLEPAAVQSTRAPRVPPEVGVEDPWAEDPVDVAVIRQREEAVVRKWKENGFRPTYWEVERRTLPRLTKRALESWFEHG 
161 240 
HsQC (1) -------------------------------------------------------------------------------- 
LmQC (161) RRAAASATAVDVAEDVLTAHAWDAVDGGDADADLFDSLAFLYPPAQQRQHYRAAMDAILRHGPRVGGTKRDALLHHLVDE 
241 320 
HsQC (1) ----------------------------------------------------------------------------- -- 
LmQC (241) GLGRRRYDAARRAYHPAPPHLSPRGKELLEKAAASWPDAPHLAAAPQDDVAGREPGWRWSLSWDNFTADI PIRIDGSSRV 
321 400 
HsQC (1) --------------------------------------------------------------------------- -- 
LmQC (321) EMQNLVFQFPGGLQFRRKQAAAASAAATGAKDALDEFVGGVPNRRRTRADDRKDVLEAEYHPADMTGETVYTQENFLQWA 
401 480 
HsQC (1) ------- MAGGRHMREVBILHLIVLLVIALPWASRGVMPE- SIIWP - EEKNYHQPJIMNSSALRQIAEGTS I SEMWQNDLQP 
LMQC (401) QDGVPFNPRPALV"PHIRV', JISPE§KGARVPLKPILIMPIAEPATQQPVKH"IAAliWDSKYFADI PFI AACDý; AMPV 
481 560 
HsQC (73) LLIIIYPGS PGSYAARQH I MQRIQRLQADWJLEI[ITFLSQTPYGYRSFSNI I STLNPTAKRHIVLACIYL).,; Kil-'ý; IIWNNR 
LmQC (481) VFLLMT I KNIAVLTDVAEALTESYKAERSCMVGG3ASAAVPGLTSTFRNATTEAEVRERIArllýý; 1114111AI' I JJQY FFARP 
561 640 
HSQC (153 VFVBATDSAVPCF&NMLELARALDKKLLSLKTVSDS KJDLSLQLj]FflýFL=PQjP 1,8H! EHMlA F MAMI IP PGA 
LMQC (561ý YSIIGEQQNFVALW, -IRNHPTKVEVDVRTWLDWVQHLJI--IISVILSIM-yKý, DMN, Iiliý, )PWj,, w!; VMRS 
641 720 
HsQC (233) O"s -- -QLHGMS! L'ýl! LZ! IIAPNPMPIFFINSARWMER-IQAIDIEHELGLLKDIIýý, lýE(-, PYFQ)NIý; Y(; GV 
LMQC (639) -'AjjFA4jYM"PAGTMRMMYjjTQSG IMYAGISQR2WMRHRAMQHSSAI SAE I, I, Wl, '51)1-: A'I'A 1, PPAE 
721 800 
HsQC (303) IQDLý --------------------------------------------- 
LMQC (719) AREY. 11M, GSPHEAVASLNAAYTRRLLANNASRPSVASLPRSWLMYGSPHEMLTI, Ilý; VAIýl"I'll[)VRl-'Vl-: NFDQLR 
801 - 880 
HBQC (317) ---- ----------------------------------------------- 
LmQC (799) VYDRLDREIAAESSFDAERYLNTINHNIFFSPSQQEDLRRNRDVFVADDDHKIiWLDTQPlUMIMK!; MMi\NlM; ý; 
881 907 
HsQC (338) MLDE IDNjNKILkVF'a]rLHL ----- 
LMQC (879) IVHDISTDMAGIIWSTMLGDYWTRKE 
FIG. 4.16. Alignment of the glutaminyl cyclase (QC) of L. major with the human QC. 
Dashes indicate gaps in the alignment. Active site residues are starred. Conserved residues are 
on black background. The predicted signal peptide is underlined. Lm, Leishmania major (GeneDB 
CDS: LmjFO5.0950); Hs, Homo sapiens (Song et al., 1994). 
L. major 
1 120 144 548 183 607/8 658 872 907 
361 
FIG. 4.17. Schematic comparison of the QC of L. major and the human QC. TIVI, trans- 
membrane domain; SP, signal peptide. Amino acids are represented using the single letter code. 
Numbers indicate the positions for the various domains/amino acids. 
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4.2.6. Recombinant expression of the glutaminyl cyclase gene of L. major in 
E. coli 
The sequence encoding the L. major QC without the trans-membrane 
domain from amino acid position 145 to 907 (L. major QC numbering), and the 
sequence encoding for a fragment of the L. major QC from amino acid position 
408 to 907 (L. major QC numbering), aligning with human QC from position 29 
(the start of the human QC without the signal peptide) were amplified and cloned 
into the pET28a(+) vector for recombinant expression in Ecoli. The 
corresponding plasmids are represented in Fig. 4.18 and Fig. 4.19. 
Smal 
rial (1340) 
LmQC 
Ncol(2239) 
(2902) 
2960) 
lacl 
FIG. 4.18. Construct for expression of recombinant QC of L. major in E. coli. 
Schematic representation of the plasmid resulting from the cloning of the sequence of the QC of 
L. major from position 145 to 907 in the pET28a(+) vector (Novagen) for expression of the QC 
with a N-terminal His-tag. Kan, kanamycin resistance gene; f1 origin, origin of replication of the 
phage fl; lacl, gene encoding the lac repressor protein. 
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Sm 
Clal 
Xshort 
mal (1340) 
Ndel (1606) 
Ncol (1664) 
FIG. 4.19. Construct for expression of recombinant truncated OC of L. major in E. 
coli. Schematic representation of the plasmid resulting from the cloning of the sequence of the 
QC of L. major from position 408 to 907 in the pET28a(+) vector (Novagen) for expression of the 
truncated QC with a N-terminal His-tag. Kan, kanamycin resistance gene; f1l origin, origin of 
replication of the phage fl; lacl, gene encoding the /ac repressor protein. 
E. coli BL21 (DE3) cells transformed with the plasmids were induced 
either for 4h at 370C with 1 mM IPTG (Fig. 4.20), or for 4h at 200C or 150C with 
1 mM IPTG (results not shown). With the pETLmQC plasmid, an over-expressed 
protein of about 98 kDa, corresponding to the expected size for N-terminal His- 
tagged protein could be detected, and with the pETLmQCshort plasmid, an over- 
expressed protein of 56 kDa, corresponding to the expected size for N-terminal 
His-tagged protein (55.7 kDa) could be detected, but it was found in the insoluble 
fraction of E. coli lysates in all cases (results shown for induction at 370C only, 
Fig. 4.20). The expression in E. coli did not result in production of soluble protein 
for enzyme characterisation. 
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FIG. 4.20. Analysis of expression of N-terminal His-tagged QC of L. major in E. coli 
BL21(DE3). Ten pl samples were separated on a SDS-PAGE gel (12% acrylamide) and then 
stained with Coomassie blue. Lane Mr, protein standards. 10-3 XMr is indicated on the left of the 
figure. (A) Analysis of expression of the full length QC of L. major. Lane 1, E. coli total cell lysate 
after 4h induction at 370C with 1 mM IPTG. (B) Analysis of expression of the truncated QC of L, 
major. Lane 1, E. coli total cell lysate after 4 In induction at 370C with 1 mM IPTG. Arrows indicate 
the over-expressed QC. 
4.2.7. Analysis of potential genes for pyroglutarnyl pepticlases 11 of L. major 
Database searches on the genornic sequence database of L. major 
using the human PPIl as a query (accession number NP 037513) detected 3 
potential genes for metal lopeptidase (clan MA(E), family M1) PPIls in L. major, 
LmjF29.2240, LmjF26.0300, LmjF12.1250, all annotated as aminopeptidase-like 
proteins, and respectively located on chromosomes 29,26 and 12. 
The proteins were aligned with the human PPII (Fig. 4.21). The similarity 
table is presented in Table 4.7. Two of the L. major proteins showed good 
similarity (42-44%) to the human enzyme, whereas the last one was not very 
similar (11 % similarity). However, the predicted active site residues (Schomburg 
et al., 1999) were all conserved between the different proteins. The 3 L. major 
putative enzymes had the typical metal-binding motif HEXXH (Schomburg et al., 
1999) at position 440-444 (human numbering). Studies for the presence of PPll- 
like activities in L. major are described in chapter 5. 
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Tatie. 4.7. Similarity table of the L mglor predicted pyroglutamyl peptidases 11 
(PRO *rIth the human PPIL Ntxnbers represent percentage of identity. Hs. Homo sapiens; Lrn, 
L major. 
HSPPII Lmppll (1) LMPPII (2) LMPPII (3) 
HsPPII 100 42 44 11 
LnPPu (1) 100 51 17 
LfnPPII (2) 100 15 
LmPpii (3) 100 
4.3. Discussion 
Cysteine peptidases In Leishmania have been shown to play an 
Important role In parasite's survival and pathogenicity (Mottram et aL, 2004). By 
database mining of the L major genomic database. using the human cysteine 
PePtidase of clan CF. family C13, pyroglutamy! pepbdase I (Dando et aL, 2003), 
a single Sequence coding for a PPI in L rwjor was identified. The sequence was 
amplirled from genomic DNA and the predicted protein contained the cysteine, 
histidine and glutamic acid catalytic triad. but surprisingly low identity with other 
PPIS from different organisms (Table 4.3). The reason for this is unclear, but 
mightSuggest a very different role for the enzyme in L major compared with that 
In humans. In humans. the enzyme may be involved in the cleavage of bloactive 
Peptides, such as neuropeptides (Dando et aL. 2003). which the parasite lacks. It 
Is unknown what may be the L m1or PPI natural substrates, but this would be 
very Informafive on the role that the enzyme might have in the parasite. Database 
searches revealed that 352 artnotated proteins start with Met-Gin in L major, and 
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can potentially be pyroglutamyt-modified after cleavage by a methionine 
arninopeptidase. This could be Investigated by a proteomic approach, in which L. 
Imior cell lysates would be treated with a broad substrate specificity 
aminopeptidase. In order to degrade unblocked peptides, and compare With cell 
lYsates fast treated with PPI before treatment with the same aminopeptidase. The 
difference beh%*een the 2 samples would theoretically correspond to pGIu- 
modified Peptides. which could be identified by mass-spectrometry. 
The recombinant L major PPI was produced in E. coli, and about 4 mg 
of soluble enzyme could be purified from a11 culture. The characteristics of the 
enzyme conform to what is expected for a marnmalian PPI; it is strictly dependent 
On reducing agent (Fig. 4.7). it has an alkaline pH optimum (Fig. 4.10), and it is 
active as a nxxiorner (Fig. 4.12). The very high pH optimum might be real or 
artefactual of recombinant expression. as it is unclear what biological significance 
this May have. The PPI did not have a signal peptide or a trans-membrane 
domain predicted. making it suggestive the enzyme would be cytosolic, as 
expected for the other PPIs. The localisation of the PPI in L major is investigated 
in chapter 5. The free-living prornastigotes propagate in the alimentary tract of 
the sandfly. primarily in the midgut where the pH is rather alkaline (7.0-9.0), and 
the nOn-MWe arnastigotes reside in phagolysosomes of mammalian 
macrOPhages. whose environment is acidic (4.5-5.5), but the intracellular pH is 
maintained close to neutrality (6.4-6.7) at all times (Zilberstein et aL. 1989). It is 
unclear why a cytosok enzyme might have such a high pH optimum. In terms of 
substrate Specificity. it cleaves preferentially pGlu synthetic substrates, but can 
also cleave glutarnic acid as a N-terminal residue (Fig. 4.13), which is unreported 
for Marnfrialian enzymes. This suggests that leishmanial PPI may have a slightly 
different conformation. which allows Glu to bind to the active site pocket. 
However. it cannot be excluded that this activity might be due to the presence of 
a Small amount of pGlu In the Glu substrate. as cyclisation of Glu to pGlu is also 
possible (SchMing et at. 2004). Activity against N-terminal glutamine may be 
zero (Fig. 4.14). as spontaneous chemical conversion of the synthetic substrate 
to the PGlu derivative would Invalidate the assay. The recombinant enzyme is 
currently being tested for substrate specificity by our collaborators (Juliano and 
CD"wcfker3. Sao Paolo, Brazil). The Kn against the pGlu substrate falls within the 
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range of expected Ka values reported for mammalian PPIs against synthetic 
pGlu substrate (20 to 80 pt. 1) (Mantle et aL. 1995. Cummins and O'Connor, 1998; 
Dando el al.. 2003). and not the range for the bacterial enzymes (1180 to 250 tLM) 
(Le Saux el aL, 1996; Ito et aL. 2001). The inhibition pattern was similar to the 
human PPI (Dando et aL. 2003); L major PPI was inhibited by transition metal 
ions and sylfhydr)i bkx: Wng agents. but not by the cysteine peptidase inhibitor 
E64 (rables 4A and 4.5). E64 is a potent inhibitor of the cysteine peptidase of 
the clan CA: the PPI belongs to the clan CIF and possesses very few common 
features with papain. except from the catalytic mechanism involving an active site 
cYsteine and histidine. The clan CIF enzymes are not produced as inactive 
Zymogens that require activation, as it is the case for the clan CA enzymes, but 
directly as mature proteins. The L rmlor PPI possesses cysteine residues, 
excluding the active site. %rhich could potentially form 2 disulfide bridges. But the 
POsitiOn of these cysteine residues among the different organisms is not 
cOnSereed. making the presence of the disuffide bridges less likely to be 
important for activity. 
The biochemical characteristics of L major PPI seemed to conform to the 
data reported for the marnmatian PPIs, and this is consistent with the 
PhYlogenetic anaWs of the enzyme. A phylogenefic tree generated using the 
arignment of the L rwjor PPI Wth various PPs from different organisms (see 
Appendix 1) showed that L rwjor PPI is more closely related to eukaryotic PPIs 
than bacterial PPs (Fog. 422). 
164 
Chapter 4: Expression and characterisation of recombinant 
pyroglutamyl peptidase, / of L. major 
V%oupF 
eamo, 
ý 
6o 
1ý 
cov 
wý 
Dmappi 
02 
FIG. 4.22. Neighbour-joining phylogenetic tree of amino acid sequences of 
pyroglutamyl peptidases. The sequences of PPs from various organisms were aligned using 
Align X (Clustal X, Vector NTI program), cut to the same amino acid length (166) and insertions 
were removed manually. The bootstrapped unrooted phylogenetic tree was generated using the 
MEGA program (Kumar et al., 2001), with 1000 bootstrap replicates. Eubacteria are on dark grey 
background, Archeabacteria are on light grey background, and Eukaryotes are on white 
background. L. major PPI is boxed. The scale bar indicates the number of estimated amino acid 
substitutions per site. Abbreviations: Cpe, Clostridium perfringens; Spy, Streptococcus pyogenes; 
Sau, Staphylococcus aureus; Tde, Treponema denticola; Bam, Bacillus amyloliquefaciens, Vvu, 
Vibrio vulnificus, Sce, Streptomyces ceolicor, Rso, Ralstonia solanacearum; Cvi, 
Chromobacterium violaceum; Pfl, Pseudomonas fluorescens; Mtu, Mycobacteriurn tuberculosis; 
Pfu, Pyrococcus furiosis; Tlit, Thermococcus litoralis; Sso, Sulfolobus solfatanicus; Ath, 
Arabidopsis thaliana; Cel, Caenorhabditis elegans; Dme, Drosophila melanogaster, Gga, Gallus 
gallus; Hs, Homo sapiens; Xtr, Xenopus tropicalis; Lin, Leishmania infantum; Lmj, Leishmania 
major, Tb, Trypanosoma brucei; Tc, Trypanosoma cruzi. 
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By active site mutagenesis, the catalytic triad cysteine-210, histidine-234 
and glutamic acid-101, predicted for a PPI enzyme from the alignment with other 
PPls, was confirmed, and the glutamic acid-107 was shown possibly to play 
some role in the catalytic reaction, such as a possible substrate stabilisation in 
the active site pocket, without being essential to the catalytic reaction (Table 4.6). 
The presence of sequences for a glutaminyl cyclase (QC) were analysed 
by database mining using the human enzyme sequences. One potential gene 
encoding a QC was detected, with very little sequence identity to the human 
enzyme. The L. major QC had a predicted trans-membrane domain, whereas the 
human enzyme possesses a signal peptide for localisation to the secretory 
pathway and subsequent modification of secreted peptides (Pohl et aL, 1991). 
This suggests a very different local isation/role for the parasite's QC, if Indeed the 
protein is expressed as a functional enzyme in the parasite. As 5' RACE was 
successful, mRNA is produced for the enzyme, but this is not indicative of 
whether or not the enzyme is expressed, as the sequence may be part of a 
transcription unit, transcribed as a polycistronic pre-mRNA, subsequently 
matured. 
The L. major genomic database contains 3 potential sequences encoding 
metal lo peptidase PPII enzymes. These enzymes all contain the active site 
residues required for activity but only 2 of the predicted proteins show good 
similarity with the human PPII (42-44% identity). The presence of sequences for 
these proteins is quite surprising, as PPII in human has a very strong specificity 
for thyrotropin-releasing hormones (TRH), thought to be absent in parasites, and 
it would unexpected for a unicellular organism to possess enzymes with such 
degree of specificity. The clan MA(E), family M1 of metal lo-aminopeptidases 
includes a whole range of peptidases cleaving acidic, neutral or basic residues, 
and it could be that the L. major enzymes with PPII similarities just happen to 
share the features classifying them in this clan, without being able to cleave a 
pGlu residue at the N-terminus. The presence of PPI, QC and PPII In L. major 
cell extracts is assessed in chapter 5, as well as localisation and functional 
analysis of the PPI. 
166 
Chapter 5: Functional study of the pyroglutamyl peptidase I of L. major 
Chapter 5 
Functional study of the 
pyroglutamyl peptidase I of L. major 
5.1. Introduction 
It was shown in Chapter 4 that L. major possesses a single gene encoding 
pyroglutamyl peptidase I (PPI), 3 potential genes for pyroglutamyl peptidases 11 
(PPII), and I potential gene for a glutaminyl cyclase (QC). Functional 
recombinant expression of the PPI of L. major in E. coli was successful. Tho 
presence of such an enzyme in L. major is very intriguing, as very few PPIs of 
mammals have been fully characterised so far and a definitive physiological rolo 
has yet to be attributed. Bacterial PPs have been widely used for unblocking of 
the N-terminus of proteins prior to N-terminal sequencing, but, as with tho 
mammalian PPIs, the physiological function of bacterial PPs is still unknown. Tho 
leishmanial enzyme may be involved in protein metabolism, as reported for 
bacteria (Awade et aL, 1994; Ito et aL, 2001), although it is unclear if L. major Is 
able to produce its own pGlu-modified peptides, as the gene encoding for a QC Is 
only putative. Therefore, it would be of interest to determine the enzyme's natural 
substrate(s), and if it interacts with proteins in the insect vector or the mammalian 
host, and consequently contribute to the parasite's pathogenicity. If so, tho 
parasite's PPI could be a new drug target. 
In order to investigate the function of the PPI in the parasite, the first aim 
was to generate gene deletion lines, where the PPI gene would be replaced by 
selectable markers, and lines over-expressing PPI. These approaches would 
give information on whether the modification in PPI expression affected the 
survival of the parasite in vitro, metacyclogenesis and infectivity to mice. 
Generation of PPI knock-out mutants would also facilitate study of whether other 
PP activities are present in L. major (for instance PPII activities), and therefore, if 
the genes encoding putative PPIls are expressed. In addition, testing the effects 
of pGlu-modified peptides such as gomesin on the different cell lines should give 
insight into the role of PPI in the host-parasite interaction, and whether the 
enzyme might confer protection against pGlu-modified peptides from the host or 
the insect vector. 
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It was also intended to carry out immuno-localisation studies to investigate 
the enzyme's location and also look for secretion. 
5.2. Results 
5.2.1. Over-expression of LmPPI in L. major promastigotes 
5.2.1.1. Over-expression 
The sequence encoding PPI of L. major, was amplified from genomic 
DNA and cloned into the derivative of the pXG vector pGL102, containing a 
selectable marker (Neo gene from transposon Tn5 encoding an aminoglycosido 
3'-phosphotransferase) for use with neomycin, for over-expression of a N- 
terminally His-tagged protein in the parasites. The sequence encoding Ppl, In 
which the active site cysteine had been changed to an alanine, was cloned In the 
same way. Both were transfected into L. major promastigotes. As a control, the 
empty pGL1 02 vector was transfected into L. major promastigotes, to check that 
the over-expression of the neomycin resistance gene did not have a detrimental 
effect on the parasite's growth or survival. All, vectors were transfected for 
expression as episomes (free plasmids), andthe maps are presented In Fig. 5.1. 
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FIG. 5.1. Constructs for over-expression of LmPPl in L. major promastigotos. (A) 
Plasmid for over-expression of the native N-terminal His-tagged enzyme. (B) Plasillid for over- 
expression of the active site cysteine mutated N-terminal His-tagged enzyme. (C) Empty vector 
Neo, neomycin resistance gene; amp, ampicillin resistance gene; Lm, L. major. 
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5.2.1.2. Analysis of over-expression 
Western blotting using anti-LmPPI antiserum on extracts of L. major 
promastigotes transfected with the different plasmids revealed high over- 
expression of both native and mutated PPI compared to control cells transfected 
with the empty pGL102 vector (Fig. 5.2). A major protein at about 31 kDa, the 
size expected for the N-terminal His-tagged PPI, could be detected in 
promastigotes transfected with the pGL102LmPPI and pGL102LmPPI* plasmid, 
Over-expression of the 2 enzymes (native and mutated) seemed to be at 
approximately the same level. No protein could be detected in the pellet fraction 
of cell lysates, proving that the enzyme is not membrane-associated (results not 
shown). The acellular fraction of cultures of the different cell lines was TCA 
precipitated and the equivalent of 5 ml of medium was analysed by western blot 
using anti-LmPPI antibodies, but no signal could be detected (results not shown). 
This suggests that the over-expressed enzymes are not released into the 
extracellular environment. 
Control PPI* PPI 
31 kDa LA *1**. 10 
FIG. 5.2. Western blot analysis of the over-expression of the pyroglutamyl poptidase 
I (PPI) of L. major in L. major promastigotes. The anti-PPI of L. majot antiscruni raised in tot 
was used at a dilution of 1.500 (v/v), and the anti-rat antibody was used at 1: 1500 (v/v). Tho 
membrane was exposed for 3 min. L. major promastigotes were grown in HOMEM media 
supplemented with 10% (v/v) HI-FBS and 50 ýtg/ml neomycin. The supernatant extract of 5x1O' L. 
major stationary phase promastigotes was loaded in each lane. Lane control, supernatant of cell 
lysate of cells transfected with the pGL102 empty vector; lane PPI*, supernatant of cell lysate of 
cells transfected with the plasmid for over-expression of the active site cysteine mutated PPI. lane 
PPI, supernatant of cell lysate of cells transfected with the plasmid for over-expression of the 
native PPI, 
The PPI activities present in the different fractions of cell lystates were 
investigated using the substrate pGlu-PNA, and the activity of the over- 
expression lines was compared to the control cells transfected with the empty 
pGL102 vector. The PPI activity was exclusively associated with the soluble 
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fraction of cell lysate, and the supernatant of cells over-expressing the dead 
mutant of PPI had very similar activity to control cells. However, the supernatant 
of cells over-expressing the active enzyme had about 7 times greater activity 
than the control (Table 5.1). 
TABLE. 5.1. Comparison of the activity towards pGlu-PNA of L. major 
promastigotes over-expressing native PPI, the active site cysteine mutant of the enzyme, 
or the empty vector. Cells were grown in presence of 50 pg/ml of neomycin. The equivalent of 
8X1 07 stationary phase cells were tested per assay. Assays were in 50 mM HEPES pH 8.0,2 mM 
TCEP, I mM EDTA, 200 pM pGlu-PNA, at 3211C. Measurements were continuous for 10 min 
(excitation 320 nm, emission 410 nm). Activity is represented in comparison with the control. 
Plasmid 
transfected pGL102 empty pGL102LMPPI* pGLI02LmPPI 
Cell lysate 
fraction Pellet Supematant Pellet Supematant Pellet Supematant 
Comparative 
<0.05 1 <0.005 1.2 10.3 <0.05 7 12 activity 
The dependence of the over-expression '6n'neomycin concentration was 
tested by growing the cell lines in the presence of different concentrations of tho 
selection drug. The supernatant of cell lysates'was' analysed by western-blot 
using anti-LmPPI antibodies, but no difference could be detected In tho 
expression after 1 growth cycle (1 passage) in t_h, e different neomycin 
concentrations (Fig. 5.3), suggesting either that the accumulation of episomes is 
a slow process and several cycles of growths would be necessary to observe a 
difference, or that the cells reached the maximum level of expression tolerable 
even at the lowest neomycin concentrations. 
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FIG. 5.3. Dependence of the over-expression of the native LrnPPl in L. major 
promastigotes cultures on the amount of selection drug. The anti-PPI of L. major antisertim 
raised in rat was used at a dilution of 1: 500 (v/v), and the anti-rat antibody was used at 1: 1500 
(v/v). The membrane was exposed for 3 min. The supernatant Of 5X107 L. major cell lysate was 
loaded per lane. Lane 1, supernatant of cell lysate of cells grown with 50 pg/ml neomycin, lane 2, 
supernatant of cell lysate of cells grown with 100 pg/ml neornycin; lane 3, supernatant of cell 
lysate of cells grown with 150 pg/ml neornycin. 
To test whether the enzyme was released into the extracellular milieu, 
supernatants of cultures of the different cell lines were TCA precipitated and the 
equivalent of 1 ml was loaded on a SDS-PAGE gel and used for western blot 
analysis, using anti-PPI antibodies. No signal could be detected in any of the 
supernatants of cultures. Furthermore, 100 [tI of crude supernatant of cultures of 
each line was assayed for activity towards 200 ýM pGlu-IMA. No activity coum 
be detected 'in any case (less than 10 pU/ml were detected, which corresponds 
to the maximum level of activity detected with buffer and substrate alone). Thi's 
was indicative that either the PPI was released into the supernatant of culture at 
a level that was not detectable, or was not released at all. 
5.2.1.3. Phenotype analysis of PPI over-expressing cell lines 
5.2.1.3.1. Morphology and growth 
The over-expression of the PPI in L. major promastigotes did not result in 
any difference detectable at the morphological level. In terms of growth, all cell 
lines were able to multiply, though the cells transfected with the empty pGL102 
vector grew significantly faster from day 3 to day 6 and the final cell density 
higher (about 1.5 fold higher) (Fig. 5.4). The cells over-expressing the dead 
mutant enzyme grew at similar rates as the cells over-expressing the active 
enzyme but reached a slightly higher density (1.6 x 107/Ml compared to 1.3 x 
107/Ml ). Thus, the decrease of the growth rate might be related to the over- 
expression, whereas the final density may be influenced by the active enzyme 
over-expressed. 
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FIG. 5.4. Growth curve of L. major pr9mastigote cell lines over-expressing the 
native LmPPI, the active site cysteine mutant of the enzyme and the empty vector. Cells 
were grown with 50 pglml of neomycin and counted at regular intervals. pGL102LmPPI, cells 
expressing the native PPI; pGL102LmPPI*, cells over-expmssing the active site cysteine mutant; 
pGL102, cells transfected with the empty vector. Results are the means ± SD from 3 Independent 
experiments. The cells transfected with the empty pGL102 vector grew significantly faster from 
day 3 to day 6 compared to the 2 other cell lines (P<0.05) and the' cells transfected with the 
pGLI 02LmPPI* plasmid grew significantly faster than the cells transfected with the pGL1 02LmPPI 
plasmid from day 4 to day 7 (P<0.05), except on day 5. 
5.2.1.3.2. Differentiation to metacyclic promastigotes 
It was interesting to determine if there was a difference in the kinetics of 
formation of infective metacyclic promastigotes in the different cultures. 
Metacyclic promastigotes were separated from the procyclic promastigotes using 
the peanut agglutinin method (Sacks et al., 1985). The method is based on the 
observation that concentrations of peanut adglutinin necessary to'agglutinate'the 
totality of log-phase Leishmania promastigotes do not, agglutinate metacyclic 
promastigotes. The difference in agglutination is due to developmental regulation 
of surface lipophosphoglycans, shed by procyclic pr omastigotes, 'and acquisition I 
of new carbohydrate determinants during metacyclogenesis'(Saý6ks and da Silva, 
1987). It was shown that the number of metacyclic'pr6mastigotes'in the culture of 
cells over-expressing the active enzyme increased significantly IM, ore slowly than 
in the 2 other cultures (Fig. 5.5), though these 
'metacyclic 
pro'mastigotes were 
morphologically identical to wild type cells. The measurements were taken In 
duplicate from the time point at which the cells entered stationary phase of 
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growth (day 4 after initiation of the cultures at 106/ml). 'It seemed that the protein 
over-expression was not responsible for this slow conversion, as the'cells over- 
expressing the PPI dead mutant produced the same' number of, metacyclic 
promastigotes as the control cells. Thus it seemed that'over-expression of the 
active PPI resulted in slower metacyclogenesis. - 
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FIG. 5.5. Production of metacyclic promastigotes in L. major. Cells were grown with 
50 pg/ml of neomycin and metacyclic proportions were assessed. using peanut agglutinin 
agglutination at regular time intervals. pGLI02LmPPI, cells expressing r the native PPI; 
pGL102LmPPI*, cells over-expressing the active site cysteine mutant; pGLI02, cells transfected 
with the empty vector. Results are the means ± SE from 2 independent measurements. 
pGLI02LmPPl transfected cells produced significantly less metacyclic promastigotes from day 3 
compared to the 2 other cell lines (P<0.05, P<0.03 at day 10). 
5.2.1.3.3. In vitro infectivity to macrophages 
Infection in vitro was assessed using peritOneal macrophages, with 
stationary phase promastigotes and purified metacYcl, ic promastigotes. Infection 
with stationary phase promastigotes over-expressing the active PPI showed a 
significantly lower level of infection compared -to the promastigotes over- 
expressing the dead PPI or the empty episome (about 2 times less) (Fig. 5.6). 
But when the macrophages were infected with purified metacyclic promastigotes, 
the infections rates observed with the different cell lines were very similar (all 
-around 40%). The culture of cells over-expressing the active PPI contained about 
2 times fewer metacyclic promastigotes compared to the other 2, lines, Which may, 
explain the lower level of infection when total populations of. promasticlotes were 
used. Using a ratio of metacyclic promastigotes of 0.51, the maximum infection 
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rate expected would be around 50%, which fits well with the results obtained; and 
when using promastigotes at a 2: 1 ratio, the infection expected would be around 
2 times the percentage of metacyclic promastigotes in the culture. In this case, 
the infection rates obtained are slightly higher; this may be due to loss of some 
macrophages during the washing steps. Comparing the percentages of 
metacyclic promastigotes in the different cultures, a 2-fold lower infection rate 
would be expected with the line over-expression the active PPI, which is the 
case. So the over-expression of the active PPI seems to hinder the production of 
metacyclic promastigotes. but the metacyclic promastigotes produced are 
infective for macrophages. 
75 
50 
25 
0 
2 
Procyclics 
Metacyclics 
FIG. 5.6. In vitro macrophage infection by L. major stationary phase 
promastigotes or purified metacyclic promastigotes. Promastigotes were infected at a ratio of 
2: 1, metacyclic promastigotes at a ratio of 0.5.1. Percentages on the bars correspond to the 
percentage of metacyclic promastigotes in the stationary phase culture. Incubations were for 6 
days. pGL102LmPPI, cells expressing the native PPI; pGL102LmPPI*, cells over-expressing the 
active site cysteine mutant, pGL102, cells transfected with the empty vector. Results are the 
means -- 
SD from 3 independent experiments. The infection rates obtained using pGL102LmPPI 
transfected promastigotes were significantly lower than the ones obtained with the 2 others Cell 
lines (P<0.004), whereas the infection rates obtained with pGL102LmPPI* and pGL102 
transfected promastigotes were not significantly different from each other (P>0.05). Infection rates 
obtained with metacyclic promastigotes from the different lines were similar (P>0.05). 
5.2.1.3.4. In vivo infectivity in mice 
5x 10 :ý stationary phase promastigotes of the cell lines transfected with 
the pGL102LmPPI, pGL102LmPPI* or pGL102 plasmids were inoculated into the 
footpad of BALB/c mice. The evolution of the infection was assessed by 
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measurement of the footpad widths over time. The results showed that cells over- 
expressing the dead mutant were infecting as well as the cells transfected with 
the empty vector, whereas the cells over-expressing the active enzyme showed a 
delay in infection of 5 weeks (Fig. 5.7). The over-expression was via an episomal 
plasmid, and the selection for neomycin resistance was not Possible, during the 
experiment, thus it was expected the plasmid would probably be slowly lost over 
time. Whether this process would take 5 weeks to occur and so the later growth 
c)f the lesions correlated with loss of the over-expression of PPI'is unknown. To 
test if the level of PPI activity might be related to the size of lesions formed, 
amastigotes from lesions of different sizes were extracted from different mice 
from this group. The cells were grown to stationary phase in medium without 
neomycin to mimic the conditions in the mice, and PPI activity in the supernatant 
of cell lysates was measured using pGlu-PNA. Interestingly, 
_ 
the parasites 
extracted from the smallest lesions (mouse 1) presented the highest level of PPI 
activity (Table 5.2). The parasites that had formed lesions of the same size as of 
the control cells (mouse 2) at the time of termination of the experiment, showed a 
very similar level of PPI activity. 
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FIG. 5.7. Mice Infectivity of L major cell lines. 5x1 05 cells resuspended in 20 lAl of 
PBS were infected into one footpad of BALBIC mice. Measurements of the width of the footpads 
were taken at regular intervals. pGL102LmPPI, cells expressing the native PPI; pGLI02LmPPI*, 
cells over-expressing the active site cysteine mutant; pGL102, cells transfected with the empty 
vector. Results are the means ± SID from 6 mice. The lesions 
^ 
provoked by pGLI02LmPpl 
transfected cells were significantly smaller from week 2 compared to the 2 other cells lines 
(P<0.0001), and the lesions provoked by pGL102 transfected cells were only significantly bigger 
than the ones provoked by pGL1 02LMPPI* transfected cells from week 2 to 4 (P<0.02). 
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TABLE. 5.2. Comparison between Infected mice footpad sizes and PPI activity of 
promastigotes generated from extracted amastigotes. At the termination time of the mice 
infectivity experiment L major amastigotes from 2 of the 6 mice infected with the. L. major cell 
line over-expressing the native PPI of L major, and from 1 of the 6 mice infected with cells 
transfected with the empty pGL102 vector were taken from the footpad lesions and grown in 
medium without neomycin. The PPI activity in the supernatants of cell lysates were measured In, 
50 mM HEPES pH 8.0,2 mM TCEP, 1 mM EDTA, 200 ýLM pGlu-PNA, continuously for 5 min at 
32"G (excitation 320 nm, emission 410 nm). 8xl 07 cell equivalents were used per assay. Activity 
is represented in comparison to activity in control. pGL102LmPPI (mouse 1), cells expressing the 
native PPI and extracted from the footpad of the mouse with the smallest footpad size from the 
group; pGL102LmPPI (mouse 2), cells expressing the native PPI and extracted from the footpad 
c)f the mouse with the biggest footpad size from the group; pGL102, cells transfected with the 
empty vector. 
Cell line pGL102LmPPI pGL102LmPPI pGL102 (mouse 1) (mouse 2) 
Duration of mice 
footpad 10 10 6 infection 
(w eks) - 
Size of footpad 
at end of 2.40 4.20 4.50 
experiment 
(mm) 
Comparative PPI 
activity In 2 03 
supernatant of . 
cell lysate I I 
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5.2.2. Knock-out of LmPPI gene in L. major pronnastigotes 
5.2.2.1. Analysis of knock-out 
Using 5' and 3' specific flanks to the PPI, a plasmid was designed for 
gene knock-out (Fig. 5.8). The selection markers used for the first allele knock- 
out was the blasticidin S resistance gene, and the selection marker used for the 
second allele knock-out was the hygromicin B resistance gene. Two knock-out 
lines were generated from independent sequential transfection events (lines 
KOPPa and KOPPb). 
HindIll 
S'flankPP 
Spel 
SI) ", //)C(; 
i)HI 
Smal 
FIG. 5.8. Construct for gene knock-out of the pyroglutamyl peptidase I (PPI) of L. 
major. Schematic representation of the plasmid resulting from the cloning of the sequences for 
the 5' and 3' flanks of the PPI of L. major in pGL345 (HYG) or pGL842 (BSD) for gene 
replacement of the PPI. amp, ampicillin resistance gene-, BSD, blasticidin resistance gene-, HYG, 
hygromycin resistance gene. 
Gene replacement was first confirmed by PCR (Fig. 5.913) (a scheme of 
the locus and the position of the primers used is shown on Fig. 5.9A). A single 
DNA fragment at -1.4 kb corresponding to the wild type PPI gene was amplified 
from the wild type cells. With the single allele knock-out line, 2 DNA fragments 
were amplified; one at -1.4 kb corresponding to the wild type PPI, and one at 
-3.2 kb corresponding to the blasticidin resistance gene. In the knock-out lines, 2 
DNA fragments were amplified; one at -3.2 kb corresponding the blasticidin 
resistance gene, and one at -4 kb corresponding to the hygromycin resistance 
gene. 
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FIG. 5.9. L. major PPI gene knock-out confirmation by PCR. (A) Schematic 
representation of the PPI gene locus on chromosome 34 and the result of the PP/ gene 
replacement. Block arrows indicate ORFs. Small arrows indicate position Of PCR primers. 1: 
checkKOPPFor; 2: checkKOPPRev (see Table 2.1). The predicted sizes of fragments amplified 
by PCIR are indicated. LmPPI, L. major pyroglutamyl pepticlase gene-, DHFR, dihydrofolate 
reductase gene; BSD, blasticidin resistance gene; HYG, hygromycin resistance gene. (B) PCR 
analysis. PCR was performed on genomic DNA with primers 1 and 2 and using the Long 
Template PCR System (Roche) and 10 pl were run on a1% (w/v) agarose gel. Lane 1, wild type; 
lane 2, single allele knock-out (11 allele replaced with BSD gene); lane 3, double PP/ gene knock- 
out, clone KOPPa; lane 4, double PPI gene knock-out, clone KOPPb. Clones KOPPa and b were 
generated from independent first and second allele replacements. The positions of the molecular 
size markers in bp are shown on the left of the figure. 
Knock-out cells lines were also confirmed by Southern-blot, using the 5' 
flank sequence as a probe (Fig. 5.10). On the wild type cells, a single DNA 
fragment at -3 kb corresponding to the wild type PPI gene was detected. On the 
single allele knock-out line, 2 DNA fragments were detected; one at -3 kb 
corresponding to the wild type PPI, and one at -3.7 kb corresponding the 
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blasticidin resistance gene insertion. In the knock-out lines, 2 DNA fragments 
were detected; one at -3.7 kb corresponding the blasticidin resistance gene 
insertion, and one at -4.3 kb corresponding to the hygromycin resistance gene 
insertion. 
A 
2996 bp 10 
BamHl Smal 
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1234 
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FIG. 5.10. L. major PPI gene knock-out confirmation by Southern blot. (A) Schematic 
representation of the PPI gene locus on chromosome 34 and the result of the PPI gene 
replacement. Arrows indicate ORFs. The predicted sizes of the BarnHIISnial fragments detected 
by Southern blot using the 5'flank as a probe are indicated. LmPPI, L. major pyroglutamyl 
peptidase gene; DHFR, dihydrofolate reductase gene; BSD, blasticidin resistance gene-, HYG, 
hygromycin resistance gene. (B) Southern blot analysis. Genomic DNA was digested with BamHI 
and Smal, run on a 1% (w/v) agarose gel, blotted on nylon membrane and hybridised with 32p_ 
labelled 5'flank sequence. Lane 1, wild type; lane 2, single allele knock-out (1 allele replaced with 
BSD gene); lane 3, double PP/ gene knock-out, clone KOPPa; lane 4, double PPI gene knock- 
out, clone KOPPb. Clones KOPPa and b were generated from independent first and second allele 
replacements. Blot was exposed for 8 days. The positions of the molecular size markers (bp) are 
shown on the left of the figure. 
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The PPI activity present in the different fractions of cell lysates was 
measured using the substrate pGlu-PNA, and the activity of knock-out lines was 
compared to the wild type cells. PPI activity was totally absent from the knock-out 
lines compared to the wild type cells (Table 5.3). 
TABLE. 5.3. Comparison of the activity towards pGlu-PNA of L. major wild type and 
knock-out cell lines for the PPI. The equivalent of 8xi 07 cells were tested per assay. Assays 
were in 50 mM HEPES pH 8.0,2 mM TCEP, 1 mM EDTA, 200 [tM pGlu-PNA, at 3211C. 
Measurements were continuous for 10 min (excitation 320 nm, emission 410 nm). 
Cell line KOPPa KOPPb Wild type 
Cell lysate 
fraction Pellet Supematant Pellet Supematant Pellet Supematant 
Activity 
(Pull 01 <5 <5 <5 <5 <5 100 ± 20 
cells) 
5.2.2.2. Phenotype analysis of PPI knock-out cell lines 
5.2.2.2.1. Morphology and growth 
Promastigotes of PPI knock-out lines of L. major did not show any 
difference detectable at the morphological level compared to wild type cells. In 
terms of growth, all cell lines multiplied at the same rate and reached the same 
final density as the wild type parasites (Fig. 5.11). Thus, the knock-out of PPI did 
not influence the growth of promastigotes in vitro. 
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FIG. 5.11. Growth of L. major wild type and PPI knock-out line as promastigotes. 
Cells were grown without selection drug and counted at regular intervals. KOPPa and KOPPb 
correspond to 2 different cell lines obtained from individual gene knock-out events; PPI knock- 
out cell lines; wt, wild type cells. Results are the means ± SID from 3 independent experiments. 
5.2.2.2.2. Conversion to metacyclic promastigotes 
The percentage of metacyclic promastigotes in the populations were 
determined from the time point at which the cells entered stationary phase of 
growth (day 4 after initiation of cultures at 106 cells/ml). There did not appear to 
be a difference either in the morphology, or the kinetics of formation of metacylic 
promastigotes over time between the knock-out cell lines and wild type cells (Fig. 
5.12). Thus, the knock-out of the PPI did not influence the conversion. 
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FIG. 5.12. Metacyclogenesis In L. major wild type and PPI knock-out cell lines. 
Cells were grown to stationary phase and metacyclic promastigotes proportions were assessed 
using the peanut agglutinin agglutination test at regular time intervals. wt, wild type', KOPPa and 
KOPPb correspond to 2 different cell lines obtained from individual gene knock-out events. 
Results are the means ± SE from 2 independent measurements. 
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5.2.2.2.3. In vitro infectivity in macrophages 
Infectivity in vitro towards peritoneal macrophages was assessed, using 
stationary phase promastigotes and purified metacyclic promastigotes. 
Prornastigotes and purified metacyclic promastigotes from wild type and the 2 
independent knock-out lines resulted in infection rates that were very similar, of 
about 60% and 40% respectively (Fig. 5.13). The numbers of metacyclics in the 
different promastigote cultures were very similar, so these results suggest that 
the knock-out of the PPI did not affect infectivity in vitro. 
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FIG. 5.13. In vitro macrophage infection by L. major stationary phase 
promastigotes or purified metacyclic promastigotes of wild type or PPI knock-out cell 
lines. Promastigotes were infected at a ratio of 2: 1, metacyclic promastigotes at a ratio of 0.5: 1. 
Percentages on the bars correspond to the percentage of metacyclic promastigotes in the 
stationary phase cultures. Incubations were for 6 days. WT, wild type; KOPPa and KOPPb 
correspond to 2 different cell lines obtained from individual gene knock-out events. Results are 
the means ± SID from 3 independent experiments. The different cells lines did not induce 
significantly different infection levels (P>0.05). 
5.2.2.2.4. In vivo infectivity in mice 
Lesions resulting from inoculation of mice footpads with 5x 105 
promastigotes of the 2 knock-out cells lines grew more slowly than those of wild 
type parasites, showing a delay of about 2-3 weeks. Subsequent growth was also 
somewhat slower than the lesions caused by wild type parasites (Fig. 5.14). The 
proportions of metacyclic promastigotes in the populations of promastigotes used 
to infect were determined and it was shown that while wild type culture contained 
12% metacyclic promastigotes, the PIPI knock-out lines contained 6%. It was 
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unclear if the difference in growth of the lesions was due to the difference in 
numbers of metacyclic: promastigotes injected into the footpads, to difference in 
infectivity of the metacyclic promastigotes in the different cultures, or to a 
difference in virulence of the amastigotes of the different lines. Therefore the 
experiment was repeated using the same number of metacyclic: promastigotes 
per injection for all lines. In this case, the infection rates observed for all 3 lines 
(wild type and 2 lines of knock-out) were the same (Fig. 5.15). So it seemed that 
the knock-out of the PPI gene did not have an effect on infectivity to mice, and 
that the delay in infectivity observed in the case of mice infection with PPI knock- 
out promastigotes may have been due to a difference in metacyclic 
promastigotes numbers compared to the wild type line, as it was suppressed 
when the same number of metacyclic promastigotes was infected for each lines. 
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FIG. 5.14. Mice Infectivity of L. major PPI knock-out and wild type cell lines. 5x1 05 
cells resuspended in 20 Id of PBS were infected into one footpad of BALB/c mice. Six mice per 
cell line were infected. Measurements of the width of the footpads were taken at regular intervals. 
KOPP, knock-out cell lines for the PPI; wt, wild type cells. KOPPa and KOPPb correspond to 2 
different cell lines obtained from individual gene knock-out events. Results are the means ± SD 
from 6 mice. The infections generated by wild type parasite were significantly greater than the 2 
others from week 1 (P=0.0002), and the infections generated by the 2 individual knock-out lines 
were only significantly different from each other at week 4 (P=0.005) and week 5 (P=0.0017). 
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FIG. 5.15. Mice infectivity of L. major PPI knock-out and wild type purified 
metacyclic promastigotes. 105 purified metacyclic promastigotes resuspended in 20 pl of PBS 
were infected into one footpad of BALB/C mice. Four mice per cell line were infected. 
Measurements of the width of the footpads were taken at regular intervals. KOPP, knock-out cell 
lines for the PPI; wt, wild type cells. KOPPa and KOPPb correspond to 2 different cell lines 
obtained from individual gene knock-out events. Results are the means ± SD from 6 mice. The 
infections generated by the different cell lines were not significantly different (P>0.05). 
5.2.3. PPI locallsation in L. major promastigotes 
Immunolocalisation studies using the anti-LmPPI antiserum on L. major 
promastigote cell lines (knock-out for the PPI gene, wild type and over- 
expressing the PPI enzyme) showed the enzyme may be cytosolic (Fig. 5.16). 
The staining was not associated with the nucleus, and was diffuse throughout the 
cytoplasm. 
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FIG. 5.16, immunolocallestion of the LmPPl In L. major promastigot" using anti- 
LmPP1 angswurn raised In rat. The secondary antibody was the Alexa FluorS 568 goat anti-rat 
IgG (Molecular Probes) at a dilution of 1: 500 (v/v). Blue staining corresponds to DAR staining of 
nucleus and kinetoplast; red staining corresponds to PPI localisation. From top to bottom, pictures 
are: differential Interference contrast (DIC), DAPI, Alexa FluorS 568 and merged. Wild type: L. 
major wild type; KOPPa: L. mi*or cell line having both alleles for the PPI gene removed; 
pGL102LmPPI: L major call line over-expressing the active PPI of L. major. (A) Anti-LmPPI 
antiserum was used at 1: 500 (vtv). (B) No Incubation with anti-LmPPI antiserum, wild type cells. 
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5.2-4. Effect of the natural antimicrobial peptide gomesin on L. major 
Gomesin and gomesin analogues were kindly provided by Dr Antonio de 
Miranda (Sao Paolo, Brazil). Gomesin is an 18-residue cysteine-rich peptide from 
the hemolymph of the spider Acanthoscurria gomesiana, carrying 2 disulfide 
bridges, a N-terminal pGlu and a C-terminal a-amidation, which showed 
leishmanicidal properties (Silva et aL, 2000). The primary amino acid structure of 
gornesin is ZCRRLCYKQRCVTYCRGR* (using the single letter amino acid code, 
were Z stands for pyroglutarnate and the asterisk indicates a C-terminal cc-amide) 
(Silva et aL, 2000). The gomesin analogues were [Ala']-gomesin, where the N- 
terminal pyroglutarnate was replaced by an alanine, and Ac-[Alal]-gomesin, 
where the N-terminal pyroglutarnate was replaced by an acetylated alanine. 
The IC50 (inhibitor concentration required to reduce by 50% the response 
obtained with untreated cells) of gomesin towards wild type, PPI over-expression 
or PPI knock-out L. major cell lines at the same culture phase (day 3 of stationary 
phase, day I being the day cells enter stationary phase) were all similar (around 
5 IN), suggesting the over-expression of PPI did not have a favourable effect on 
parasite survival in the conditions tested in vitro (Fig. 5.17). The N-terminal 
blocking of gomesin was not essential to the activity of the peptide, as the 
unblocked [Ala']-gomesin was still toxic to L. major stationary cells. However, 
[Ala']-gomesin showed reduced toxicity (3-fold reduction, IC50 of about 15 PM) 
towards all L. major cell lines tested (Fig. 5.17). The replacement of the N- 
terminal pGlu by an acetyl-alanine slightly decreased the toxicity of gomesin (1.2 
to 1.5-fold, IC50 of about 7 pt% but not as much as unblocking of the N-terminus. 
So it seems that the pGlu modification plays a role, but is not essential to 
gomesin's toxicity. Interestingly, the IC50S of the different compounds towards late 
log-phase L. major promastigotes (wild type, PPI over-expressing and PPI knock- 
out cell lines) were about 5-fold lower than the IC50 towards stationary phase 
promastigotes at day 3 of stationary phase (data for wild type cells are shown on 
Fig. 5.18). The' wild type culture contained about 15-20% metacyclics 
promastigotes at, day 3 of stationary phase (see Fig. 5.13). The decreased 
susceptibility of stationary phase promastigotes compared to log-phase 
promastigotes was probably due to surface remodelling during stationary phase 
and transformation to metacyclic forms (Sacks and da Silva, 1987). 
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Fig. 5.17. IC50 of gomesin and gomesin analogues on L. major cell lines. 5x 10'ý 
stationary phase L. major promastigotes (day 3 of stationary phase) were incubated with various 
concentrations of gomesin (Silva et al., 2000) or gomesin analogues. After 1h incubation at 250C, 
MTT was added to a final concentration of 1 mg/ml. The samples were incubated for a further 1h 
at 250C, before the absorbance at 620 nrn was read in a microtiter plate reader. wt, L. major wild 
type; pGL102LmPPI, L. major cell line over-expressing the LmPPI; KOPPa, PP/ knock-out L. 
major cell line. [Ala']-gomesin, the N-terminal pyroglutarnate of gomesin was replaced by an 
alanine; Ac-[Alal]-gomesin, the N-terminal pyroglutarnate of gomesin was replaced by an 
acetylated alanine. Values are the means ± SID of 3 independent experiments. The ICý,, Js of each 
compound towards the different cell lines were not statistically different from each other (PAA), 
but the IC50S of the 3 compounds towards the same cell lines were statistically different from each 
other (P<0.025). 
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Fig. 5.18. Dependence of the IC50 of gomesin on L. major culture phase. 5x 10'ý wild 
type late log or stationary phase L. major Promastigotes were incubated with various 
concentrations of gomesin (Silva et al., 2000) or gomesin analogues. After 1h incubation at 250C, 
MTT was added to a final concentration of 1 mg/ml. The samples were incubated for a further 1h 
at 251C, before the absorbance at 620 nm was read in a microtiter plate reader. [Ala']-gomesin, 
the N-terminal residue is an alanine; Ac-[Alal]-gomesin, the N-terminal residue is an acetylated 
alanine. Values are single measurements or means ± SID of 3 independent experiments. 
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5.2.5. Glutaminyl cyclase (QC) and PPII activities 
In order to determine if L. major possesses a QC activity, polyclonal 
antibodies reactive against QC of L. major had been raised in rat (see Chapter 
4). The antibodies were used on western blots of L. major promastigote cells 
lysates, but no protein could be detected at the size predicted for the full length 
QC (98 kDa) and many other proteins could be detected with similar intensities, 
suggesting the antiserurn produced was of poor specificity (results not shown). 
Measurement of the enzyme activity of QC relies on the use of an indirect assay, 
using the QC as a primary enzyme for cyclisation of the H-Gln substrate, followed 
by cleavage of the cyclised substrate (pGlu) by PPI (Chikuma et al., 2004; 
Schilling et al., 2002). But as shown in Chapter 4, spontaneous cyclisation of H- 
GIn substrate does occur, making the- measurement of any QC activity 
problematic. These fluorometric assays do not permit one to distinguish the 
signal generated from spontaneously generated pGlu substrate from that of the 
enzymatically produced pGlu substrate (Chikuma et al., 2004). Precise 
quantification of pGlu formed from the H-Gln substrate in presence or absence of 
QC requires HPLC analysis, and this was not attempted. Thus, it is still unknown 
if L. major possesses its own QC activity and is able to produce pGlu-modified 
peptides. 
The generation of knock-out cells lines for PPI provided a good means to 
study the presence of other PP activities. It was shown that under the assay 
conditions for PPI activity, no activity could be detected against pGlu-PNA in the 
knock-out cell line promastigote extracts (Table 5.3). The same assays as 
described in Table 5.3 were performed in a buffer composed of 50 mM Tris/HCI 
pH 8.0, which is a buffer that has been shown to be appropriate for the 
measurement of QC activity (Czekay and Bauer, 1993). No activity could be 
detected under these conditions against the pGlu-PNA substrate, suggesting the 
level of PPII activity was too low for detection or the enzyme was absent from the 
cells. 
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5.3. Discussion 
The presence of a pyroglutamyl peptidase I (PPI) sequence in L. major is 
most intriguing, as one presumed role of PPI is to inactivate bioactive peptides, 
such as neuropeptides in human, which the parasite apparently lacks. However, 
this study has shown that the parasite indeed possesses such a PPI activity 
(Table 5.1) and that the PPI is the major, if not the only PP activity in L. major 
promastigotes. The anti-QC antiserum of L. major was found to be poorly 
specific, and the absence of an easy straightforward assay for the QC activity 
meant that I was unable to determine if L. major is indeed able to produce its own 
pGlu-modified peptides. 
Over-expression of the PPI in L. majorwas successfully achieved using an 
episomal vector, and an increase of 5-9 fold in activity in the cell extract against 
the pGlu substrate could be detected in the cells over-expressing the active 
enzyme. The activity was exclusively associated with the soluble fraction of cell 
lysates, which would be consistent with the enzyme being cytosolic, and no PPI 
protein nor PPI activity could be detected in the supernatant of culture, being 
suggestive that the enzyme is not released. Immunolocalisation study of the PPI 
in L. major promastigotes showed the enzyme is cytosolic and is not found 
associated with a particular organelle in the cell (Fig. 5.16), which coincides with 
what was found for other PPIs in different organisms (Mantle et a/., 1991). 
The over-expression of the active PPI in L. major promastigote did not 
seem to influence much the growth of the parasite, though lower cell density was 
reached at stationary stage (Fig. 5.4). A difference was detected in the ability of 
the parasite to transform to infective metacyclic promastigotes at stationary phase 
of growth, (Fig 5.5), though the morphology of the metacyclics promastigotes 
produced was identical to that of wild type cells. The over-expression of the active 
PPI seemed to render the rate of production of metacyclic promastigotes very 
slow, whereas 
' 
over-expression of the dead PPI and the empty episome resulted 
in cell lines with comparable metacyclogenesis rates. Both formed about 3-fold 
more metacyclic promastigotes by 10 days . than did the cells over-expressing the 
active PPI. In terms of infectivity to macrophages in vitro, the cells over- 
expressing 
' 
the active PPI showed a2 times lower infectivity rate when total 
promastigotes, were used, but no difference when purified metacyclic 
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promastigotes were used (Fig. 5.6). The lower infection rate may be explained by 
the lower number of metacyclics present in the promastigote culture, and though 
the over-expressing line (for the active PPI) does not produce as many 
metacyclic promastigotes as the control lines, these metacyclic promastigotes are 
as infective for macrophages as metacyclics purified from the cells over- 
expressing the dead PPI or the empty episome. In vivo, the cells over-expressing 
the active PPI showed a5 weeks delay in infection of mice footpads, whereas 
cells over-expressing the dead PPI showed the same pattern of infection as the 
cells over-expressing only the selection marker (Fig. 5.7). It was unclear if the 
delay in infection might correlate with the amount of PPI activity present in cells, 
which would indicate that over-expression of the PPI in an active form is 
detrimental to infection and that the lesion growth with this line was due to slow 
loss of the episome in the absence of the selection drug in the mice. An 
alternative possible explanation is that the number of metacyclic promastigotes 
injected differed, being significantly lower in the culture of cells over-expressing 
the active PPI, though the 5 week delay in infection observed is longer than what 
would be anticipated; a2 week delay was observed when 5x 104 as opposed to 
5x 105 promastigotes were injected (Susan Baillie, personal communication). So 
these results would suggest that to explain a5 week delay the number of 
infective metacyclics promastigotes in the culture of cells over-expressing the 
active PPI at the time of infection would have to be more than 10-fold decreased 
compared to the other cultures. Based on the data in Fig. 5.5, this was not the 
case as the number of metacyclics promastigotes was at the most 4-fold 
decreased in the PPI over-expressing cell line compared to the other 2 lines in 
cultures at the same phase of growth, and cultures at the same stage of growth 
were used for mice infections. It would be very interesting to analyse the effect of 
infecting the same number of metacyclic promastigotes for the different cell lines 
in the mice. 
The results in vivo differ slightly from the results in vitro, but this is not 
unexpected as with the in vitro studies only the ability to infect isolated 
macrophages is tested, whereas with the in vivo investigations, the host's 
immune response may have an influence on how the parasites infect (Liew et a/., 
1990; Alexander and Russell, 1992). As an example, the targeted gene disruption 
of the CPB gene array of L. mexicana, encoding for cathepsin L-like enzymes, 
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resulted in a >80% decreased infectivity to macrophages compared to wild-type 
parasites, but lesions in mice, though smaller than those induced by wild type 
parasites, still occurred (Mottram et al., 1996). 
Two individual knock-out cell lines for the PPI were successfully 
produced (Fig. 5.9 and 5.10). The absence of PPI activity did not result in a 
difference in morphology or growth compared to the wild type cells (Fig. 5.11) 
and metacyclic promastigotes were formed at the same rate in stationary phase 
cultures of the knock-out line compared to the cultures of wild type parasites (Fig. 
5.12). The maximum proportion of metacyclic promastigotes seemed to also 
depend on the time the parasites had been maintained in culture, the cells freshly 
transformed from amastigotes giving higher numbers of metacyclic promastigotes 
(in this case, wild type, and knock-out lines have been maintained in culture for 2 
weeks, whereas the over-expression lines had been kept for 16 weeks). In vitro 
infection in macrophages showed both wild type and knock-out lines were 
generating the same levels of infection (Fig. 5.13). In vivo infection in mice using 
the same number of promastigotes (but about half the number of metacyclic 
promastigotes in the knock-out lines compared to the wild type) showed a delay 
in infection of about 3-4 weeks in the knock-out lines (Fig. 5.14). To test if this 
delay was due to the different number of metacyclic promastigotes infected or 
difference of infectivity of the metacyclic promastigotes, the same number of 
metacyclic promastigotes was injected for knock-out and wild type lines. In this 
case, the infection rates for all lines were comparable, indicating the metacyclic 
promastigotes produced in the PPI knock-out lines were as infective to mice as 
the wild type parasites (Fig. 5.15). 
So it appears that the over-expression rather than the knock-out of the 
PPI activity is detrimental to the parasites, in terms of infectivity in mice. It is still 
unclear what may be the significance of the presence of such an enzyme in L. 
major. 
Upon microbial infection, the mammalian host has at its disposal various 
mechanisms to kill the pathogen. The first barrier involves the innate immune 
system, machinery present in all other animals and also plants and mainly 
composed of peptides with antimicrobial activity. These peptides are cationic 
potent antibiotics of 15-45 amino acids, active against a wide range of organisms, 
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including bacteria, fungi (Tang et a/., 2002), viruses, protozoa (Aley et al., 1994; 
Lugli et al., 2004), and tumour cells. 
The peptides are classified in different families, depending on their 
structure. In human, there are 2 main families: the defensins, divided in the 2 
classes a- and P-defensins, and the cathelicidins. Many of the P-defensins and 
the pro-mature human cathelicidin carry a N-terminal pGlu modification (Selsted 
et al., 1993; Andersson et al., 2002; Sahl et al., 2004). Defensins are peptides 
with 3 disulfide bonds and a flat dimeric P-sheet structure, with a difference in 
disulfide bridges pattern between the (x- and P-class, whereas cathelicidins are 
linear peptides free of cysteines and with a (x-helical and amphipatic solution 
structure. Other antimicrobial peptides that occur, but are less widespread, have 
a bias in certain amino acids, like proline, arginine, tryptophane or histidine 
(Boman, 2003). a-defensins are produced by neutrophils in a constitutive 
manner, while P-defensins are inducible and produced in neutrophils, 
macrophages and epithelial cells, where they act as anti-microbial agents 
(Hoover et al., 2001). The disulfide bridges are essential to the activity (Torres 
and Kuchel, 2004) and their mechanism of action relies initially on electrostatic 
interaction of the cationic poles of the peptide with negatively charged moieties 
on the target cell surface; the peptide is then inserted into the phospholipid 
bilayer, and diffusion of the peptides in the membrane eventually promotes the 
formation of pores, provoking cell lysis (Boman, 2003). Cathelicidin production is 
induced in the epithelium following epithelial wounding and infectious challenge 
(Schaller-Bals, et al., 2002). In human, the only cathelicidin, hCAP-18, is 
produced as a 19 kDa pre-pro-peptide, with a conserved cathelin-like sequence 
in the pro-domain and a variable antimicrobial C-terminal sequence (Gennaro et 
al., 1998). Cathelin is a 12 kDa peptide isolated from porcine neutrophils, that 
shares similarities with the cystatin superfamily of cysteine peptidases inhibitors 
(Scocchi et al., 1997). Two distinct activities have been attributed to the pro- 
domain; a role of inhibition of bacterial growth, and a role of inhibition of cysteine 
peptidase-mediated tissue damage (Zaiou et al., 2003). The C-terminal fragment, 
namely LL-37, is thought to provoke cell lysis using a similar mechanism to the 
defensins (Sahl et al., 2004). The pro-mature precursor is targeted to granules for 
storage, and upon activation, the content of the granules is released or delivered 
to phagolysosomes (Sorensen et al., 2001). But hCAP-1 8 is not processed to the 
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active LL-37 form in the phagolysosomes. The main function of hCAP-18 seems 
to be extracellular, where LL-37 is formed and acts as a chemotactic agent for 
neutrophils, monocytes and T cells; LL-37 seems therefore to be an important 
mediator of the extracellular immune activity (Sorensen et al., 2001). 
So how might the PPI activity in L. major act on these compounds? First, 
as the activity of the defensins is mainly due to the arrangement of disulfide 
bridges, and for LL-37 to the amphipatic properties, it is unlikely the pGlu 
modification at the N-terminus of some of these compounds might play a role in 
the activity, but rather in the stabilisation of these compounds. Furthermore, the 
LL-37 compound is most probably not active in the phagolysosomes, but present 
as the inactive hCAP-1 8 precursor. 
On hypothesis is that the PPI might protect L. major from pGlu-modified 
natural peptides from the host, by either cleaving off the pGlu residue essential 
for the activity of the peptide, or destabilising the peptides by making them prone 
to exopeptidase degradation, one would expect an increase in the infectivity 
when the active PPI is over-expressed, which is not the case here. In the case of 
hCAP-18, the cleavage of the N-terminal pGlu might destabilise the protein and 
make it more likely to be processed to its active LL-37 form in the 
phagolysosomes. Although release of PPI activity from amastigote cells was not 
tested, the PPI enzyme did not seem to be released from the parasite cell in 
promastigote cultures, and would therefore have to act on internalised 
compounds. PPI seems to be the main, if not the only, PP activity present in L. 
major but the expression of other PP activities, such as PPII, in the amastigote 
stage cannot be excluded. 
A way by which Leishmania has been shown to evade the immune 
response from the host is to promote phagocytosis by macrophages and so avoid 
humoral immunoglobulin mediated response. The presence of 
lipophosphoglycans (LPS) on the parasite cell surface makes it rather resistant to 
acid hydrolases released from the lysosomes upon fusion with the phagosome 
(Desjardins, 2003). Resistance to Leishmania has been shown to rely on the 
development of CD4+ Thl cells, which promote an effective cellular mediated 
immune response, by increasing the release of the cytokine IFN-y, which 
promotes macrophage activation and parasite killing (Jones et al., 1998). On the 
contrary, susceptibility to Leishmania infection is characterised by a mainly Th2 
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response, promoting the release of IL-4, which stimulates the production of 
immunoglobulins, ineffective against phagocytosed parasites. Adaptive immunity 
relies on the degradation of the pathogen proteins into peptides, which can be 
presented on the surface on the macrophage as antigens in conjunction with 
MHC-I or -11 molecules, and trigger a cell mediated immune response. It is 
unclear though why the over-expression of the active PPI enzyme may lead to 
decreased infectivity compared to over-expression of the inactive PPI, and the 
results of the experiments in vivo cannot therefore be clearly explained by an 
increase in antigenicity when the enzyme is over-expressed in the parasite in its 
active form, unless major structural perturbation has occurred in the mutant 
enzyme. Furthermore, the PPI enzyme is not secreted, and immune response 
would have to be triggered by released PPI from dead cells. It would be 
interesting to determine if indeed there is a difference in the immune response 
generated with the different cell lines in the mice. 
Another hypothesis is that the over-expression of the active PPI may 
perturbate some essential functions in the parasite, such as formation of infective 
metacyclic promastigotes and infectivity of these cells. The presence of a 
glutaminyl cyclase could not be determined in the promastigote form of L. major, 
due to lack of assay for the enzyme. The gene seemed to be expressed, but no 
evidence of the expression of the protein could be found. Again it cannot be ruled 
out that the cyclase might be expressed in the promastigote form or/and in the 
amastigote form. As the over-expression -of active PPI seemed to impair the 
formation of metacyclic promastigotes, important regulatory proteins, which might 
carry a pGlu modification may be excessively degraded and perturb the normal 
progression to metacyclic form. Also, there might be a perturbation of the signals 
involved in the modulation of the immune response in the host, in the hypothesis 
pGlu-modified peptides might be involved. So the over-expression of the active 
PPI might influence the composition of pGlu modified peptides in the parasite 
more than in the hosts, hence the relevance of trying to determine what are the 
natural substrates of PPI of L. major, and if indeed they might play a role in the 
parasite's infectivity. Mass-spectrometry approaches, involving the complete N- 
terminal degradation of whole cells peptide extracts from wild-type and PPI 
knock-out lines, should allow the isolation of the totality of N-terminal modified 
peptides, and the subsequent unblocking using the PPI would allow selection of 
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all modified peptides except the ones carrying the N-terminal pGlu. By proteomic 
analysis on 2-dimensions (2-D) gels of the different treated extracts, N-terminally 
pGlu-modified proteins might be isolated and identified. This would identify the 
natural substrates of PPI in the parasites, and if the parasites are indeed able to 
generate pGlu-modified peptides on their own. 
Another possible explanation might be that the over-expression of the 
active PPI may perturb the parasite cell in a non-specific way, as a result of 
excessive processing by the PPI. A complete analysis of the substrate specificity 
may give an insight on what other residues might be susceptible to cleavage by 
the enzyme, especially in conditions where the enzyme is used in excess. The 
over-expression of the active enzyme may have some detrimental effect on the 
cell, not only specific to the cleavage of pGlu residues on the proteins, but also to 
other possible non-specific cleavage of proteins. 
Could it be that the enzyme might have a more important role in the insect 
vector9 The genome of the Plasmodium vector, the mosquito Anopheles gambia, 
has been extensively searched for the presence of anti-microbial peptides. Four 
defensins and 4 cecropin genes have been shown to be induced in the insect 
vector by a malaria infection (Christophides et al., 2002). But none of these 
compounds carry a pGlu modification at the N-terminus. A defensin-like 
antimicrobial peptide was isolated from the hemolymph of the sandfly 
Phlebotomus duboscqi, a vector of Leishmania. The peptide showed anti- 
parasite properties on L. major, and its expression was induced by L. major 
infection in the insect (Boulanger et al., 2004). The peptide was synthesised as a 
pre-pro-peptide, the sequence of the pro-peptide starting with a glutamic acid, 
which could potentially be cyclised to pGlu. Gomesin, the antimicrobial peptide 
from the spider Acanthoscurria gomesiana, which showed leishmanicidal 
properties, is an 18-residue cysteine-rich peptide, carrying 2 disulfide bridges and 
a N-terminal pGlu (Silva et a/., 2000). The IC50 of gomesin towards wild type, PPI 
over-expression or PPI knock-out L. major cell lines were all similar, suggesting 
the over-expression of PPI did not have a favourable effect on parasite survival in 
the conditions tested in vitro (Fig. 5.17). This suggests a different 
compartmentation between the site of action of gomesin and the localisation of 
PPI in L. major promastigotes. This is consistent with the fact that cysteine-rich 
antimicrobial peptides promote the formation of pores into the parasite's 
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membrane, provoking cell lysis (Boman, 2003), and that PPI is a cytosolic 
enzyme that is not released by L. major promastigotes. The N-terminal blocking 
of gomesin was not essential to the activity of the peptide, but the unblocked 
[Ala']-gomesin showed reduced toxicity (3-fold reduction) towards all L. major cell 
lines tested (Fig. 5.17). The replacement of the N-terminal pGlu by an acetyl- 
alanine also decreased the toxicity of gomesin (about 1.2-1.5-fold, Fig. 5.17). So 
it seems that the N-terminal blocking of gomesin is not essential to the peptide 
toxicity, and that the toxic activity of gomesin mainly relies upon features that are 
independent from this N-terminal blocking. However, the N-terminal pGlu 
modification, or N-terminal blocking by acetylation, is favourable to the 
leishmanicidal activity of gomesin, probably by increasing the peptide's stability. 
The leishmanial PPI might play a role in the protection against pGlu-modified 
peptides in the sandfly vector, provided PPI can act on these peptides. The study 
of the propagation of PPI knock-out and over-expressing cell lines in the insect 
vector would be of high interest. 
So in conclusion, no phenotype could be observed in the PPI knock-out 
cell lines, but an impairment in the production of metacyclic promastigotes and 
infectivity in vivo could be observed with the active PPI over-expressing lines. 
What significance could this have in terms of therapy? The over-expression of 
PPI is not likely to occur in the field, nor can the induction of such over- 
expression be easily achieved. Many naturally occurring anti-microbial peptides, 
in mammals and insect, carry a pGlu modification at the N-terminus, but also an 
amidation at the C-terminus (Silva et aL, 2000), which is not thought to play a 
role in the activity of the peptides. Post-transcriptional modifications are more 
likely to stabilise the compounds. Whether the cleavage of such modification in 
the wild may impair their efficiency in a significant way, is unknown. The 
mechanism by which an intracellular enzyme, not secreted, may influence the 
effect of the extracellular peptides, thought to provoke membrane 
destabilisation of the microbial agent, is unclear. The over-expression of the 
active PPI might influence the composition of pGlu-modified peptides in the 
parasite more than in the hosts, provided L. major is able to catalyse the N- 
terminal glutamic acid cyclisation. Thus, a gene khock-out of the glutaminyl 
cyclase might be more informative. If indeed pGlu modified peptides are among 
regulatory peptides that participate in metacyclogenesis or infectivity in vivo, the 
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absence of cyclisation may have some detrimental effect on the parasite. Very 
low sequence similarity was detected between the putative glutaminyl cyclase 
of L. major and the human enzyme (11 %), which could potentially make the 
design of specific inhibitors to the L. major glutaminyl cyclase possible. This 
may be more realistic in terms of therapy. But no reports has been made 
previously on pyroglutamyl peptidases in parasites, and no biological function 
has been attributed to the PP in bacteria yet, though they have been known for 
almost 30 years (Exterkate, 1977). Hopefully the years to come will bring more 
knowledge in this field and provide insight into the roles of PPs. 
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Appendix 1 
Alignment of the edited pyroglutamyl peptidase sequences for 
generation for the phylogenetic tree (Fig. 4.22) 
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Multiple alignment of pyroglutamyl peptidases from various organisms (edited 
sequences). The Align X (Vector NTI) program was used. Identical residues are on block 
background; conservative residues are on grey background. Cpe, Clostridiurn perfringeos 
(GenBank Accession No.: NP 562341); Spy, Streptococcus pyogenes (NP 268785): Sau, 
Staphylococcus aureus (NP 375809); Tcle, Treponema denticola (NP 970791)ý Barn, Bacillus 
amyloliquefaciens (JX0244), Vvu, Vibrio vulnificus (NP 936141), Sce, Streptomyces ceolicor (NP 
624759); Rso, Ralstonia solanacearum (NP 520286); Cvi, ChromobacteriLI171 violaceum (NP 
902846); Pfl, Pseudomonas fluorescens (A55583); Mtu, Mycobacterium tuberculosis (NP 
334743); Pfu, Pyrococcus furiosis (NP 579028); Tlit, Thermococcus litoralis (CAA74299); Sso, 
Sulfolobus solfatanicus (NP 343028); Ath, Arabidopsis thaliana (NP 173758); Cel, Caenorhabdifis 
elegans (NP 492491); Dme, Drosophila melanogaster (NP 730035); Gga, Gallus gallus (NP 
418244); Hs, Homo sapiens (NP 060182); Xtr, Xenopus tropicalis (AAH75524); Lin, Leishniallia 
infanturn (GeneDB CIDS'. LinJ34.1440)- Lmj, Leishmania major (GeneDB CIDS: LmjF34.200ft Tb, Trypanosoma brucei (GeneDB CIDS: ýb04.1 H 19.1350). Tc, Trypanosoma cruzi (GeneDB CIDS: TcOO. 1047053506635.60). 
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